




**WATA  
CHEMICALS  
LIMITED**

# **ANNUAL REPORT 2024-2025**

**17/B, MONIPURIPARA, SANGSHAD AVENUE, DHAKA-125**



**03**

Transmittal Letter

**CONTENTS ANNUAL REPORT 2024-2025**

**04**

Corporate Historical & Financial Highlights

**05-06**

Profile Of Board Of Directors

**07**

Message From The Chairman

**08**

Message From Managing Director

**09-10**

Notice Of 43rd Annual General Meeting

**11-20**

Director's Report

**21-22**

Audit Committee's Report

**23-24**

Management Discussion & Analysis

**25-28**

Corporate Governance Report

**29**

NRC Report

**30-39**

Certificate on Compliance of Conditions of Corporate Governance Guidelines

**40**

Declaration by CEO and CFO as per Condition No. 1(5)(xxvi)

**42-46**

Auditor's Report

**47**

Statement of Financial Position

**48**

Statement of Profit or Loss and Other Comprehensive Income

**49**

Statement of Changes in Equity

**50**

Statement of Cash Flows

**51-103**

Notes & Schedules on Financial Statements

**104-108**

Some Photographs of Wata Chemicals Ltd

**LAST PAGE**

Proxy & Attendance Form



# BOARD OF DIRECTORS: CORPORATE INFORMATION

## CHAIRMAN

Mr. Md. Nurul Huda  
Deputy Managing Director (ICB)  
(Nominated Director)

## MANAGING DIRECTOR & CEO

Mr. Md. Nazrul Islam

## DIRECTOR

Mr. A.H.M. Abdullah  
BSc. in Chemical Engineering (BUET)

Mr. Md. Mahmudul Hasan  
MBA (DU)

## INDEPENDENT DIRECTOR

Mr. AMM Zeaul Haq  
(Former General Manager of BDBL)

## AUDIT COMMITTEE

Mr. AMM Zeaul Haq  
Independent Director  
Chairman of Audit Committee

Mr. Md. Monwar Hossain  
Non Executive Director  
Member of Audit Committee

Mr. A.T.M. Najmul Hussain  
Non Executive Director  
Member of Audit Committee

## NRC COMMITTEE

Mr. AMM Zeaul Haq  
Independent Director  
Chairman of NRC

Mr. Md. Monwar Hossain  
Non Executive Director  
Member of Audit Committee

Mr. A.T.M. Najmul Hussain  
Non Executive Director  
Member of Audit Committee

## COMPANY SECRETARY

Mr. Shamsul Huq

## CHIEF FINANCIAL OFFICER

Mr. Md. Ali Ahsan

## GENERAL MANAGER (FACTORY)

Mr. Abu Taher Bhuiyan

## FINANCE CONTROLLER

Mr. Md. Mahbubul Hassan Bhuiyan- FCMA

## HEAD OF MAINTENANCE ENGINEER CIVIL

Mr. SM Farhan Ali Reza  
BSc. in Civil Engineering (KUET)

## HEAD OF MAINTENANCE ENGINEER MECHANICAL

Mr. Md. Basherul Islam  
BSc. in Mechanical Engineering (KUET)

## HEAD OF INTERNAL AUDIT

Mr. Md. Milan Hossain- MBA, LL.B, ACS, ITP, CA (PL)

## MANAGER ACCOUNTS

Mr. Tapos Chandra Sarkar

## COMMERCIAL MANAGER

Mr. Mohammad Ali

## MARKETING INCHARGE

Mr. Md. Abdul Jobbar

## PRODUCTION MANAGER

Mr. Babul Das

## ACCOUNTS OFFICER

Mr. Md. Abdul Hakim

## STATUTORY AUDITOR

Khan Wahab Shafique Rahman & Co.  
Chartered Accountants  
Rupali Bima Bhaban, 7 Rajuk Avenue  
(5th & 6th Floor) Motijheel  
Dhaka- 1000

## AUDITOR OF CGG

MABS & J PARTNERS  
Chartered Accountants  
SMC Tower (7th Floor)  
33, Banani C/A, Road No- 17  
Dhaka-1213

## PRINCIPAL BANKERS

Agrani Bank Ltd.  
Principal Branch, Motijheel C/A  
Dhaka.

## LEGAL ADVISOR

Sekander Ali & Associates  
TMC Bhabon, New Eskaton Road  
Dhaka-1000.

## CREDIT RATING AGENCY

Emerging Credit Rating Limited  
Shams Rangs, House 104, Park Road  
Level-A1 & Level-A2, Baridhara  
Dhaka-1212

## REGISTERED HEAD OFFICE

17/B, Monipurpara (3rd Floor)  
Sangshad Avenue, Dhaka-1215

## FACTORY

Murapara, Rupgonj, Narayangonj.

## PHONE

58152001, 58155206

## FAX

+880-2-5855091

## WEB SITE

[www.watachemical.com](http://www.watachemical.com)

## E-MAIL

watachemicals@gmail.com



# TRANSMITTAL LETTER

02 December 2025

The Valued Shareholders  
Bangladesh Securities and Exchange Commission  
Dhaka Stock Exchange PLC  
Chittagong Stock Exchange PLC  
Central Depository of Bangladesh Ltd.  
Registrar of Joint Stock Companies & Firms


Sub: Annual Report 2024 - 2025, for the year ended on 30 June 2025.

Dear Sir(s),

We are pleased to enclose Notice of the 43rd Annual General Meeting, a copy of Annual Report Containing Directors Report together with Audited Financial Statements including Statement of Financial Position as on 30 June 2025, Statement of Profit or Loss and Other Comprehensive Income, Statement of Changes in Equity and Statement of Cash Flows for the year ended on 30 June 2025 along with notes thereon of WATA CHEMICALS LIMITED for your kind information, records and necessary measures.

Thanking you.

Yours faithfully,



(Shamsul Huq)

Company Secretary

# CORPORATE HISTORICAL & FINANCIAL HIGHLIGHTS



## CORPORATE HISTORICAL HIGHLIGHTS:

YEAR
1981
1986
1987
1991
1994
1997
2002
2003-2004
2018
2021-2022
1992
1994
1992
1997
2011
1995
1997
2012
2013
2014
2015-2016
2016-2017
2017-2018
2018-2019



## CORPORATE FINANCIAL HIGHLIGHTS AS ON 30.06.2025

AMOUNT BDT
Tk. 15.00 Crore
Tk. 14.82 Crore
Tk. 35.15 Crore
Tk. 03.24 Crore
Tk. 39.75 Crore
Tk. 61.09

## CORPORATE OPERATIONAL RESULTS OF LAST 5 YEARS

PARTICULARS	2024-2025	2023-2024	2022-2023	2021-2022	2020-2021
Turnover	931,902,906	819,837,945	1,110,394,363	1,036,043,378	649,079,365
Gross profit	240,763,287	218,896,554	282,663,882	279,137,551	216,830,312
Net Profit Before tax	18,145,944	18,967,671	52,487,194	80,879,845	98,049,177
Net Profit After tax	11,040,592	9,861,014	44,986,626	59,958,120	90,957,313
Paid up Capital	148,226,180	148,226,180	148,226,180	148,226,180	148,226,180
Earnings per share	0.74	0.67	3.03	4.05	6.14
Dividend (%)	10% Cash (Proposed)	12% Cash	15% Cash	General Sharholder 20% cash ,Directors 10% Cash	30% Cash

# PROFILE OF BOARD OF DIRECTOR



## MR. MD. NURUL HUDA CHAIRMAN

Born in 1972 in a respected Muslim family in Pirojpur district, Mr. Md. Nurul Huda continues to contribute significantly to the banking and financial sector of Bangladesh through his visionary leadership and professional excellence. Mr. Md. Nurul Huda was promoted to the position of Deputy Managing Director and joined the Investment Corporation of Bangladesh (ICB) on 10 April 2025, in accordance with the notification issued by the Financial Institutions Division, Ministry of Finance, Government of the People's Republic of Bangladesh. Prior to joining ICB, he served as General Manager of Agrani Bank PLC, overseeing both the Khulna Circle and Barishal Circle. Mr. Huda began his professional career in 1996 as a Senior Officer at Agrani Bank PLC. Throughout his distinguished career, he served in various key branches and divisions, including the Risk Management Division, Treasury Division, Industrial Credit Division, Principal Branch, and Foreign Exchange Corporate Branch, holding diverse positions with increasing levels of responsibility. Mr. Huda holds a B.Com (Honours) in Finance & Banking and an M.Com in Banking from the University of Dhaka. He also completed his EMBA in Marketing from the same university. He is a Diplomate Associate of the Institute of Bankers, Bangladesh (IBB). Renowned for his foresight, dynamism, dedication, and innovative approach, Mr. Huda has participated in numerous training programs and seminars both at home and abroad.

## MD. NAZRUL ISLAM MANAGING DIRECTOR & CEO

Mr. Md. Nazrul Islam, son of Late Alhaj Shakhat Hossain and Late Motijan Nessa, is a reputed businessman. He has wide Experience in Management of Chemical Industry, Construction & Survey Firm and Import businesses. He is the functional head of the company who manages the affairs of WATA with appropriate delegation of authority and accountability while the Chief Executives of all strategic business units directly report to him. His business strategy and various backward and forward linkages have diversified the business in manifold resulting WATA a largest Basic Chemical Manufacturing Company in Bangladesh. He is also Chairman of Board of Trustee of Sakhawat H. Memorial Trust having under it different educational organizations named S.M. Institute of Medical Technology & MATS, Sakhawat H. Memorial Nursing College. He has also established Autism Centre to bring Autistic Children in the main stream of society. He has traveled different countries of the World for business development purposes.

# PROFILE OF BOARD OF DIRECTOR



## A.M.M. ZEAUL HAQ INDEPENDENT DIRECTOR

Mr. A M M Zeaul Haq is an Independent Director of this Company . He is also Chairman of the Audit Committee and Nomination & Remuneration Committee of Wata Chemicals Limited. He was General Manager of Bangladesh Development Bank Ltd. He had been in-charge of different Banking division during his tenure of service with BDBL. Mr. Haq started his career as a research associates in Chittagong University, Department of Economics in 1976. He joined with Bangladesh Shilpa Bank in 1978 as senior Officer. He was retired from BDBL from the post of Head of Internal Control and Compliance Division as General Manager. Before that he served his responsibility as Head of Branch Management Department, Head of Documentation and Machinery Procurement, Head of control Recovery Department, Head of Principal Branch, Dhaka, Head of Chittagong zonal office etc. During his tenure of service at Research and Statistics Department, he prepared Market Report, Sectoral study, Project profile, act as administrator of "Data Bank" of the Bank as designed by World Bank .

During his service, he worked in Banking & Finance sector, Operational Management units, law and Legal affairs Department. He has received various Training from home & abroad on Financial matters.

He is a life member of Bangladesh Statistical Association, Guest speaker of Different Training Institute. He was an Ex rover scout, cadet, BNCC.

Mr. Haq is associated with different social, cultural and sports Organizations. He is writer of different books on Banking and Investments.



## A.H.M. ABDULLAH DIRECTOR

A.H.M. Abdullah is a Director of the Company. He is a BSc. in Chemical Engineering from BUET, Dhaka. He has completed HSC from Notre Dame College and SSC from Dhaka Residential Model College in Science Discipline. He has wide experience on Technology of Chemical Plant/Industries. He has significant contribution in the advancement of industrial as well as import sector of the company. He is also engaged in social work.



## MD. MAHMUDUL HASAN DIRECTOR

Md. Mahmudul Hasan is a Director of the Company. He has completed MBA from University of Dhaka, BA (Hon's) in English, HSC from Notre Dame College, Dhaka, SSC from Dhaka Residential Model College and Engaged with foreign correspondences relating to procurement & Import of Chemical Raw Materials, Capitated Machineries of WATA CHEMICALS LIMITED. Md. Mahmudul Hasan has continued to maintain management style in WATA, with special emphasis on quality, productivity and customers services. He is currently serving as the head of the administration department. He is also engaged in social work and with Autism Center, Nursing College at Sirajgonj.



## MESSAGE FROM THE CHAIRMAN



### MESSAGE FROM THE CHAIRMAN

Dear Shareholders,  
Assalamu Alaikum

At the very outset, I express my heartfelt gratitude to the Honorable Shareholders and to all concerned. It is my privilege to welcome you all to the 43rd Annual General Meeting of Wata Chemicals Limited. I am deeply thankful to our partners, team members, and all stakeholders for their relentless support and collaboration throughout the year.

I was promoted to the position of Deputy Managing Director and joined the Investment Corporation of Bangladesh (ICB) on 10 April 2025. Subsequently, I was nominated by ICB as Director and Chairman of Wata Chemicals Limited. The relationship between ICB and Wata Chemicals Limited dates back to 1992, when Wata Chemicals first entered the capital market. Since then, ICB has continued to hold shares of the Company and remains an important institutional stakeholder to this day.

The global economy continues to operate under significant uncertainty. Nevertheless, Wata Chemicals Limited remains committed to navigating these challenges with prudence, caution, and foresight. Despite facing multiple constraints—including the embargo on sulphur imports from our principal source country, Russia; the devaluation of the Bangladeshi Taka against the US Dollar; rising bank interest rates; and an unprecedented cost push—your Company has recorded a Net Profit after Tax of Tk. 1,10,40,592 in the financial year 2024–2025. For FY 2024–2025, the Board of Directors has recommended a 10% cash dividend, subject to approval by the Honorable Shareholders at this AGM. We remain steadfast in our commitment to building a more sustainable and resilient specialty chemical business that enhances long-term value for all stakeholders. Our dedication to responsible growth has always been central to our strategy, and we strongly believe that sustainable and purposeful enterprises are best positioned to endure challenges and deliver superior long-term performance.

I extend my sincere appreciation to our Management Team, Officers, Staff, Bankers, Business Associates, and all other partners who have worked tirelessly during the year. My profound gratitude also goes to the Board of Directors for their continued guidance and support. I further acknowledge our valued vendors and business partners who have stood by the Company even in times of adversity. Above all, we deeply value the trust, confidence, and support of our esteemed Shareholders, which continues to inspire us as we strive to overcome challenges and look forward to brighter prospects ahead.

Best wishes for a bright and healthy life.



Md. Nurul Huda  
Chairman



## MESSAGE FROM THE MANAGING DIRECTOR

Dear Shareholders,  
Assalamu Alaikum

It is my great pleasure to welcome you all to the 43rd Annual General Meeting of WATA Chemicals Limited.

Despite significant external challenges and an intensely competitive business landscape, I am pleased to report the successful completion of another operational year for your Company. The period under review was shaped by global crises; nevertheless, we continued our operations with resilience, strategic discipline, and sustained profitability.

During the financial year 2024–2025, WATA Chemicals Limited achieved a Net Profit after Tax of Tk. 11,040,592, despite various constraints stemming from the ongoing Russia–Ukraine conflict, substantial devaluation of the Bangladeshi Taka against the US Dollar, volatility in the international market, rising bank interest rates, and domestic political uncertainties.

The Company recorded gross revenue of Tk. 931,902,906, compared to Tk. 819,837,945 for the year ended 30 June 2024. Net profit for the year stood at Tk. 11,040,592, compared to the previous year's Tk. 9,861,014. Total revenue increased by 13.67% compared to FY 2023–2024, primarily driven by higher sales volume.

Gross sales during 2024–2025 amounted to BDT. 93,19,02,906, reflecting an increase of BDT. 11,20,64,961 over the previous year. Gross profit increased by BDT. 2,18,66,733, but the unexpected rise in bank interest rates significantly inflated financial expenses, adversely affecting the net profit ratio. Prolonged geopolitical instability, currency depreciation, inflationary pressure on raw materials, and elevated borrowing costs collectively contributed to an unexpected impact on EPS.

Considering the overall performance and current liquidity position of the Company, the Board of Directors has recommended a 10% cash dividend for the year ended 30 June 2025, subject to approval at this 43rd AGM. We remain focused on strengthening our foundations, driving sustainable growth, and enhancing our readiness for future challenges.

At WATA, we firmly believe that our success is shaped by hard work, creative vision, and timely execution. These core values define our relationships with our customers, employees, and business partners. We are confident that, together, we will continue to unlock new opportunities, enhance value, improve returns, and contribute meaningfully to the national economy.

As always, I convey my heartfelt gratitude to our esteemed shareholders for your continued trust, confidence, and guidance. Your unwavering support inspires us as we continue our journey toward progress and excellence.

Thank you once again for joining us through the digital platform and for your cooperation throughout the year.



Md. Nazrul Islam  
Managing Director  
WATA Chemicals Limited



# ওয়াটা কেমিক্যালস্ লিঃ ৪৩ তম বার্ষিক সাধারণ সভার বিজ্ঞপ্তি

এতদ্বারা ওয়াটা কেমিক্যালস্ লিমিটেড- এর সম্মানিত শেয়ারহোল্ডারগণের জ্ঞাতার্থে জানানো যাচ্ছে যে, কোম্পানীর ৪৩ তম বার্ষিক সাধারণ সভা নিম্নলিখিত বিষয়াদি সম্পাদনকল্পে আগামী ২৪ ডিসেম্বর, ২০২৫ইঁ (বাংলা- ০৯ই পৌষ, ১৪৩২) রোজ বুধবার, সকাল- ৯:০০ ঘটিকায় ভার্চুয়াল প্লাটফর্মে অনুষ্ঠিত হবেঁ।

## আলোচ্য মুক্তি:

০১. ৩০.০৬.২০২৫ইঁ তারিখে সমাপ্ত কোম্পানীর নিরীক্ষিত আর্থিক হিসাব বিবরণী, নিরীক্ষকের প্রতিবেদন, পরিচালক মন্ডলীর প্রতিবেদন গ্রহণ, বিবেচনা ও অনুমোদন করা,
০২. ৩০.০৬.২০২৫ইঁ তারিখে সমাপ্ত আর্থিক হিসাব বছরের লভ্যাংশ অনুমোদন করা,
০৩. কোম্পানীর সংযুক্ত বিধি অনুযায়ী পরিচালক নিয়োগ/পুনঃ নিয়োগ করা,
০৪. ৩০.০৬.২০২৬ইঁ তারিখে সমাপ্ত ২০২৫ - ২০২৬ হিসাব বছরের জন্য সংবিধিবদ্ধ নিরীক্ষক নিয়োগ ও তাদের পারিশ্রমিক অনুমোদন করা,
০৫. ৩০.০৬.২০২৬ইঁ তারিখে সমাপ্ত ২০২৫ - ২০২৬ হিসাব বছরের জন্য কর্পোরেট গভর্ন্যাল কমপ্লায়েন্স নিরীক্ষক নিয়োগ ও তাদের পারিশ্রমিক অনুমোদন করা,
০৬. চেয়ারম্যান মহোদয়ের অনুমতিক্রমে সাধারণ সভায় আলোচনাযোগ্য অন্যান্য যে কোন বিষয়াদি সম্পাদন করা।

তারিখঃ ০২.১২.২০২৫ইঁ  
ঢাকা।

পরিচালনা পর্ষদের আদেশক্রমে,  
*Shamimul Haque*  
(সামছুল হক)  
কোম্পানী সচিব

## দ্রষ্টব্যঃ

০১. ৱেকর্ডেট ২৭.১১.২০২৫ইঁ ৱেকর্ডেট অনুযায়ী সিডিবিএল ৱেকর্ডেট এবং শেয়ার রেজিস্ট্রারে যে সকল শেয়ারহোল্ডারগণের নাম নথিভৃত থাকবে কেবল মাত্র তাহারাই ৪৩তম বার্ষিক সাধারণ সভায় অংশ গ্রহণ এবং অনুমোদিত লভ্যাংশ পাবার যোগ্য হবেন।
০২. বার্ষিক সাধারণ সভায় চূড়ান্ত অনুমোদনের জন্য পরিচালনা পর্ষদের সর্বসম্মতিক্রমে ০৬.১১.২০২৫ইঁ তারিখের সিদ্ধান্ত মোতাবেক সকল শেয়ারহোল্ডারবৃন্দের জন্য পরিশোধিত মূলধনের ১০% হারে নগদ লভ্যাংশ প্রদানের সুপারিশ করেছে।
০৩. বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশন (বিএসইসি) এর নির্দেশনা মোতাবেক কোম্পানীর ৪৩ তম বার্ষিক সাধারণ সভা ডিজিটাল প্লাটফর্ম (ভার্চুয়াল মিটিং) এ অনুষ্ঠিত হবে। অনলাইন লাইভ পোর্টাল এর মাধ্যমে ৪৩ তম বার্ষিক সাধারণ সভায় উপস্থিত হওয়ার জন্য অনুরোধ করা হলো।
০৪. বার্ষিক সাধারণ সভা শুরুর ২৪ ঘন্টা পূর্বে ও সভা চলাকালীন শেয়ারহোল্ডারবৃন্দ তাহাদের নাম, বিও হিসাব নম্বর/ফলিও নম্বর, শেয়ার সংখ্যা নির্দিষ্ট লিংক এ প্রদান করে তাহাদের ভোটাধিকার, প্রশ্ন ও মন্তব্য প্রদান করতে পারবেন। 

০৫. শেয়ারহোল্ডারবৃন্দ ভয়েস ৱেকর্ডিং করে তাহাদের মন্তব্য ই-মেইল নম্বর [watachemicals@gmail.com](mailto:watachemicals@gmail.com) এ ২১.১২.২০২৫ সকাল ৯:০০ ঘটিকার মধ্যে প্রেরণ করতে পারবেন। মন্তব্য/বক্তব্য অবশ্যই সংক্ষিপ্ত হতে হবে যেন তাহা আপলোড করা সম্ভব হয়।
০৬. বার্ষিক সাধারণ সভা শুরুর ২৪ ঘন্টা আগে পোর্টাল খুলে দেয়া হবে।
০৭. বার্ষিক সাধারণ সভার নোটিশ, ডিজিটাল প্লাটফর্মে সংযুক্ত হবার লগ-ইন প্রক্রিয়া শেয়ারহোল্ডারবৃন্দকে ই-মেইল এর মাধ্যমে জানিয়ে দেয়া হবে।
০৮. ভার্চুয়াল সভায় অংশগ্রহনের প্রক্রিয়া সমূহ কোম্পানীর ওয়েব সাইটে [www.watachemical.com](http://www.watachemical.com) পাওয়া যাবে।
০৯. ভার্চুয়াল সভা সংক্রান্ত লগ ইন প্রক্রিয়া ও যে কোন প্রয়োজনে মোবাইল নম্বর- +৮৮০ ১৬৪৩-২৪৯৪৬০, +৮৮০ ০১৩০-১০১৬৩৯০ এ যোগাযোগ করার জন্য অনুরোধ জানানো যাচ্ছে।
১০. বার্ষিক সাধারণ সভায় অংশ গ্রহণ ও ভোট প্রদানের জন্য প্রক্রসী (প্রক্রসীকে অবশ্যই একজন শেয়ারহোল্ডার হতে হবে) নিয়োগ করতে পারবেন যথাযথ রেভিনিউ স্ট্যাম্প সম্বলিত প্রক্রসী ফরম কোম্পানীর রেজিস্টার্ড অফিসে/প্রধান কার্যালয়ে সভার নির্ধারিত সময়ের ৪৮ ঘন্টা পূর্বে অবশ্যই জমা দিতে হবে। শেয়ারহোল্ডার কোম্পানী/কর্পোরেশন হলে তাদের মনোনীত প্রতিনিধি সভায় অংশগ্রহণ করতে পারবেন।
১১. বার্ষিক প্রতিবেদন এর কপি শেয়ারহোল্ডারবৃন্দের ই-মেইল ঠিকানায় প্রেরণ করা হবে। আগ্রহী শেয়ারহোল্ডারবৃন্দ কোম্পানীর প্রধান কার্যালয় ১৭/বি মনিপুরীপাড়া, সংসদ এভিনিউ, ঢাকা-১২১৫ হতে “বার্ষিক প্রতিবেদন” এর কপি লিখিত আবেদনের মাধ্যমে সংগ্রহ করতে পারবেন। বার্ষিক প্রতিবেদন কোম্পানীর ওয়েব সাইট এ পাওয়া যাবে।
১২. শেয়ারহোল্ডারগণকে কাণ্ডে শেয়ার ডিমেট করাতে, ব্যাংক হিসাব নম্বর কমপক্ষে ১৩ ডিজিট এবং ব্যাংকের রাউটিং নম্বর, টিআইএন, মোবাইল নম্বর ও ই-মেইল ঠিকানা ইত্যাদি সিকিউরিটিজ হাউজে হালনাগাদ করনে অনুরোধ করা হলো।

বিঃদ্রঃ বার্ষিক সাধারণ সভায় অংশগ্রহণকারীদের কোন ধরনের খাবার, ড্রিম্প সামগ্রী বা বেনিফিট প্রদান করা হবে না।



## WATA CHEMICALS LIMITED

### NOTICE OF THE 43RD ANNUAL GENERAL MEETING


Notice is hereby given that the 43rd Annual General Meeting of WATA CHEMICALS LIMITED will be held at 9:00 AM, Wednesday, 24th December- 2025 at the virtual platform to transact the following businesses:

#### AGENDA:

01. To receive, consider and adopt the Audited Financial Statements for the year ended on 30th June' 2025 together with Reports of the Auditors and the Directors.
02. To approve dividend for the year ended on 30 June, 2025 as recommended by the Board of Directors.
03. To elect/re-elect Director(s) of the Company as per the Articles of Association of the Company.
04. To appoint statutory Auditors for the Accounting Period 2025-2026 ended on 30.06.2026 and to fix their remuneration.
05. To appoint Corporate Governance Compliance Auditor for the year 2025-2026 ended on 30.06.2026 and to fix-up their remuneration.
06. Others, on approval of Chairman of the Meeting.

Dhaka

December 02, 2025

By order of the Board  
  
(Shamsul Huq)  
Company Secretary

#### NOTES:

01. The Shareholders as per CDBL record or names in Share Register on the 'Record Date' (November 27, 2025) will be entitled to attend the meeting and for Dividend subject to approval at the 43rd AGM.
02. The Board in its meeting date 06.11.2025 recommended 10% Cash Dividend.
03. In view of directive of Bangladesh Securities & Exchange Commission (BSEC), the ensuing 43rd AGM of the company would be conducted through digital platform (Virtual meeting). Therefore, the Shareholders are requested to attend the 43rd AGM through online live portal. The detailed procedures and link of the online live portal to attend the meeting will be communicated to the Shareholders in due course.
04. The Members will be able to submit their questions/comments electronically 24 hours before commencement of the AGM and during the AGM. For logging into the system, the Members need to put their Beneficial Owner BO ID number/Folio number and other credentials as proof of their identity by visiting the link <https://agmbd.live/watachemicals2025>. 
05. The Members may also send their comments/queries through voice recording (video/audio) via email to [watachemicals@gmail.com](mailto:watachemicals@gmail.com) on or by 9:00 AM, 21 December, 2025. The content must be briefed otherwise it is difficult for uploading.
06. Portal will be opened for Shareholders 24 hours before at 9:00 AM on 24 December, 2025. The Members may also send their comments/queries through Portal.
07. AGM Notice, Link for joining in the Digital platform (audio-visual meeting) and detail login process will be mailed to the respective Member's email address available with us.
08. The detailed procedures to participate in the virtual meeting are available on the Company's website at: <http://www.watachemical.com>
09. We encourage the Members to login to the system prior to 9:00 AM on December 24, 2025. Please allow ample time to login and establish your connectivity. The webcast will start at 9:00 AM (Dhaka Time). Please contact +880 1643-249460, +880 0130-1016390 on the appropriate time i.e. 5 minutes before commencement of the Meeting for avoiding any technical difficulties in accessing the Virtual Meeting.
10. Shareholders are eligible to attend the Annual General Meeting is entitled to appoint a Proxy (Proxy must be a Shareholder of the Company) to attend and vote on his/her behalf (through digital platform). The "Proxy Form" must be affixed with requisite Revenue Stamp and deposited it at the Registered Office of the Company not later than 48 hours before the time fixed for the meeting. If Shareholder is a Company/Corporation, they can nominate representative to attend the meeting.
11. The softcopy of the Annual Report 2024-2025 of the company will be sent to the Shareholder's respective e-mail addresses. However, interested Shareholders may collect hard copy of the Annual Report from the company's Head office at 17/B, Monipuripara, Sangshad Avenue, Dhaka-1215 by submitting a written requests. The Annual Report is available on 'Investor Relations' section of the Company's website: [www.watachemical.com](http://www.watachemical.com)
12. Shareholders are requested to Demat their Paper Shares, up-date Bank A/C number 13 digit minimum, their Bank's Routing Number, TIN Number, Mobile Number & E-mail address with Brokerage House on top priority basis.

**N.B.: FOOD, GIFT OR BENEFIT IN CASH OR KIND SHALL NOT BE GIVEN AT THE ANNUAL GENERAL MEETING.**



# Director's Report to the Shareholders

## Director's Report to the Shareholders

Bismillaher Rahmanir Rahim

Dear valued Shareholder,

Assalamu Alaikum,

On behalf of the Board of Directors, I am pleased to extend a warm welcome to all of you attending the 43rd Annual General Meeting (AGM) of WATA Chemicals Limited.

The Directors of WATA Chemicals Limited are delighted to present the Annual Report, along with the Report of the Board of Directors and the Auditor's Report on the audited financial statements of the Company for the year ended 30 June 2025, for your valued review, consideration, adoption, and approval.

We are honored by your presence at this 43rd AGM of WATA Chemicals Limited. It is our privilege to place before our esteemed shareholders the Directors' Report for the financial year ended 30 June 2025. The audited financial statements have been prepared in full compliance with the Companies Act, all relevant laws and regulations, directives and notifications of the Bangladesh Securities and Exchange Commission, and in accordance with International and Bangladeshi Accounting Standards, including BFRS and IFRS, as adopted by the Institute of Chartered Accountants of Bangladesh.

Despite the challenging economic environment, the Company has continued its operations responsibly and efficiently. Key financial activities, future prospects, performance results, compliance status, legal matters, and other relevant information have been detailed in the report so that our respected shareholders may provide their valuable guidance and suggestions.

WATA Chemicals Limited was listed on the Dhaka Stock Exchange in 1992 with a paid-up capital of BDT. 16.20 million. Through sustained profitability, the paid-up capital has progressively increased to BDT. 148.20 million. Over the years, production capacity has been expanded and new units have been established, contributing to business diversification and growth.

We are pleased to inform you that the Company has declared a cumulative 537% dividend up to 30 June 2025. The Board of Directors remains committed to the continuous progress and long-term sustainability of the Company and expresses sincere appreciation to the shareholders and all stakeholders for their continued trust, support, and cooperation.

## OPERATING RESULTS FOR THE YEAR 2024-2025 (ENDED 30 JUNE 2025)

During the year under review, the Company recorded 14.03% increase in sales volume compared to the previous financial year. However, despite this positive growth in sales, the overall cost structure was adversely affected. Prices of key raw materials and bank interest rates rose significantly, although factory and administrative expenses decreased to some extent. Consequently, the total cost and expenses increased in proportion to the year's sales.

These cost escalations were primarily driven by heightened volatility in the international market, the ongoing geopolitical tensions arising from the Russia-Ukraine conflict, the continued devaluation of the Bangladeshi Taka against the US Dollar, and broader macroeconomic challenges influenced by both local and global political conditions.

As a combined outcome of these factors, the Company experienced a notable impact on its Earnings Per Share (EPS). A comparative summary of the financial performance for the last two years is presented below for your review.

Particulars	Amount in Taka	
	2024-2025	2023-2024
Revenue (Net of VAT)	813,487,372	713,392,353
Cost of Sales	(572,724,085)	(494,495,799)
<b>Gross Profit</b>	<b>240,763,287</b>	<b>218,896,554</b>
Administrative, Selling and Distribution Expenses	(38,322,490)	(45,066,463)
<b>Operating Profit</b>	<b>202,440,797</b>	<b>173,830,091</b>
Finance Expenses	(187,885,642)	(160,704,849)
Non Operating Income	4,498,086	6,790,812
<b>Profit before contribution to WPPF &amp; Welfare Fund</b>	<b>19,053,241</b>	<b>19,916,055</b>
Contribution to WPPF & Welfare Fund	(907,297)	(948,384)
<b>Profit before Tax</b>	<b>18,145,944</b>	<b>18,967,671</b>
<b>Income Tax Expenses</b>	<b>(7,105,352)</b>	<b>(9,106,657)</b>
<b>Profit after Tax</b>	<b>11,040,592</b>	<b>9,861,014</b>
<b>Other Comprehensive Income / Expenses</b>		
Deferred Tax on Revaluation of PPE	(942,503)	(1,028,278)
<b>Total Comprehensive Income</b>	<b>10,098,089</b>	<b>8,832,736</b>
<b>Earning Per Share (EPS) in Taka</b>	<b>0.74</b>	<b>0.67</b>

## MAIN ACTIVITIES OF THE COMPANY

WATA Chemicals Ltd. is engaged in the production of essential industrial chemicals, including Sulfuric Acid, Aluminium Sulphate, Zinc Sulphate, and Magnesium Sulphate. In addition, the installation and commissioning work of SLES (Sodium Lauryl Ether Sulphate) and LABSA (Linear Alkyl Benzene Sulphonic Acid) plants have been completed with successful test operation. However, commencement of commercial production has been delayed due to the impact of the Covid-19 pandemic and the prevailing volatile international and local market conditions.

Our products are widely used across numerous industries and utility service providers, including the Dhaka WASA: Saidabad Water Treatment Plant (Phase I, II & III), Lalbagh Water Works, Sonakandi Water Works, Godnail Water Works Chattogram WASA: Sheikh Hasina Water Treatment Plant, Mohara Water Treatment Plant, Sheikh Russel Water Treatment Plant Fertilizer & Chemical Industries: Ashuganj Fertilizer and Chemical Co. Ltd., Ghorashal Urea Fertilizer Co. Ltd., Polash Urea Fertilizer Co. Ltd., Jamuna Fertilizer Co. Ltd., Mixed Fertilizer Plants Power Sector: Ashuganj Power Station, Ghorashal Power Station Industrial Sectors: Battery Industries, Steel & Re-rolling Mills, Textile and Garments Industries and their backward/forward linkage units, Tannery Industries, Paper Mills, Effluent Treatment Plants (ETP), Soap & Detergent Manufacturers, Pharmaceutical Industries, Gold Processing Units, and various Color, Glue, Ether, and Rubber Industries Other Customers: Various Engineering and Chemical Industries and many other industrial users.

### **INDUSTRY OUTLOOK:**

The basic chemicals sector in Bangladesh is entering a cautiously optimistic phase. Domestic demand for core inorganic chemicals (sulfuric acid, aluminium sulfate, zinc sulfate, magnesium sulfate) remains supported by steady activity in textiles, fertilizer, water treatment, pulp & paper and metal processing, Battery industry, leather processing etc. At the same time, downstream growth in detergents and personal-care formulations is creating significant opportunity for surfactant intermediates such as LABSA and SLES – products for which Wata has invested in new capacity. The macro picture for 2024–25 is therefore one of sustained end-market demand tempered by elevated input-cost volatility, tightening environmental scrutiny, and competitive pressure from imports.

**Demand drivers and market growth:** End-market resilience. Bangladesh's export-oriented textile and apparel sector continues to be the largest single consumer of many basic chemicals (processing, finishing, sizing, wastewater treatment). Infrastructure and local government water projects also support demand for aluminium sulfate and sulfuric acid, underpinning a steady baseline of domestic consumption. Recent market studies project modest but steady growth in sulfuric acid and related products over the 2025 horizon.

**Local substitution opportunity for surfactant intermediates.** Domestic production of LABSA and SLES is expanding: in 2024–25 several local initiatives reached commercial readiness with the stated aim of meeting most or all of domestic demand for LABSA/SLES. Increasing local availability of these feedstocks reduces reliance on imports for detergent and cleaning-product manufacturers and creates a near-term addressable market for Wata's new LABSA/SLES capability.

### **Supply, raw-material dynamics and pricing**

The industry's cost base is sensitive to global commodity movements (sulfur and caustic prices, shipping) and to domestic energy and logistics costs. Across 2024–2025 global caustic and other chemical feedstock prices were volatile regionally, with short-term spikes and troughs driven by logistics, seasonal demand and inventory cycles. That volatility transmits quickly to local margins, particularly for manufacturers who import key inputs or rely on international contract pricing. Wata's strategy to secure longer-term feedstock contracts, maintain strategic inventories, and localize certain inputs where possible will be central to margin stability.

### **Regulatory, environmental and safety environment**

Regulatory expectations are tightening: water quality standards, restrictions on persistent organic pollutants, and heightened enforcement around chemical storage and occupational safety have become more prominent public issues. High-profile incidents and independent studies have increased scrutiny of industrial effluents and hazardous storage practices, creating both compliance cost pressure and market opportunity for firms that can demonstrate safe, low-impact operations and certified waste-management. For Wata, demonstrating strong environmental compliance and transparent safety protocols is now a commercial differentiator, especially when supplying large exporters and local government contracts.

### **Competitive landscape**

Local manufacturing capacity for several basic chemicals has grown, but gaps remain in high-purity grades and specialty formulations. Imports still play a role where local supply is limited or inconsistent in quality. The ongoing expansion of local LABSA/SLES capacity will increase competition in surfactant intermediates but also expands addressable demand (by reducing raw-material logistics for detergent makers). Competitive advantage will accrue to producers who can combine reliable quality, cost-effective logistics and regulatory compliance.

### **Risks and headwinds**

- Input price volatility – swings in global feedstock and shipping costs can compress margins.
- Foreign-exchange risk – import dependence exposes companies to currency depreciation and higher landed costs.
- Regulatory and environmental compliance costs – tighter enforcement raises CAPEX/OPEX for effluent treatment, storage and safety.
- Operational safety & reputational risk – industrial incidents in the sector have broader reputational and regulatory consequences.

### **Opportunities & strategic priorities for Wata Chemicals Ltd.**

1. Commercialise and scale LABSA/SLES production – capture domestic substitution demand and supply local detergent/formulation manufacturers with lower logistics lead times and competitive pricing. (Wata's completed SLES/LABSA plant positions the company well to capture this opportunity.)
2. Focus on higher-value grades and niche specialties – production of high-purity aluminium sulfate and specialty salts for water treatment, paper and electronics can command premium margins. Hedge and diversify feedstock sourcing – use long-term contracts, local suppliers, and inventory buffers to mitigate input price shocks.
3. Invest in compliance & sustainability – accelerate effluent treatment upgrades, adopt best-practice storage and incident-prevention systems, and pursue public transparency to win institutional and export customers. Customer integration & technical support – offer formulation support, quality guarantees and just-in-time supply to large buyers (textile groups, detergent manufacturers, municipal buyers) to lock in offtake and reduce price sensitivity.

### **Outlook (near term – FY 2025–2026)**

We expect modest volume growth in core inorganic chemicals driven by steady textile and water-treatment demand, accompanied by potential margin pressure from feedstock price movements and energy costs. For surfactant intermediates (LABSA, SLES), FY 2025–26 presents an immediate growth window: domestic substitution is accelerating and Wata is well placed to commercialize existing assets. Overall, the sector will reward manufacturers who combine reliable quality, supply continuity, and demonstrable environmental and safety credentials.





## Concluding note for shareholders



The basic chemicals industry is stable but evolving: steady end-market demand, structural opportunities for import substitution, and increasing regulatory and price volatility. Wata Chemicals' product mix, recent capacity investments, and focus on compliance provide a sound platform to grow in this environment – but success will require disciplined input procurement, operational excellence, and visible leadership on environmental and safety performance.

## COMPARISONS OF FINANCIAL RESULT:

The key financial results of WATA Chemicals Ltd. for five years including current year are presented below:

PARTICULARS	2024-2025	2023-2024	2022-2023	2021-2022	2020-2021
Turnover	931,902,906	819,837,945	1,110,394,363	1,036,043,378	649,079,365
Gross profit	240,763,287	218,896,554	282,663,882	279,137,551	216,830,312
Net Profit Before tax	18,145,944	18,967,671	52,487,194	80,879,845	98,049,177
Net Profit After tax	11,040,592	9,861,014	44,986,626	59,958,120	90,957,313
Paid up Capital	148,226,180	148,226,180	148,226,180	148,226,180	148,226,180
Earnings per share	0.74	0.67	3.03	4.05	6.14
Dividend (%)	10% Cash (Proposed)	12% Cash	15% Cash	General Shareholder 20% cash ,Directors 10% Cash	30% Cash





#### SEGMENT-WISE OR PRODUCT-WISE PERFORMANCE:

Production, sales and marketing have been increased after severe Covid-19 pandemic. Sulfuric Acid is our principal product its yearly production capacity is about 48,000 MT but in 2024-2025 capacity utilization is 44,034.390 MT which is 91.74% of yearly capacity. Aluminium Sulphate measuring 6,067.400 MT has been manufactured out of yearly capacity 18,000 MT, percentage achieve 33.71%. Production and Sale value has been increase as compared with the previous year. It is to be noted that LABSA & SLES is our other products which is produced 266.028 MT for test operation purpose. Sales volume has been increased by 14.03 %as compared with the corresponding period of the previous year, Raw material price factory & interest expenses also increased in proportionate to sales of the respective year due to volatile international market, devaluation of taka against US Dollar and increase of finance expense due to increase of rate of bank interest causes significant deviation in EPS.

#### POSSIBLE FUTURE DEVELOPMENTS IN THE INDUSTRY

WATA Chemicals Limited remains committed to expanding its footprint in the basic chemical manufacturing sector. Under the leadership of our Director, Mr. A.H.M. Abdullah, a distinguished Chemical Engineering graduate from BUET, the Company continues to explore opportunities for establishing additional basic chemical plants to further contribute to the national economy and enhance the Company's long-term growth prospects.

The Board of Directors and Management are working diligently—guided by the valuable support and constructive recommendations of our esteemed shareholders—to strengthen and diversify our production capacity. These initiatives aim to reinforce our market position, enhance capacity building, and support sustainable industrial development in Bangladesh.

We are pleased to report that the setup and trial production of the SLES/LABSA plant have been successfully completed. The Company is now actively working toward commencing at the earliest opportunity. This development is expected to significantly broaden our product portfolio and create new avenues for growth in the coming years.

#### ENVIRONMENTAL ISSUES

WATA Chemicals Limited remains fully committed to maintaining the highest standards of environmental compliance. All operations strictly adhere to the rules and regulations set forth by the Directorate of Environment. The Company continues to operate its Air Treatment Plant (ATP) and Effluent Treatment Plant (ETP) with utmost efficiency to ensure that all emissions and effluents meet the mandatory environmental parameters.

Regular monitoring and laboratory testing conducted by the concerned authority consistently demonstrate that our environmental performance remains satisfactory and within acceptable limits. Furthermore, the installation of a Zero-Discharge Treatment Plant has been successfully completed, enhancing our capability to achieve more effective, sustainable, and responsible environmental management across all production processes.

#### DISCUSSION ON COST OF GOODS SOLD, GROSS PROFIT MARGIN AND NET PROFIT MARGIN

During the financial year 2024–2025, Gross Sales inclined by Tk.112,064,961 compared to the previous year (2023–2024). While sales of Sulfuric Acid and others recorded an increase, but price of Raw materials proportionately increased more resulting proportionate lower Earnings Per Share (EPS).

Cost of Goods Sold (COGS) proportionately declined. Despite the increase in sales volume, Gross Profit for 2024–2025 Increased by 9.99% compared to the preceding year, primarily due to the higher cost of raw materials of key products.

Furthermore, a substantial increase in Financial Expenses driven by the rise in bank interest rates adversely impacted the Net Profit Margin. This increase in financing cost further compressed profitability and ultimately the EPS not so inclined proportionately as expected.

#### STATEMENT OF REMUNERATION PAID TO THE DIRECTORS INCLUDING INDEPENDENT DIRECTORS:

Detailed are shown in Audited Financial Statements Note 28.01

#### ACCOUNTING POLICIES AND ESTIMATION:

Accounting policies are determined by applying the relevant IFRS. Where there are no available guidelines of IFRS, management uses its judgment in developing and applying an accounting policy that results in information that is relevant and reliable. The company selects and applies its accounting policies for a period consistently for similar transactions, other events and conditions, unless an IFRS or specifically requires or permits categorization of items for which different policies may be appropriate. The accounting policies set out below have been applied consistently in all material respects to all periods presented in these financial statements. We have followed International Financial Reporting Standards (IFRSs) and the Companies Act, 1994 in preparation of financial statements. These financial statements follow the requirements of IFRSs which are to some extent different from the requirement of the Companies Act, 1994. The company changes its accounting policy only if the change is required by a IFRS or results in the financial statements providing reliable and more relevant information about the effects of transactions, other events or conditions on the company financial position, financial performance or cash flows. Changes in accounting policies is made through retrospective application by adjusting opening balance of each affected components of equity i.e. as if new policy has always been applied and Estimates arise because of uncertainties inherent within them, judgment is required but this does not undermine reliability. Effect of changes of accounting estimates is included in profit or loss account. The preparation of the financial statements are in conformity with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgment in the process of applying the Company's accounting policies. However, the Company also complied with the requirements of following laws and regulations from various Government bodies: i. Bangladesh Securities and Exchange Rules 1987; ii. The Income Tax ordinance, 1984; and Income Tax Act 2023 iii. The Value Added Tax Act, 1991; iv. The Value Added Tax and Supplementary Duty Act, 2012. In preparing financial statements, management has made judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to estimates are recognized prospectively. Information about judgments made in applying accounting policies that have the most significant effects on the amounts recognized in the financial statements is included in note 1, Page- 51 of this Annual Report.

### **INTERNAL CONTROL SYSTEMS:**

The Company's internal control procedures which include internal financial controls ensure compliance with various policies, practices and statutes and keeping in view the organization's pace of growth and increasing complexity of operations. The internal auditors' team carries out extensive audits throughout the year across all locations and across all functional areas and submits its reports to the Audit Committee of the Board of Directors.

### **HUMAN RESOURCE AND WELFARE DEVELOPMENT:**

WATA Chemicals Ltd maintain preference for Development of Human Resource and Welfare of all involved with the Company, 5% profit before Tax is being maintained with "Workers Profit Participation Fund & Welfare Fund" yearly. Guidelines of Directorate General of Health Services, World Health Organization for protection from Dengue, viruses and other issues relating to Health and Hygiene are being maintained and regular follow up has been there.

### **BOARD MEETING & ATTENDANCE:**

The total number of Board meetings held during the year and attendance by each director are shown in ANNEXURE: 01, Page- 17

### **SHAREHOLDING PATTERN:**

Pattern of shareholding disclosing the aggregate number of shares (along with name-wise details) held by: (a) Parent or Subsidiary or Associated Companies and other related parties (name-wise details); (b) Directors, Chief Executive Officer, Chairman, Non-Executive Director (name-wise details); and (c) Shareholders holding ten percent (10%) or more voting interest in the company (name-wise details); are shown in ANNEXURE : 01, Page- 17... of this Annual Report.

### **RECOMENDATION OF DIVIDEND & PAY-OUT RATIO:**

The Board of Directors is pleased to recommend 10% cash dividend on paid up Capital for the year ended 30 June 2025 to those share owners whose names were appeared in the Share Register of Members of the Company or in the Depository list of CDBL on the Record Date which is 27 November, 2025 subject to confirmation /approval by shareholder at 43rd AGM. No Stock Dividend was declared during the year.

### **CONTRIBUTION TO THE NATIONAL EXCHEQUER:**

For the year ended 30 June 2025, the company paid/deposited Taka 1693.54 million to the National Exchequer in the form of corporate tax, custom duty and Value Added Tax (VAT) only. This is equivalent to 18.17% of the Company's gross sales revenue for the year 2024-2025.

### **APPOINTMENT AND ELECTION OF DIRECTORS AS PER THE ARTICLES OF ASSOCIATION**

In accordance with the provisions of the Articles of Association of the Company, Mr. A.H.M. Abdullah and Mr. Md. Mahmudul Hasan will retire from the Board of Directors by rotation at the 43rd Annual General Meeting. Both retiring Directors, being eligible, have offered themselves for re-election. The appointment or re-election of Directors will be placed before the shareholders for approval at the 43rd Annual General Meeting.

### **STATUTORY AUDITOR:**

In accordance with statutory requirements, the current Statutory Auditors, M/S. Khan Wahab Shafique Rahman & Co., Chartered Accountants, will retire at the 43rd Annual General Meeting. Having completed their Third-year tenure, they will not eligible for reappointment in compliance with applicable regulations.

Auditors have expressed their willingness to continue as the Statutory Auditors for the financial year 2025–2026. Among them the Audit Committee recommended and the Board of Directors proposes the appointment of MABS & J PARTNERS, Chartered Accountants as the Statutory Auditors of the Company for the year 2025–2026, to hold office until the conclusion of the next Annual General Meeting, at a remuneration of Tk. 3,50,000 (Taka Three Lac Fifty Thousand) only, excluding VAT. The Board seeks approval from the shareholders for this appointment.

### **COMPLIANCE AUDITOR:**

Pursuant to Code 9.2 of the Corporate Governance Code issued by the Bangladesh Securities and Exchange Commission (BSEC), the shareholders at the 42nd Annual General Meeting (AGM) appointed M/S MABS & J Partners, Chartered Accountants, as the Compliance Auditor of the Company for the year 2024–2025 ended on 30 June 2025.

Based on the proposal of the Audit Committee and the recommendation of the Board of Directors, the appointment of M/S MABS & J Partners, Chartered Accountants, as the Compliance Auditor of the Company for the year 2025–2026 will be placed before the shareholders at the 43rd AGM for their approval. The proposed audit fee is Tk. 65,000 (Sixty-Five Thousand) only, excluding VAT.

### **AUDIT COMMITTEE**

The Audit Committee is presently composed of Independent Director Mr. A.M.M. Zeaul Haq, serving as Chairman, alongside Mr. Md. Monwar Hossain, Non-Executive Director, and Mr. A.T.M. Najmul Husain, Non-Executive Director, as members.

The Committee, inter alia, oversees and reviews the Company's internal control framework, evaluates reports submitted by the Internal Auditors, and examines the Key Audit Matters presented by the Statutory Auditors. It also ensures compliance with relevant laws, regulations, and corporate governance requirements. Furthermore, the Audit Committee reviews the audited financial statements prior to their submission to the Board of Directors for approval.

The Audit Committee Report for the year ended 30 June 2025 is presented in Annexure: 05, Page: 21

### **NOMINATION AND REMUNERATION COMMITTEE**

The Nomination and Remuneration Committee currently comprises Mr. A.M.M. Zeaul Haq, Independent Director, serving as Chairman, along with Mr. Md. Monwar Hossain, Non-Executive Director, and Mr. A.T.M. Najmul Husain, Non-Executive Director, as members.

The Committee is responsible for overseeing the nomination process for directors and key executives, as well as reviewing and recommending the remuneration policy in alignment with the Company's corporate governance framework.

The Nomination and Remuneration Committee Report for the year ended 30 June 2025 is presented in Annexure: 06, Page: 29

### **DISCLOSURE FOR SIGNIFICANT DEVIATION:**

#### **Earnings Per Share (EPS):**

Sales volume has been increased by 13.67% as compared with the corresponding period of the previous year, Through Factory and Administration expenses has been decrease, Raw material price increased by 30.96% significantly about Raw material price increased in proportion to sale of the respective year due to volatile international market, devaluation of taka against US Dollar and finance expenses increased due to increase of interest rate of Bank which causes significant deviation in EPS.

#### **Net Operating Cash Flow Per Share (NOCFPS):**

Payment for Raw Materials & administrative, selling and distribution expense including VAT & TAX payment were decreased against the same period of the previous year, Collections from Sales and Trade Debtors were increased more for which NOCFPS has increased significantly.

#### **MANAGEMENT DISCUSSION & ANALYSIS:**

The discussion and analysis duly signed by the Managing Director of the Company presenting, among others, the detailed analysis of the company's operations, financial position, performance, risk and concern, accounting policies & estimation to the financial statements, any changes thereof have been disclosed on page- 23 of annual report.

## CORPORATE GOVERNANCE

Our Company has complied with applicable notifications, directives, guidelines, and instructions issued by the Bangladesh Securities and Exchange Commission (BSEC) relating to Corporate Governance. These measures are rigorously followed to safeguard the interests of shareholders, investors, and regulatory authorities, and to ensure transparency, accountability, and integrity in all aspects of corporate management. The Corporate Governance Compliance Report prepared by M/S MABS & J PARTNERS, Chartered Accountants, along with their certification, has been included on page 25 of this Annual Report. Moreover, Compliance Report as per BSEC notification has been in page- 30 to 39 of this report. Other inclusions in the report are : Curriculum Vitae (CV) of the Directors been recommended by the Board of Directors for appointment of next one year term Page # 06, Report of the Audit Committee Page # 21, Report of the NRC Page # 29, Certificate of CEO and CFO Page # 40, Certificate on Compliance of Corporate Governance Page # 30 to 39 write it for Annual Report Presentation

## EXPLANATION ON QUALIFIED OPINION

Regarding qualified opinion no. 01 we would like to state that The Company would like to clarify that the concerned plants have remained out of operation since 2004. Accordingly, no depreciation has been charged on these assets, in compliance with Paragraph 55 of IAS 16. Charging depreciation on these idle plants would have disproportionately increased the cost of production of other operating units, thereby distorting the cost structure of the running operations. Regarding qualified Opinion 02. We affirm that the Company has been fully compliant with this requirement since 2012. As per BAS 16, Paragraph 82 of the Bangladesh Financial Reporting Standards 2013 (Volume II), the Standard is applicable for annual periods beginning on or after 1 January 2013, with earlier adoption encouraged subject to proper disclosure. The Company has adhered to these provisions in the relevant reporting periods. As against Qualified Opinion 03 the Trust Deed has already been executed, and the disbursement process is currently underway. The Company remains committed to completing all related formalities in a timely manner. Regarding Qualified Opinion 04 our explanation is -in accordance with Section 163, Sub-section (3) (Kha) of the Income Tax Act 2023, minimum tax is not applicable on amounts deducted at the import stage under Section 120 for entities engaged in manufacturing. Since WATA Chemicals Limited imports raw materials solely for its own production, the Company's position is fully compliant with the applicable tax provisions. Regarding Qualified Opinion 05: The amounts received from Directors were duly transacted through proper banking channels as per regulatory guidelines. In a few instances, cash cheques were used solely to facilitate immediate repayment of loans. The Company acknowledges this observation and commits to ensuring full adherence to the prescribed repayment procedures in the future.

## RELATED PARTY TRANSACTIONS

During the year under review, all related party transactions were carried out on an arm's length basis and in the ordinary course of business. Details of such transactions are disclosed in Note 51 of the Notes to the Financial Statements.

The Company confirms that it has not entered into any related party transaction that may pose a potential conflict of interest with the Company. Furthermore, there were no material related party transactions outside the ordinary course of business or not conducted on an arm's length basis, except as disclosed in Note 51 of the Notes to the Financial Statements.

## WE WOULD LIKE TO CONFIRM THAT:

- The financial statements prepared by the management of the issuer company present fairly its state of affairs, the result of its operations, cash flows and changes in equity.
- Proper books of account of the issuer company have been maintained.
- Appropriate accounting policies have been consistently applied in preparation of the financial statements and that the accounting estimates are based on reasonable and prudent judgment.
- International Accounting Standards (IAS) or International Financial Reporting Standards (IFRS) as applicable in Bangladesh have been followed in preparation of the financial statements and any departure there from has been adequately disclosed.
- The system of internal control is sound in design and has been effectively implemented and monitored.
- Minority shareholders have been protected from abusive actions by, or in the interest of, controlling shareholders acting either directly or indirectly and have effective means of redress;
- There are no significant doubts upon the Company's ability to continue as a going concern.
- Significant deviations from last year's operating results of the Company have been highlighted in the report and reasons thereof have been explained.
- Key operating and financial data of preceding five years have been provided on page- 17 in Annexure- 01
- During the year Four Board meetings were held and the attendance by each director is given on page- 17 in Annexure- 01
- The pattern of shareholding is provided on pages- 17 in Annexure- 01
- A management discussion and analysis signed by CEO or MD presenting detailed analysis of the company's position and operations along with brief discussion of changes in the financial statements, is provided on page- 23 to 24
- Declaration or certification by the CEO and the CFO to the Board as required under condition no. 3(3)(c) of Corporate Governance Code; is provided on page- 40
- In accordance with the requirement of the Bangladesh Securities and Exchange Commission, "Compliance of conditions of Corporate Governance Code as required under condition no. 9 " is provided on page- 30
- During the year the company did not pay any remuneration to its Independent Director. Only meeting attendance fees were paid.

## ACKNOWLEDGMENT

In the face of ongoing global and domestic uncertainties, the Board of Directors recognizes that the results achieved during the year may not fully meet the expectations of our esteemed shareholders and stakeholders. Nevertheless, we remain confident that the Company will overcome the prevailing challenges and move toward improved performance in the coming periods.

The Board of Directors of WATA Chemicals Limited extends its sincere appreciation and highest regard to the valued shareholders and stakeholders for their continued trust, support, and guidance, which have been fundamental to the Company's sustained progress. We also express our profound gratitude to the Bangladesh Securities and Exchange Commission (BSEC), Dhaka Stock Exchange (DSE), Chittagong Stock Exchange (CSE), Registrar of Joint Stock Companies and Firms (RJSC), Ministry of Home Affairs, National Board of Revenue (NBR), Central Depository Bangladesh Limited (CDBL), the Offices of the Deputy Commissioners of Narayanganj and Chattogram, Department of Explosives, Department of Environment, Department of Inspection for Factories and Establishments (DIFE), Fire Service and Civil Defence, our banking partners, and all other business associates for their continued cooperation and constructive support.

We place on record our deep appreciation for the dedication and resilience demonstrated by all WATA employees, who have adapted to evolving circumstances while ensuring uninterrupted service to our valued customers and stakeholders. Finally, we extend our heartfelt thanks to our customers, whose continued confidence and partnership remain central to our success.

We reaffirm our commitment to advancing toward a stronger and brighter future and look forward to the continued support of all stakeholders in the financial year 2024–2025 and beyond.

For the Board of Directors of WATA Chemicals Limited.



(Md. Nurul Huda)  
Chairman

## Annexure-1

### KEY OPERATING AND FINANCIAL DATA OF LAST FIVE YEARS:

[FIGURE IN TAKA EXCEPT DIVIDEND]

PARTICULARS	2024-2025	2023-2024	2022-2023	2021-2022	2020-2021
Turnover	931,902,906	819,837,945	1,110,394,363	1,036,043,378	649,079,365
Gross profit	240,763,287	218,896,554	282,663,882	279,137,551	216,830,312
Net Profit Before tax	18,145,944	18,967,671	52,487,194	80,879,845	98,049,177
Net Profit After tax	11,040,592	9,861,014	44,986,626	59,958,120	90,957,313
Paid up Capital	148,226,180	148,226,180	148,226,180	148,226,180	148,226,180
Earnings per share	0.74	0.67	3.03	4.05	6.14
Dividend (%)	10% Cash (Proposed)	12% Cash	15% Cash	General Shareholder 20% cash ,Directors 10% Cash	30% Cash

## Annexure-2

THE NUMBER OF BOARD MEETING HELD ,THE ATTENDENCE BY EACH DIRECTOR DURING THE PERIOD JULY 2024 TO JUNE 2025

NAME OF DIRECTORS	POSITION	NUMBER OF MEETING HELD	NUMBER OF ATTENDANCE
MMr. Md. Anwar Shamim General Manager- I.C.B. (Nominated Director)	Chairman up to 30.04.2025	4	4
Mr. Md. Nurul Huda Deputy Managing Director- I.C.B. (Nominated Director)	Chairman from 30.04.2025	0	0
Mr. Md. Nazrul Islam	Managing Director	4	4
Mr. AMM Zeaul Haq	Independent Director	4	4
Mr. A.H.M. Abdullah	Director	4	4
Mr. Md. Mahmudul Hasan	Director	4	4

## Annexure-3

### SHARE HOLDING PATTERN

NAME	STATUS	SHARES HELD
A) PARENT/SUBSIDIARY/ASSOCIATED COMPANIES AND OTHER RELATED PARTIES	NONE	NONE
<b>B) DIRECTORS,CHIEF EXECUTIVE OFFICER ,NON-EXECUTIVE DIRECTORS</b>		
Mr. Md. Anwar Shamim, (ICB Nominated Director)	Chairman	NIL
Mr. Md. Nazrul Islam	Managing Director	48,04,032
Mr. AMM Zeaul Haq	Independent Director	NIL
Mr. A H M Abdullah, (Son of Mr. Md. Nazrul Islam)	Director	2,96,453
Md. Mahmudul Hasan, (Son of Mr. Md. Nazrul Islam)	Director	2,96,453
ATM Najmul Hussain	Non-Executive Director	NIL
Md. Monwar Hossen	Non-Executive Director	NIL
<b>c) SHAREHOLDERS HOLDING 10% OR MORE :</b>		
Md. Nazrul Islam	48,04,032	
M/S Investment Corporation of Bangladesh (ICB)	39,84,091	

# Annexure-4

## Risk Factors and Management's Perception About the Risks at Wata Chemicals Limited

Most entrepreneurs are risk-takers by nature, or at minimum, calculated visionaries with a clear plan of action to launch products or fill a gap in the industry.

Risks are always associated with investments, and investing in the Company involves inherent risk factors. There are a number of factors, both specific to Wata Chemicals Ltd. (hereinafter referred to as WCL) and of a general nature, which may affect the future operating and financial performance of WCL and the value of an investment in WCL. Some of these factors can be mitigated by the use of safeguards and appropriate risk management actions. However, some are outside the control of WCL and cannot be mitigated.

The objective of WCL's risk management system is to identify, measure, and manage risks, and thereby protect our stakeholders.

Risk and Concern of WATA chemicals Ltd. remains consistently sincere and diligent in identifying key business risks and implementing effective mitigation measures. The Company recognizes that risk monitoring is a continuous process and therefore maintains close oversight of socio-economic conditions, strategic investment policies, product pricing strategies, long-term planning, international trade barriers, and other factors that could adversely affect its business operations.

The information given below does not claim to be exhaustive. Additional risks or uncertainties presently unknown to the Company, or currently considered immaterial, may also have a material adverse effect on WCL's business, financial condition, and operating results. The order in which the risks are presented below is not intended to indicate their likelihood of occurrence or their severity or significance.

### INTEREST RATE RISKS:

Interest rate is always a concern of the management. Higher rate of interest increases costs of fund of a company and consequently its profit is squeezed.

### MANAGEMENT PERCEPTION:

The management of the Company is always aware of interest rate, which is connected to the cost of fund of the Company. The Management prefers procuring long-term fund with minimum fixed interest rate and the short-term fund with reasonable competitive rate. On the other hand management of the Company is emphasizing on equity based financing.

### EXCHANGE RATE RISK:

The company uses raw materials by importing from Asian & European countries. Devaluation of taka has been significantly decreased against dollar and WCL has been suffering due to exchange rate fluctuation in case of import of raw materials.

### MANAGEMENT PERCEPTION:

Appropriate and responsible mechanisms exercised by WCL in the past in case of significant taka devaluation in order to keep the costs minimum and same will be followed in future. However, if the price of US dollar rises so sharply against Taka, this will be a nationwide phenomenon to experience by the whole industrial sector, the company cover such possibilities by adjusting price of its products.

### LIQUIDITY RISKS:

This is the risk that cash may not be available to pay obligations when fall due. The Risk Primarily arise due to the maturity mismatch associated with Assets and liabilities.

### MANAGEMENT PERCEPTION:

The company has regular sale of its products to Govt. Organization/industries and to other in Private Sector. Items have very wide market. Generally Goods are not sold on Credit. As per experience of last 30 years. Products became sold immediately on Production and with good profit margin. After full completion of newly installed plants the project shall become more profitable and sale value shall attain/find at a new dimension.

### MANAGEMENT RISKS:

There may arise Management Risk in the Company which associates ineffectiveness, destructive or underperforming management which may hurts the smooth operation of the company resulting a loss.

### MANAGEMENT PERCEPTION:

WCL has well established management structure with diverse knowledge, skills, experience and expertise in core area of business in its bid to attain optimal utilization of available resources. Company Management is headed by General Manager of ICB. One of its Director is a Graduate in Chemical Engineering from Bangladesh University of Engineering & Technology(BUET). The company has also a well proven track record of having strong and effective leadership which already has shown an effect on the Chemical Business of the country. Under this circumstance management risk is not a concerning factor for the WCL.

### OPERATIONAL RISK:

Operational risk of the company is directly related to performance of Machineries, Power supply, Technical man power, Raw material supply continuity, Natural calamities, Political situation and availability of labor etc.

### MANAGEMENT PERCEPTION:

Management is aware of and maintenance of machineries are has been done regularly. The company has adequate electric & GAS supply arrangement from REB & Titas Gas Transmission & Distribution Company Ltd. Two Gas generators has been setup within thefactory to ensure uninterrupted supply. More powerful Steem Turbine Generator has installed for greater power requirement of plants. The company has sufficient & experienced technical manpower for smooth running of the existing plants and also new plants.

The company maintains excellent relationship with several suppliers is Asian and European countries and continuous supply of rawmaterials can be maintained for the existing and new plants. The company maintain adequate stock of Raw Materials to cover possible risk of supplier's failure to comply with contractual terms of shipment.

CONTINUED



The project is situated on a high land near Dhaka, adjacent to a wide concrete road and all its machineries and stocks of Raw materials, finished products, and spare parts are stored within pucca, wide & strong buildings. During last 32 years of its setup, the company never experienced any loss/damage by natural calamity.

Since we maintain adequate stock of Raw-materials, productions do not become frustrated on political unrest. Referring to marketing- ALUM is sold mainly to Dhaka WASA, Chattogram WASA, Industries under BCIC do not face problem in supply process. Acid and others materials are sold to nearby industries and trade companies. So it has very little risk in supply processes during political unrest.

#### **BUSINESS RISKS:**

Business risk is the possibility that a company will have lower than anticipated profits, or that it will experience a loss rather than a profit. Business risk is influenced by various factors, including business environment, economic situation and Government Regulations.

#### **MANAGEMENT PERCEPTION:**

Business Risk for this company is very minimum for its products are compulsory for the Government Organization ie; Dhaka & Chittagong WASA, Fertilizer Factory under Govt. Control, Power Plant etc. need Aluminium Sulphate and Sulfuric Acid for their Operational Processes. Leather, Textile and other export oriented Industries use our products to meet their requirement in their production process. In agriculture sector sulphate fertilizer uses are growing day by day. So the management find very minimum Risk on it's business.

#### **INDUSTRY RISKS:**

The company mainly produce and sale sulfuric acid. Major consumers of the products of WCL are Fertilizer Factories, leather industry, soap, detergent, battery industry, glue, rubber, paints, dyes, plastics, water treatment plant, paper mill, iron pickling, steel mill, Textiles and its backward linkage industry etc. ETP plants and other chemical & Engineering sectors. There are a huge demand for the product of the Company in the Industrial sectors. Its main product Sulfuric Acid is of toxic character and has effects including water and environmental Pollution.

#### **MANAGEMENT PERCEPTION:**

The Company has internal risk Mitigate system like using the modern equipped Water Treatment Plant (ETP), Air Treatment Plant (ATP) and using of experience technician for hazard identification, risk analysis and risk management. It has ETP and ATP for environment pollution control. Workers and Employees of the factory use appropriate Uniform, Mask, Gloves, shoes etc. for security & safe guard of their life and these are effectively monitored by the management.

#### **MARKET & TECHNOLOGY RELATED RISK & MANAGEMENT PERCEPTION:**

WCL's product is Sulfuric Acid, Aluminium Sulphate, Zinc & Magnesium Sulphate, LABSA & SLES etc. Consumption of sulfuric acid is a main indicator of Industrial development of a country. Its demand is being increased day by day. It has very few competitors in market yet. Aluminium sulphate is the most essential item in Water Purification. Its demand is being increased day by day. It also has very few competitors in market. At rising of production of high yielding variety of all agricultural products, sulphate fertilizer use has also similar rising trend all over the country. Market risk for the product is as good as nil. Political unrest may have a factor on overall market position of the country.

The technology being utilized for its products are the latest standard. It has technical manpower and the company never faced any technological difficulties during life of the plant units. Management always has intention to adopt developed technologies in future and when it is found innovative in productivity.

#### **RISK RELATED TO POTENTIAL OR EXISTING GOVERNMENT REGULATIONS:**

The business activities of WCL is fully controlled by Policies, Rules and Regulations framed by Regulatory Authorities of the Government, Sudden change in Government policies in this regard may impact business operation.

#### **MANAGEMENT PERCEPTION:**

The Company operates under Company's Act-1994, Taxation Policy adopted by NBR, Bangladesh Security And Exchange Commission (BSEC)'s, Dhaka Stock Exchange (DSE), Chittagong Stock Exchange Ltd. (CSE) Rules Regulations adopted by other Regulatory organizations. Any abrupt change of the policies formed by those bodies may impact the business of the Company.

WCL maintain its production and marketing processes in full compliance with Act, Rules, Regulations of the regulatory authorities like Ministry of Home, Department of Explosive ,DC Office of Narayangonj & Chittagong (Licensing Authority) etc;



#### **RISK RELATED TO POTENTIAL CHANGES IN GLOBAL OR NATIONAL POLICIES:**

The performance of the company may be affected by the political and economical instability both in Bangladesh and worldwide. Any instance of political turmoil and disturbance in the country may adversely affect the economy in general. Since our products are of basic and fundamental uses in developing/developed countries, there is very little risk for changes in Global & National Policies.

#### **MANAGEMENT PERCEPTION:**

The company can prosper in a situation of political stability and a congenial business environment. Political turmoil and disturbance have adverse effect on the economy and so also on this sector. This is why WTO and Asian Development Bank emphasize development of chemical sector in chalking out their respective policies. The Company is always aware of all types of turmoil and even though if the smooth supply of raw material is hampered or faces any kind of disruptions, it will try to keep the production smooth. The global and national policies for production of sulfuric acid are favorable since long and at present.

Though the Government has strict monitoring and follow up the retail use of any type of acid due to abusing inhuman way, there is no restriction on production considering the dire necessity of sulfuric acid as raw materials of various local & export oriented industries in Bangladesh. So, the demand of sulfuric acid will increase day by day with the increase of the relevant industries those who are using sulfuric acid.

#### **RISK RELATED TO PANDEMIC SITUATION:**

A pandemic is an epidemic of an infectious disease that has spread across a large region, for instance multiple continents or worldwide, affecting a substantial number of individuals. In a pandemic situation most of the factor are like that

- (1) Supply Chain Disruption
- (2) Interruption of operation
- (3) Effect on consumer demand
- (4) Work related measure
- (5) Market volatility, Credit risk and financial performance

#### **MANAGEMENT PERCEPTION:**

During unavoidable Pandemic situation guideline has been introduced and as such no employee & workers at factory will not be affected. As our basic chemicals used in all WASA, Govt. Enterprise and huge member of local Industries in Bangladesh, So far we have not had to close our Factory. We have continued our production may be at a smaller scale.

#### **SUPPLY RISK:**

WCL is dependent on import for its raw materials. The company imports major raw material i.e Sulphur from Russia and UAE, Saudi Arabia, India. The company maintains import relationship with several suppliers. So, it thinks very minimum supply risk.

Raw materials are imported from different Asian and European countries. Risk has been there for procurement/import of raw materials for Covid 19 pandemic has affected almost all countries around the Globe. Container crisis, ship's unavailability, insufficient feeder vessel, congestion at port of transshipment etc; have been reason for import lots taking much long time from port of loading to reach destination.

#### **MANAGEMENT PERCEPTION:**

Management is aware of the risk and has been importing sufficient quantity so that risk of raw material supply is minimized and production continuation is maintained properly. The risk is being covered by effective supervision, timely purchase and by utilizing experience of the Management.

# AUDIT COMMITTEE REPORT FOR THE YEAR ENDED 30TH JUNE, 2025 TO BOARD OF DIRECTORS OF WATA CHEMICALS LIMITED

Annexure: 05

We, the members of Audit Committee of Wata Chemicals Ltd. have reviewed the Audited Financial Statement as well as performance of the company for the year covering from 1st July, 2024 to 30th June, 2025.

Based on our study and review of draft audited accounts as well as annual performance of company for the year covering from 1st July, 2024 to 30th June, 2025 following facts along with observations and recommendations on the variations, if any, came to our notice are appended in the undernoted paragraphs:

## **SCOPE OF AUDIT:**

We have conducted our audit and review on financial statements for the year from 1st July, 2024 to 30th June, 2025 in line with Generally Accepted Auditing Standards, financial reporting process, accounting policies and principles, internal Audit & compliance plan & process the hiring and performance of external auditors etc; in order to obtain reasonable assurance on the accounts whether financial statements are free of material misstatement.

We have discussed with Managing Director, Head of Accounts and Head of Internal Audit, Statutory auditors in the matter where clarifications were necessary. We have also made check with all relevant records and books of accounts on test basis. Our review work includes assessing of accounting systems and principles used for preparation of financial statements.

## **CONSTITUTION OF AUDIT COMMITTEE:**

The present Audit committee had been constituted as per guidelines issued by BSEC as well as subsequently Corporate Governance Code brought by BSEC with following members:

- (i) Mr. A.M.M. Zeaul Haq, Independent Director and Chairman of Audit Committee, Wata Chemicals Ltd.
- (ii) Mr. Md. Monwar Hossain, Non-Executive Director, Wata Chemicals Ltd. and Member of Audit Committee
- (iii) Mr. A.T.M. Najmul Hussain, Non-Executive Director, Wata Chemicals Ltd. and Member of Audit Committee
- (iv) Mr. Shamsul Huq, Company Secretary, Wata Chemicals Ltd. and Secretary of Audit Committee.

We, the members of Audit Committee met together in a meeting held on 02.11.2025 to review of draft audit report & accounts and performance of company for the period from 1st July, 2024 to 30th June, 2025.

## **ROLE OF AUDIT COMMITTEE:**

The assignments and responsibility of Audit Committee are laid down as under:

- (a) To oversee the financial reporting process and comments on significant deviations, if any, found.;
- (b) To monitor and study the Accounting Policy and Principles as followed by the company;
- (c) To monitor Internal Audit and Compliance process to ensure that it is adequately resourced, including approval of the Internal Audit and Compliance Plan review of the Internal Audit and Compliance Report;
- (d) To oversee performance of external auditors;
- (e) To hold meeting with the external or statutory auditors for review of the Annual Financial Statements before submission to the Board for approval or adoption;
- (f) To review along with the management, the Annual Financial Statements before submission to the Board for approval;
- (g) To review along with the management, the quarterly and half yearly financial statements before submission to the Board for approval;
- (h) To review the adequacy of internal audit function;
- (i) To review the Management's Discussion and Analysis before disclosing in the Annual Report;
- (j) To review statement of all related party transactions submitted by the management;
- (k) To review Management Letters or Letter of Internal Control weakness issued by statutory auditors ;
- (l) To oversee the determination of audit fees based on scope and magnitude, level of expertise deployed and time required for effective audit and evaluate the performance of external auditors; and
- (m) To review and study first quarterly, second quarterly and third quarterly unaudited Financial Statements as well as draft Audit Report and Accounts and submit before the Board alongwith committee's observations and comments on deviations, if any. Discussion with Management should also be held about significant deviations, if any found.

The duties and responsibilities of Audit Committee are clearly set forth in writing by the Board in the Audit Committee's chart of responsibilities. Accordingly audit committee are responsible to the Board of Directors.

## **THE SALIENT ISSUES TO BE COVERED BY AUDIT COMMITTEE'S REPORT:**

The audit committee's report would cover following issues for reporting to the Board of Directors as per BSEC's Guidelines:

- (a) Report on conflict of interest, if any.
- (b) Report on any suspected transactions, fraud or misappropriation of fund, irregularity or material financial impact involved in any transaction, weakness in internal control system.
- (c) To identify the risks, if any, in internal control system and management process.
- (d) To review and study the appointment process of external auditor.
- (e) To review management letter on internal control weakness issued by auditor.
- (f) Deviations, if any, in compliance of company laws, security related laws and other rules and regulations.
- (g) Any other matters involving financial adverse impact to be disclosed in the report for knowledge of Board of Directors.
- (h) To review statement of significant related party transactions, if any.

#### **Committee meetings and attendance**

The Committee held 04 (four) meetings for review of financial statements including among others.

At least one meeting to be held every quarter, in which the Committee reviewed issues relating to business operations, compliance, finance and accounts, among others. The Managing Director & Chief Executive Officer, Chief Financial Officer and Head of Internal Audit and Compliance were permanent invitees to the meeting. Relevant departmental heads and other members of the management also attended the meetings as required. The proceedings of the meetings are properly recorded in minutes and regularly reported to the Board of Directors. All members of Audit Committee were present in all meetings ie; attendance percentage is 100%.

#### **COMMITTEE'S OBSERVATION AND RECOMMENDATIONS :**

The committee has laid down the following observations alongwith recommendations regarding compliance of corporate laws and the Financial Affairs of the Company for the period 2024 - 2025 as under:

- a) Laws and regulations relating to business and internal policies/guidelines should have been carefully complied.
- b) VAT Department had raised claim for amount of Tk. 414.28 lac against which company has filed appeal on payment of 10% of claim amounts (Another demand claimed by Customs Excise & VAT Commissionerate Dhaka by cancelling rebate for Tk. 22,81,103 and imposed fine for Tk. 45,62,206/- as because non-submission of price declaration in time. Against this claim a writ petition has been filed before the Hon'ble High Court Division Hon'ble Justice stayed the order of claim and the writ petition now pending for hearing. No accounted additional liability had been accounted.)


In financial statements for the year ended 30th June, 2025 against which contingent liability have been disclosed in disclosure by the management in accordance with International Accounting Standards (IAS) and International Financial Reporting Standards (IFRS) as adopted by the Institute of Chartered Accountants of Bangladesh.

- c) Appropriate Management Information Systems (MIS) and budgetary control system should be properly introduced and reviewed from time to time.
- d) Physical inventory at end of each financial year have been carried out through inventory committee. Difference, if any, have also be accounted for.
- e) Fixed assets register should be maintained properly.
- f) To mitigate financial risk, management should take effective steps and reviewed from time to time.
- g) Company's staff organogram with responsibility chart should be prepared more effectively and reviewed whether deficit or surplus staff/workers carrying on pay roll.
- h) Management should consider the recommendations of statutory auditor of the company in their respective reports as well as recommendations of audit committee.

The findings and recommendations of the committee are reported to the Board of Directors meeting and the Board of Directors may take appropriate measures thereof. The minutes of all Audit Committee meetings are circulated among head of all concerned department and Managing Director of company.

#### **APPRECIATION:**

We thanks to Managing Director, Directors and all Officers and staff of office and factory who had extended their best co-operation and necessary assistance through necessary papers and data as and when required, to accomplish our assignment.



A.M.M. Zeaul Haq

Independent Director and Chairman of Audit Committee  
Wata Chemicals Ltd.

# Management's Discussion and Analysis

## Overview of the Company

WATA Chemicals Limited is one of the leading basic chemical manufacturing industries in Bangladesh, producing and supplying a diversified range of industrial and laboratory chemicals. The Company continues to prioritize sustainable growth, improved operational efficiency, and adherence to international quality standards. During the Accounting year 2024–2025, the Company remained focused on strengthening its production capacity, minimizing costs, and expanding market reach despite challenges in the international and national present macroeconomic environment.

## Industry and Economic Scenario

During the Accounting year 2024–2025 ended on 30.06.2025, Bangladesh's industrial sector experienced moderate growth driven by export-oriented industries, construction, and pharmaceuticals. The chemical industry faced pricing volatility and supply-chain instability during FY 2024–2025 due to global and local geopolitical tensions. However, the chemical industry basically our manufactured product faced the challenges including:

- Currency fluctuation and rising import cost of raw materials.
- Higher overseas freight, local transportation and utility costs.
- Increased global uncertainty for Russia & Ukraine war, volatile market in Middle East countries and South East Asia affecting supply chain.
- Local political situation.
- Pressure on working capital due to inflationary trends.

Despite these constraints, demand for our industrial chemicals in local markets moderately stable, particularly in battery industries, Fertilizer factory, textile, Dying, garment washing, tanneries, Steel & Rerolling Mills, Gold, Either, glue, gold processing and drinking & industrial water treatment, other chemicals and engineering sectors.

## Operating Performance

The Company maintained stable operational performance supported by efficient production planning and more emphasis on quality control.

### Key operational highlights:

- Continuous improvement initiatives in production units
- Effective raw material management and inventory control
- Expansion of product variety and improved packaging standards
- Strengthening of distribution channels

Production remained consistent compared to the previous year, with a focus on cost reduction and process efficiency.

## Financial Performance

The Company recorded for earning more revenue during the Accounting year 2024–2025, though profitability was influenced by increased raw material and utility costs. Key points:

- Revenue: Increased due to market expansion/price adjustments.
- Gross Profit: Impacted by higher input costs
- Operating Expenses: Managed through cost-control measures
- Net Profit: Influenced by financial expenses, tax expenses, and cost of goods sold.

## Financial Results (BDT) for last five years are as follows:

Particulars	2024-2025	2023-2024	2022-2023	2021-2022	2020-2021
Gross Turnover	931,902,906	819,837,945	1,110,394,363	1,036,043,378	649,079,365
Net Turnover	813,487,372	713,392,353	1,010,976,301	953,804,600	569,812,320
Cost of Goods Sold	-572,724,085	-494,495,799	-728,312,418	-674,667,049	-352,982,008
Gross Profit	240,763,287	218,896,554	282,663,882	279,137,551	216,830,312
Administrative Selling & Distribution Expense	-38,322,490	-45,066,463	-86,867,348	-68,569,557	-47,063,922
Operating Profit	202,440,797	173,830,091	195,796,535	210,567,995	169,766,390
Finance Expense	-187,885,642	-160,704,849	-143,505,161	-129,909,518	-73,734,448
Non-Operating income	4,498,086	6,790,812	2,820,180	4,265,360	6,919,694
Profit before Contribution to WPPF& welfare fund	19,053,241	19,916,055	55,111,554	84,923,837	102,951,636
Contribution to WPPF	-907,297	-948,384	-2,624,360	-4,043,992	-4,902,459
Profit before Tax	18,145,944	18,967,671	52,487,194	80,879,845	98,049,177
Income Tax Expense	-7,105,352	-9,106,657	-7,500,568	-20,921,725	-7,091,864
Profit after Tax	11,040,592	9,861,014	44,986,626	59,958,120	90,957,313

During the year, there was a gross sale of BDT. 93,19,02,906. during 2024-2025 which has been increased by BDT. 11,20,64,961 compare to the year of 2023-2024. Gross profit has been increased in 2024-2025 in compare to with preceding year by BDT 2,18,66,733 but unexpected bank interest increases of Financial Expenses affect negatively in the net profit ratio.

Ratios Analysis of performance table 2024-25 and 2023-24 are described below:

Particulars	2024-2025	2023-2024	Variance
Gross Profit ratio (%)	29.6	30.68	-1.08
Operating profit ratio (%)	24.89	24.37	0.52
Net Profit ratio (%)	1.36	1.38	-0.02
Inventory turnover ratio (days)	29	86.5	-57.5
Debt equity ratio Long Term Debt Equity Ratio	42.76: 57.24	47.15:52.86	-
Current ratio	0.54	0.72	-0.18
Interest coverage ratio (Times)	1.07	1.08	-0.01
Debtors turnover /Trade Receivables turnover ratio (Days)	99	194	-95

## Dividend:

In view of the performance of the company and considering the current liquidity position, the Board of Directors has recommended a cash dividend of 10% per share in the year ended 30 June 2025, to be approved at the ensuing 43nd Annual General Meeting.

With this recommendation of proposed cash dividend, the summary of the dividend in last five years represented below:

**Comparison of financial performance with peer industry:**

WATA Chemicals Limited is the BASIC CHEMICAL MANUFACTURING INDUSTRIES in Bangladesh. Also, the nature of the Chemicals business is different from the other Chemical industries in the capital market and hence it is not possible to compare the financial and cash flow position with peer companies.

Particulars	2024-2025	2023-2024	2022-2023	2021-2022	2020-2021
Profit after Tax	11,040,592	9,861,014	44,986,626	59,958,120	90,957,313
Earnings per Share	0.74	0.67	3.03	4.05	6.14
Cash Dividend %	10% Cash (Proposed)			20% for General Investors	
		12% Cash	15% cash	10% for Sponsors /Directors	30%
Stock Dividend %	-	-	-	-	-

**Finance:**

The gross revenue of the Company was BDT 931,902,906 for the year under review as compared to BDT. 819,837,945 for the year ended 30th June 2024. The Company registered a net profit of BDT. 11,040,592 as compared to net profit of BDT. 9,861,014 for the previous year ended 30th June 2024. For the year ended 30 June 2025, Gross revenue of WATA Chemicals Limited was BDT. 931,902,906 against BDT. 819,837,945 of financial year 2023-2024, resulting 13.67% more revenue over Accounting Year 2023-2024. Raw material price also increased in proportion to sale of the respective year due to volatile international market, devaluation of Bangladeshi taka against US Dollar and finance expenses increased due to increase of interest rate of Bank which causes significant deviation in EPS.

**Cash flow Movement:**

Particulars	2024-2025	2023-2024	2022-2023	2021-2022	2020-2021
Cash Flows from Operating Activities	295,465,055	249,504,125	151,022,336	86,395,426	68,409,867
Cash Flows from Investing Activities	-113,776,902	-27,456,737	-126,343,170	-62,645,356	-111,585,061
Cash Flows from Financing Activities	-183,586,246	-192,742,686	3,866,635	-25,357,927	68,905,756
Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)	-1,898,093	29,304,703	28,545,802	-1,607,857	25,730,562
Effect of movements in exchange rate on cash held	-	-	-33,504,222	-18,641,248	-2,194,524
Opening Cash & Cash Equivalents	35,465,524	6,160,822	11,119,242	31,368,347	7,832,309
Closing Cash & Cash Equivalent at Reporting Date	33,567,431	35,465,524	6,160,822	11,119,242	31,368,348
Net Operating Cash Flow Per Share (NOCFPS) in Taka	19.93	16.83	10.19	5.83	4.62

**Risks and concern issues related to the financial statements:**

The Managing Director and Chief Finance Officer is required to confirm annually that all information relevant to the audit has been provided to the Board of Directors through the Audit Committee and that reasonable steps have been taken to ensure full disclosure in response to requests for information from the external auditor. In addition, The Finance and Accounts Department to fully review account reconciliations on regular and annual basis. The integrity of the Company's public financial reporting is further supported by several processes and steps to provide assurance over the completeness and accuracy of the content including review and recommendation by the Audit Committee and review and approval by the Board. The Company has policies, practices and controls in place in relation to the financial reporting.

WATA Chemicals Limited faces several risks inherent to the chemical industry: Operational Risks like dependence on imported raw materials, Market Risks like fluctuating demand in local industries, Competitive pricing pressure Financial Risks like exchange rate fluctuation, interest rate uncertainty, Regulatory & Compliance Risks like stringent environmental, safety, and compliance requirements, Changes in VAT, tax, and import regulations. The management continuously monitors these risks and implements mitigation strategies.

**Liquidity and Capital Resources**

The Company's liquidity position remained satisfactory. Cash flows from operating activities supported meeting short-term obligations, procurement of raw materials, and financing day-to-day operations. Major observations are: Accounts receivable and inventory management improved, strengthened internal monitoring of cash management processes, no significant long-term borrowing undertaken during the year, Investment in plant maintenance funded through internal resources. The Company has no major overdue liabilities and maintains a strong relationship with financial institutions.

**Corporate Governance & Compliance**

Declaration or Certification by the CEO and the CFO to the Board as required shall be disclosed as per Annexure- 40; and the report as well as certificate regarding compliance of conditions of this Code as required under condition No.9 were disclosed as per Page # 30 & 39 to .....Internal control systems were strengthened, and regular audits were conducted to ensure transparency and accountability

**Human Resources and Safety**

The Company emphasizes employee development, training, and workplace safety. Efforts were taken to: Enhance technical skills of employees, ensure compliance with occupational health and safety standards, Promote a safe, hazard-free work environment

**Future Outlook**

The Company remains cautiously optimistic for the upcoming year. Key strategic priorities include: Increasing production efficiency and cost optimization, expanding market share in local and regional markets, introducing new chemical products based on market demand.

Management have been utilizing best efforts in support and suggestion of the shareholders for strengthening and widening field of production, Capacity Building for the wellbeing of the economy of the country and so for the SLES and LABSA plant has been completed and efforts are being utilized for quick starting commercial production but present volatile market situation we cannot start yet. Our Director Mr. A.H.M Abdullah Graduate in Chemical Engineering from BUET with his team have been utilizing their best efforts for set up more basic chemical plants for more contribution to the economy of the country as well as for WATA chemicals Ltd.

Management expects that with stable economic conditions and strategic execution, WATA Chemicals Limited will achieve sustainable growth in FY 2025–2026.



(Md. Nazrul Islam)  
Managing Director

# CORPORATE GOVERNANCE

Corporate Governance is the procedure of directing & controlling listed companies by its Management in the best interest of all stakeholders to ensure greater transparency, better and timely financial reporting. Board of Directors is responsible for proper Governance in setting out company's strategic aims, providing appropriate leadership in implementing aims, supervising business Management and reporting to the shareholder.

WATA CHEMICALS LTD (later on mentioned as 'WCL') is committed to continuous reviewing all Corporate Governance policies and practices to ensure transparency of the company's business and to deliver high standards and quality information to stakeholders.

Maintenance of effective corporate governance remains a key priority of the Board of WCL. To exercise clarity about Directors' responsibilities towards the shareholders, Corporate Governance must be dynamic and remain focused on the business objectives of the Company and create a culture of openness and accountability. Keeping this in mind, clear structure and accountabilities supported by well understood policies and procedures to guide the activities of the Company's Management have been instituted.

## STATEMENTS OF COMPLIANCE:

As WCL is listed on the Stock Exchanges in Bangladesh provision contain with BSEC's notification on Corporate Governance (BSEC/CMRRC-D/2006-158/207/Admin/80, Dated: 03 June, 2018) and subsequent amendment are being complied with.

## CORPORATE GOVERNANCE FRAMEWORK:

### ROLE OF THE BOARD:

The Directors of the Board are appointed by the Shareholders at the Annual General Meeting (AGM) and accountable to the Shareholders. The Board is responsible for ensuring that the business activities are soundly administered and effectively controlled. The Directors of the Board keep themselves informed about the Company's financial position and ensure that its activities, accounts and asset management are subject to adequate control.

In addition to the other legal guidelines, the Board has also adopted "Governance Guidelines" for the Board for ensuring better Governance. The Code on Corporate Governance of the company sets out the principles and best practices to be applied by the company in its operations towards achieving the optimal governance framework.

The Board of Directors is responsible for protecting the rights and interests of all shareholders and also accountable for the overall Management of the entity. Besides its usual legal and statutory responsibilities, the Board is responsible for the following:

- Reviewing and adopting a strategic plan for the company;
- Overseeing the conduct of the company's business to evaluate whether the business is being properly managed;
- Identifying principal risks and ensuring the implementation of appropriate systems to manage these risks;
- Succession planning, including appointing, training, fixing the compensation and where appropriate, replacing senior management;
- Developing and implementing an investor relations program or shareholder communications policy for the company;
- Reviewing the adequacy and the integrity of the company's internal control systems and management information systems, including systems for compliance.
- Approving the financial statements and accounting policies of the company;
- Approving changes in the policy;
- Recommending dividend for declaration in AGM;
- Establishing committees, including the Audit Committee, Nomination & Remuneration Committee and the Compensation Committee and determining the authorities to be delegated to committees of the Board;
- Receiving and reviewing reports from committees of the Board;
- Establishing and monitoring compliance with the company's standards of business conduct and other policies of the company;
- Establishing appropriate systems of corporate Governance in the company;
- Considering and approving other relevant matters.
- Constantly guide and assist the company in external stakeholder management.

### BOARD COMPOSITION:

At present the Board in WCL is comprised of 5 Directors. The post of Chairman and Managing Director are filled by two different Directors. Managing Director acts as Chief Executive Officer. The Board of Directors define respective roles responsibilities of the Chairman, Managing Director and Independent Director.

### THE NAME OF THE BOARD OF DIRECTORS:

01.	Mr. Md. Nurul Huda Deputy Managing Director- I.C.B.	Chairman (Director- Nominated by I.C.B)
02.	Mr. Md. Nazrul Islam	Managing Director
03.	Mr. A.M.M Zeaul Haq	Independent Director
04.	Mr. Md. A.H.M. Abdullah	Director
05.	Mr. Md. Mahmudul Hasan	Director

### BOARD MEETINGS:

The meetings of the Board of Directors of WCL are normally held at the Registered Head Office of the Company. The meetings are held at least once in a quarter, to discharge its responsibilities and functions as mentioned above. Meeting is scheduled well in advance and the notice of each Board meeting is given in writing to each Director.

The WCL Board meeting 4 times during the period from July 2024 to June 2025 and took decisions on key matters.

The details of Board Meeting and attendance are given in Annexure- 01 of annual report.

The Board is reconstituted every year at its Annual General Meeting by the rotation and reelection of one-third of the directors in order to meet the requirements of the Companies Act 1994 and the Articles of Association of the Company. Directors are liable to comply with the provisions of the Companies Act 1994, the rules of the Articles of Association of the Company, the Rules & Regulations of the Bangladesh Securities and Exchange Commission, and the listing regulations of the stock exchanges. **Role & Responsibilities** The main role of the Board of Directors, which is the highest level of authority, is to provide general superintendence, oversee the operations, and control the affairs of the company through appropriate delegation and accountability processes via the lines of command. However, the Board of Directors holds the ultimate responsibility and accountability with due diligence for conducting the activities of the company as per provisions of the law in the interest of the shareholders, the stakeholders, the state, and society.

The Board of Directors, in fulfillment of its responsibility, holds periodic meetings, at least once a quarter, and provides appropriate decisions/directions to the Executive Management. Such meetings usually consider operational performance, financial results, review of budgets, capital expenditure proposals for BMRE or new projects/divisions/ product lines, procurement of funds by issue of shares or borrowing, procurement of raw materials, plant & machinery, pricing of products/discounts, recruitment, training, and promotion of officers, approval of audited accounts and distribution of dividends and other interest of the stakeholders including the employees and workers. The Board of Directors takes special care in designing and articulating productivity and compensation plans for employees and workers and rewarding them appropriately on the basis of quality and quantity of performance as an incentive. The Board also remains responsible for the removal of operational hazards to the life and health of workers, friendly environmental work conditions, and social relationships as demanded of good citizens in a country.

#### **ELECT AND RE-ELECT OF DIRECTORS**

As per the Articles of Association of the company, one-third of the Directors to retire in every year shall be those who have been longest in office since their last election.

#### **INDEPENDENT DIRECTOR**

Appointment of Mr. A.M.M Zeaul Haq, Ex-General manager of BDBL as Independent Director of WATA Chemicals Limited for One tenure confirmed by 42th Shareholder meeting will be held on 26.12.2024. Short profile of Independent Director published in the Annual Report of 2024-2025.

#### **DIVISION OF WORK FOR THE BOARD AND MANAGING DIRECTOR**

The roles of the Board and Managing Director are separate and delegation of responsibilities is clearly established set out in writing and agreed by the Board to ensure transparency and better corporate governance. To that end, WCL has also adopted "Governance Guidelines for Managing Director". The Managing Director is the authoritative head for day to-day management. He acts as Chief Executive Officer of WCL to ensure that WCL operates business as per the Articles of Association, decisions made by the Board and Shareholders and according to WCL Policies, Procedures and relevant regulatory legislations.

#### **ROLE OF THE CHAIRMAN:**

The Chairman leads the Board indetermination of its strategy and achievement of its objectives. The Chairman is responsible for organizing the business of the Board, ensuring its effectiveness and setting its agenda. The Chairman is also responsible for ensuring that the Directors receive accurate, timely and clear information. The Chairman has no engagement in the day-to-day business of the Company. The Chairman facilitates the effective contribution of Independent Directors and ensures that constructive relations exist amongst the Directors. Minutes of Board meeting are signed by the Chairman.

#### **RESPONSIBILITIES:**

The responsibilities of Chairman include, among others, the following:

- Attend and preside over the meetings of the Board of Directors
- Ensure that the members of the Board actively participate in the discussions and voice their opinions to make effective decisions
- Ensure that the meeting agendas are properly discussed and decisions are harmoniously taken by the Board, as well as help assuage discord and resolve disagreements when necessary
- Ensure that the Board of Directors performs well, achieves the objectives of the company, and discharges its responsibilities to the various stakeholders
- Support and guide the Managing Director in discharging his responsibilities properly and smoothly
- Ensure that Board Committees are properly formed, and that they discharge their functions adequately.

#### **ROLE OF THE MANAGING DIRECTOR & CEO:**

The Managing Director & CEO is responsible for running the business and for formulating and implementing Board strategy and policy. He exercises overall control of the Company on a day-to-day basis and is accountable to the Board for the financial and operational performance of the Company. The managing Director is the visionary, guide and key decision maker of the company.

#### **RESPONSIBILITIES:**

The Managing Director has the following responsibilities:

- Set goals for the company, formulate policies and guidelines, lead and empower the company's key management to achieve these goals
- Present to the Board various plans, projects, and strategies, as well as arrange funding for the implementation of various plans
- Ensure that proper recruitment takes place through effective human resource planning
- Maintain a convivial working environment, discipline, and team spirit in the organization
- Maintain effective dialogue between the company and its stakeholders
- Effectively control costs, reduce wastage, and improve efficiency at all levels in order to fulfill the objectives of the company
- Promote and maintain management succession and development plans
- Identify various risks for the company and develop strategies to overcome those risks
- Ensure that performance is consistent and is recognized
- Ensure that the obligations of the company to its various stakeholders and to the society at large are fulfilled.

#### **ROLE OF COMPANY SECRETARY**

To ensure effective integration and timely flow of information required by the Board and to maintain necessary liaison with internal resources as well as external agencies, the Board has appointed a Company Secretary. The Corporate Governance Guidelines issued by the Bangladesh Securities and Exchange Commission (BSEC) also require a listed company to appoint a full fledged Company Secretary, as distinct from other managers of the Company. In pursuance of the same, the Board of Directors has appointed Company Secretary and defined his following roles & responsibilities:

Assist the members of the Board under the Companies Act, BSEC & Stock Exchange requirements.

Acts as a channel of communication and information

Ensures that the Board's decisions are properly implemented and communicated by assisting in the implementation of corporate strategies and policies.

Ensures proper compliance with all relevant statutory and regulatory requirements.

Communicates with the stakeholders of the company

In addition he attends all Board Meetings and presents and reviews all quarterly and periodical results.

#### **ROLE OF CHIEF FINANCIAL OFFICER:**

The chief financial officer (CFO) is the officer of the company that has primary responsibility for managing the company's finances, including financial planning, management of financial risks, record-keeping, and financial reporting. In some sectors, the CFO is also responsible for analysis of data.

#### **ROLE OF CHIEF FINANCIAL OFFICER:**

The chief financial officer (CFO) is the officer of the company that has primary responsibility for managing the company's finances, including financial planning, management of financial risks, record-keeping, and financial reporting. In some sectors, the CFO is also responsible for analysis of data.

The CFO is a senior manager with the primary role of overseeing the management of the company's finances and financial activities, including financial risk management, financial planning, financial reporting, recordkeeping, and analysis of data. The chief financial officer usually reports to the CEO, as well as the board of directors and to Shareholder. They may also seat on the board. They are the head of the company's finance personnel and are also the key financial spokesperson. They normally support on both tactical and strategic matters concerning cost-benefit analysis, securing of new funding, forecasting needs, and budget management.

The CFO is in charge of the financial support of the corporate strategy, meaning they ensure that sufficient cash is available to cover strategic needs and alleviate risk.

The CFO also plays an important liaison role, since they build relationships with lenders, banks, investors, regulators, and other financial institutions.

#### **ROLE OF THE HEAD OF INTERNAL CONTROL & COMPLIANCE:**

The Head of Internal Control is responsible for reporting to the Board Audit Committee regarding any deviation from accounting and internal control systems of the Company. He is also responsible for ensuring regulatory compliance of the Company.

#### **PRICE SENSITIVE INFORMATION:**

The Board of WCL through the Company Secretary always ensures it's any or all price sensitive information by Fax and or email within 30 minutes of the decision or immediately upon getting such information to the BSEC and the Stock Exchanges and to other concerned. In special cases by publishing the same in two widely circulated daily newspapers, one in Bangla and the other in English and upload PSI in Companies Website.

#### **DISCLOSURE ON THE PERFORMANCE AND PROSPECT OF THE COMPANY:**

WCL attaches high priority on timely publication of quarterly, Quarterly and annual report as per regulatory requirements. Price Sensitive Information is released to the regulators within half an hour of the decision. The Financial Statements are prepared in accordance with IAS and IFRS and other applicable laws.

#### **DIVIDEND POLICY:**

The Board of Directors has a Dividend Policy which is based on company's performance and company's objectives.

#### **BOARD COMMITTEES:**

##### **AUDIT COMMITTEE:**

The Board of Directors has constituted an Audit Committee of the Board Consisting of three Non-Executive Directors, At present The Audit Committee headed by the Independent Director, Mr. A.M.M Zeaul Haq, Non-Executive Director and Mr. Md. Monwar Hossain, Non Executive Director and Mr. A.T.M. Najmul Hussain, Non Executive Director. The Audit Committee carries out its responsibilities as per the provisions of law and submits its report to the Board of Directors from time to time. The Audit Committee shall also Co-Ordinate with the Internal and External Auditor's as and when required. The Audit Committee also ensures compliance of requirements of BSEC and others agencies. Mr. Shamsul Huq Company Secretary has been working as Secretary of the Audit Committee.

##### **NOMINATION AND REMUNERATION COMMITTEE:**

At present Nomination and Remuneration Committee (NRC) Comprising of three members namely Mr. A.M.M Zeaul Haq, Independent Director and Mr. Md. Monwar Hossain, Non Executive Director and Mr. A.T.M. Najmul Hussain, Non Executive Director. Independent Director is the Chairman of NRC. NRC committee carries out its responsibilities as per provision of BSEC Notification.

##### **A. Purpose**

- (i) The objective of the Nomination and Remuneration Committee ("NRC") is to assist the Board of WATA CHEMICALS LIMITED in formulation of the nomination criteria or policy for determining qualifications, positive attributes, experiences and independence of directors and top level executive as well as a policy for formal process of considering remuneration of directors, top level executives;
- (ii) The Committee shall ensure that the Board and Executive Committee's retain an appropriate structure, size and balance of skills to support the strategic objectives and values of the company.

##### **B. Constitution**

- (i) The Committee shall comprise of at least three members including an independent director;
- (ii) All members of the Committee shall be non-executive directors;
- (iii) Members of the Committee shall be nominated and appointed by the Board;
- (iv) The Board of Wata Chemicals Limited shall have authority to remove and appoint any member of the Committee;
- (v) In case of death, resignation, disqualification, or removal of any member of the Committee or in any other cases of vacancies, the board shall fill the vacancy within 90 (Ninety) days of occurring such vacancy in the Committee;
- (vi) The Chairperson of the Committee may appoint or co-opt any external expert and/or member(s) of staff to the Committee as advisor who shall be non-voting member, if the Chairperson feels that advice or suggestion from such external expert and/or member(s) of staff shall be required or valuable for the Committee;
- (vii) The Committee shall have delegated authority from the Board in respect of the functions and powers set out in these Terms of Reference;
- (viii) The Committee shall have the authority to investigate any matter within its Terms of Reference and to obtain such information as it may require for such investigation.

- C. Chairperson**
  - (i) The Board shall select 1 (one) member of the NRC to be Chairperson of the Committee, who shall be an independent director;
  - (ii) In the absence of the Chairperson of the NRC, the remaining members may elect one of themselves as Chairperson for that particular meeting, the reason of absence of the regular Chairperson shall be duly recorded in the minutes;
  - (iii) The Chairperson of the NRC shall attend the annual general meeting (AGM) to answer the queries of the shareholders: Provided that in absence of Chairperson of the NRC, any other member from the NRC shall be selected to be present in the annual general meeting (AGM) for answering the shareholder's queries and reason for absence of the Chairperson of the NRC shall be recorded in the minutes of the AGM.
- D. Secretary**
  - (i) The company secretary shall act as the secretary of the Committee;
- E. Frequency of Meetings**
  - (i) The NRC shall conduct at least one meeting in a financial year;
  - (ii) The Chairperson of the NRC may convene any emergency meeting upon request by any member of the NRC.
- F. Quorum**
  - (i) The quorum of the meeting of the NRC shall be constituted in presence of either two members or two third of the members of the Committee, whichever is higher;
  - (ii) The quorum of the NRC meeting shall not constitute without attendance of at least one independent director.
  - (iii) A duly convened meeting of the Committee at which a quorum is present shall be competent to exercise all or any of the authorities, powers and discretions vested in or exercisable by the Committee.
- F. Proceedings of Meetings**
  - (i) The proceedings of each meeting of the NRC shall duly be recorded in the minutes and such minutes shall be confirmed in the next meeting of the NRC;
  - (ii) The Secretary shall minute the proceedings and resolutions of all committee meetings, including the names of those present and in attendance and shall circulate the minutes of meetings of the Committee to all members of the Committee.
  - (iii) All the observations/ findings/ recommendations of the Committee shall be recorded in the minutes of meetings of the Committee.
  - (iv) Minutes of the Committee's meetings shall be kept by the secretary of the committee;
- G. Remuneration / Fees**
  - (i) No member of the NRC shall receive, either directly or indirectly, any remuneration for any advisory or consultancy role or otherwise, other than meeting fees or honorarium from the company.
- H. Role & Major Responsibilities of NRC are as under:**
  - (i) Recommend a policy on Board's diversity taking into consideration age, gender, experience, education and nationality;
  - (ii) Formulate the criteria for determining qualification and independence of Directors;
  - (iii) Identify persons who are qualified to become Directors and in top level executives and recommend their appointment and removal;
  - (iv) Formulate the criteria for evaluation of performance of Independent Directors and the Board;
  - (v) Recommend a policy to the Board relating to the Selection, Appointment, Remuneration of the Directors, and top level executives;
  - (vi) Assess that the level and composition of remuneration is reasonable and sufficient to attract, retain and motivate suitable Directors to run the company successfully;
  - (vii) Evaluate that remuneration to Directors and top level executives involves a balance between fixed and incentive pay reflecting short and long-term performance objectives appropriate to the working of the company and its goals;
  - (viii) Identify the company's needs for employees at different levels and determine their selection, transfer or replacement and promotion criteria;
  - (ix) Recommend and review annually the Company's human resources and training policies;
  - (x) Recommend the remuneration policy of the Company, particularly in relation to the yearly increment principle; and
  - (xi) Recommend the Code of Conduct for the Chair of the Board, other Board Members and Chief Executive Officer of the Company.
- I. REPORTING**
  - (i) NRC shall be independent and responsible or accountable to the Board and to the shareholders;
  - (ii) The company shall disclose the nomination and remuneration policy and the evaluation criteria and activities of NRC during the year at a glance in its annual report;
  - (iii) Minutes of each Committee meeting will be disclosed at the next meeting of the Board unless there are privacy and confidentiality reasons that prevent disclosure beyond the members of the Committee;
  - (iv) Periodically the Chairperson of the Committee shall report to the Board on matters within its roles and responsibilities.
- J. REVIEW OF THE TERMS OF REFERENCE**
  - (i) The Committee shall review annually its Terms of Reference and may recommend to the Board any amendments to its Terms of Reference.
  - (ii) The Board shall have the authority to make amendment to this Terms of Reference at any time.

**EXTERNAL /STATUTORY AUDITORS:**

M/S. KHAN WAHAB SHAFIQUE RAHMAN & CO., Chartered Accountants is the External /Statutory Auditors of the company. They carry out systematic examination of books & records and ascertain, verify and report upon the facts regarding the financial operation and results of the company maintaining compliance of the BSEC Notification.

**CORPORATE GOVERNANCE COMPLIANCE AUDITORS:**

The Compliance Auditor is responsible in certification on Compliance of Conditions of Corporate Governance Code 2018 of Bangladesh Securities and Exchange Commission as well as the provisions of relevant Bangladesh Secretarial Standards of Institute of Chartered Secretaries of Bangladesh.

M/S. MABS & J PARTNERS, Chartered Accounts is the Corporate Governance Compliance Auditor of WATA CHEMICALS LIMITED for the year ended on 30.06.2025.

**SUBSIDIARY COMPANY:**

WCL do not have any subsidiary or Associate or Parent company.

**WEBSITE:**

WATA chemicals Limited maintains a functional official website [www.watachemical.com](http://www.watachemical.com) linked with the websites of the Stock Exchanges. The required disclosures are made available on the website.

## **REPORT OF THE NOMINATION & REMUNERATION COMMITTEE- 2024-2025 OF WATA CHEMICALS LTD.**

Date: 02 November 2025

The Board of Directors  
WATA Chemicals Limited  
17/B, Monipuripara Sangshad Avenue  
Dhaka-1215.

Dear Sirs,

We, the following members of Nomination and Remuneration Committee (NRC) of WATA Chemicals Limited take pleasure in presenting our Report for the year ended on 30 June 2025:

### **Members of NRC:**

Mr. A.M.M Zeaul Haq, Independent Director - Chairperson  
Mr. Md. Monwar Hossain, Non-Executive Director- Member  
Mr. ATM Najmul Husain, Non-Executive Director- Member  
Mr. Shamsul Huq Secretary also acts as Secretary of the Committee.

(NRC) comprising 1 Independent Directors and 2 non-executive Director. The Independent Director is the Chairperson of NRC. The Board of Directors have formulated the detailed guidelines for NRC comprising the responsibilities of NRC to the Board, authority of the Board over constitution of NRC, functioning and remuneration criteria of NRC, terms of reference or role of NRC, guidelines for meeting of NRC, etc. Besides other routine functions, the NRC determined and recommended the Codes of Conduct i.e. the Roles and Responsibilities of Chairman of the Board, all other Board members and Managing Director of WATA Chemicals Limited and submitted those to the Board of Directors of the company which have accordingly been approved by the Board for implementation.

Nomination and Remuneration Committee arranged One meeting in FY 2024-2025 to review the determining qualifications, positive attributes, Independence and others for recommendation of Appointment of Non-Executive Director. Necessary advice, guidelines and recommendation were provided by NRC so that the company run properly.

Thanking you,



A.M.M Zeaul Haq Independent Director &  
Chairperson Nomination and Remuneration Committee

**Report to the Shareholders of WATA Chemicals Limited  
on compliance on the Corporate Governance Code  
[Certificate as per condition No. 1(5)(xxvii)]**

We have examined the compliance status to the Corporate Governance Code by WATA Chemicals Limited for the year ended on 30 June 2025. This Code relates to the Notification No. BSEC/CMRRC-D/2006-158/207/Admin/80, dated 03 June 2018 and BSEC/CMRRC/2009-193/66/PRD/148, dated 16 October 2023 of the Bangladesh Securities and Exchange Commission.

Such compliance with the Corporate Governance Code is the responsibility of the Company. Our examination was limited to the procedures and implementation thereof as adopted by the Management in ensuring compliance to the conditions of the Corporate Governance Code.

This is a scrutiny and verification and an independent audit on compliance of the conditions of the Corporate Governance Code as well as the provisions of relevant Bangladesh Secretarial Standards (BSS) as adopted by Institute of Chartered Secretaries of Bangladesh (ICSB) in so far as those standards are not inconsistent with any condition of this Corporate Governance Code.

We state that we have obtained all the information and explanations, which we have required, and after due scrutiny and verification thereof, we report that, in our opinion:

- (a) The Company has complied with the conditions of the Corporate Governance Code as stipulated in the above-mentioned Corporate Governance Code issued by the Commission; except condition no. 1(2)(a), 5(2)(a), 5(2)(b), 6(2)(a) & 6(2)(b).
- (b) The Company has complied with the provisions of the relevant Bangladesh Secretarial Standards (BSS) as adopted by the Institute of Chartered Secretaries of Bangladesh (ICSB) as required by this code;
- (c) Proper books and records have been kept by the company as required under the Companies Act, 1994, the securities laws and other relevant laws; and
- (d) The Governance of the company is satisfactory except the abovementioned opinion para(a).



Masud Alam Chowdhury, ACA  
Partner  
MABS & J Partners  
Chartered Accountants

Place: Dhaka  
Dated: 03 December 2025

Corporate Office:  
SMC Tower (Level 5 & 7) 33, Banani C/A  
Road 17, Dhaka- 1213, Bangladesh  
Phone : +880-2-222275057-58  
: +880-2-222275365-66  
E-mail : [info@mabsj.com](mailto:info@mabsj.com)  
Web : [www.mabsj.com](http://www.mabsj.com), [www.nexia.com](http://www.nexia.com)

Chattogram Office:  
Jahan Building 5 (Level 3),  
74 Agrabad C/A, Chattogram- 4100, Bangladesh  
Phone : +88-01722-156260  
E-mail : [info@mabsj.com](mailto:info@mabsj.com)  
Web : [www.mabsj.com](http://www.mabsj.com), [www.nexia.com](http://www.nexia.com)

Member firm of Nexia International, UK

**WATA CHEMICALS LIMITED**  
**CORPORATE GOVERNANCE COMPLIANCE STATUS**  
**[AS PER CONDITION NO. 1(5)(XXVII)]**

Status of compliance with the conditions imposed by the Commission's Notification No. SEC/CMR-RCD /2006-158/207/Admin/80 dated 3 June 2018 and BSEC/CMRRC/2009- 193/66/PRD/148 dated 16 October 2023 issued under section 2CC of the Securities and Exchange Ordinance, 1969 (XVII of 1969):

(REPORT UNDER CONDITION NO. 9)

Condition No.	Title	Compliance Status (Put ✓ in the appropriate column)		Remarks (if any)
		Complied	Not Complied	
<b>1.0</b>	<b>Board of Directors</b>			
1(1)	<b>Size of the Board of Directors:</b> The total number of members of a company's Board of Directors (hereinafter referred to as "Board") shall not be less than 5 (five) and more than 20 (twenty).	✓		The Board is comprised of 5 (five) Directors
<b>1.2</b>	<b>Independent Directors:</b>			
1(2)(a)	At least 2 (two) directors or one-fifth (1/5) of the total number of directors in the company's Board, whichever is higher, shall be independent directors; any fraction shall be considered to the next integer or whole number for calculating number of independent director(s);		✓	There is 1 (one) Independent Director (ID) out of total 5 (five) Directors.
1(2)(b)(i)	Without contravention of any provision of any other laws, for the purpose of this clause, an "independent director" means a director- who either does not hold any share in the company or holds less than one percent (1%) shares of the total paid-up shares of the company;	✓		A Declaration was received from IDs in this regard.
1(2)(b)(ii)	who is not a sponsor of the company or is not connected with the company's any sponsor or director or nominated director or shareholder of the company or any of its associates, sister concerns, subsidiaries and parents or holding entities who holds one percent (1%) or more shares of the total paid-up shares of the company on the basis of family relationship and his or her family members also shall not hold above mentioned shares in the company: Provided that spouse, son, daughter, father, mother, brother, sister, son-in-law and daughter-in-law shall be considered as family members;	✓		Do
1(2)(b)(iii)	who has not been an executive of the company in immediately preceding 2 (two) financial years;	✓		Do
1(2)(b)(iv)	who does not have any other relationship, whether pecuniary or otherwise, with the company or its subsidiary or associated companies;	✓		Do
1(2)(b)(v)	who is not a member or TREC (Trading Right Entitlement Certificate) holder, director or officer of any stock exchange;	✓		Do
1(2)(b)(vi)	who is not a shareholder, director excepting independent director or officer of any member or TREC holder of stock exchange or an intermediary of the capital market;	✓		Do
1(2)(b)(vii)	who is not a partner or an executive or was not a partner or an executive during the preceding 3 (three) years of the concerned company's statutory audit firm or audit firm engaged in internal audit services or audit firm conducting special audit or professional certifying compliance of this Code;	✓		Do
1(2)(b)(viii)	who is not independent director in more than 5 (five) listed companies;	✓		Do
1(2)(b)(ix)	who has not been reported as a defaulter in the latest Credit Information Bureau (CIB) report of Bangladesh Bank for nonpayment of any loan or advance or obligation to a bank or a financial institution; and"	✓		Do
1(2)(b)(x)	who has not been convicted for a criminal offence involving moral turpitude;	✓		Do
1(2)(c)	The independent director(s) shall be appointed by the Board and approved by the shareholders in the Annual General Meeting (AGM): Provided that the Board shall appoint the independent director, subject to prior consent of the Commission, after due consideration of recommendation of the Nomination and Remuneration Committee (NRC) of the company;	✓		In Practice
1(2)(d)	The post of independent director(s) cannot remain vacant for more than 90 (ninety) days; and	✓		No such vacancy occurred in the reporting period
1(2)(e)	The tenure of office of an independent director shall be for a period of 3 (three) years, which may be extended for 1 (one) tenure only: Provided that a former independent director may be considered for reappointment for another tenure after a time gap of one tenure, i.e., three years from his or her completion of consecutive two tenures [i.e. six years]: Provided further that the independent director shall not be subject to retirement by rotation as per Companies Act, 1994.	✓		

Condition No.	Title	Compliance Status (Put ✓ in the appropriate column)		Remarks (if any)
		Complied	Not Complied	
<b>1.3</b>	<b>Qualification of Independent Director.</b>			
1(3)(a)	Independent director shall be a knowledgeable individual with integrity who is able to ensure compliance with financial laws, regulatory requirements and corporate laws and can make meaningful contribution to the business;	✓		The qualifications and background of IDs rationalize their abilities
1(3)(b)(i)	Independent director shall have following qualifications: Business Leader who is or was a promoter or director of an unlisted company having minimum paid-up capital of Tk.100.00 million or any listed company or a member of any national or international chamber of commerce or registered business association; or			Not Applicable
1(3)(b)(ii)	Corporate Leader who is or was a top level executive not lower than Chief Executive Officer or Managing Director or Deputy Managing Director or Chief Financial Officer or Head of Finance or Accounts or Company Secretary or Head of Internal Audit and Compliance or Head of Legal Service or a candidate with equivalent position of an unlisted company having minimum paid-up capital of Tk. 100.00 million or of a listed company; or			Not Applicable
1(3)(b)(iii)	Former or existing official of government or statutory or autonomous or regulatory body in the position not below 5th Grade of the national pay scale, who has at least educational background of bachelor degree in economics or commerce or business or Law: Provided that in case of appointment of existing official as independent director, it requires clearance from the organization where he or she is in service; or"	✓		
1(3)(b)(iv)	University Teacher who has educational background in Economics or Commerce or Business Studies or Law; or			Not Applicable
1(3)(b)(v)	Professional who is or was an advocate practicing at least in the High Court Division of Bangladesh Supreme Court or a Chartered Accountant or Cost and Management Accountant or Chartered Financial Analyst or Chartered Certified Accountant or Certified Public Accountant or Chartered Management Accountant or Chartered Secretary or equivalent qualification;			Not Applicable
1(3)(c)	The independent director shall have at least 10 (ten) years of experiences in any field mentioned in clause (b);	✓		
1(3)(d)	In special cases, the above qualifications or experiences may be relaxed subject to prior approval of the Commission.			No such approval required
<b>1.4</b>	<b>Duality of Chairperson of the Board of Directors and Managing Director or Chief Executive Officer.</b>			
1(4)(a)	The positions of the Chairperson of the Board and the Managing Director (MD) and/or Chief Executive Officer (CEO) of the company shall be filled by different individuals;	✓		
1(4)(b)	The Managing Director (MD) and/or Chief Executive Officer (CEO) of a listed company shall not hold the same position in another listed company;	✓		
1(4)(c)	The Chairperson of the Board shall be elected from among the non- executive directors of the company;	✓		
1(4)(d)	The Board shall clearly define respective roles and responsibilities of the Chairperson and the Managing Director and/or Chief Executive Officer;	✓		The Board clearly defined roles and responsibilities of the Chairperson and the MD.
1(4)(e)	In the absence of the Chairperson of the Board, the remaining members may elect one of themselves from nonexecutive directors as Chairperson for that particular Board's meeting; the reason of absence of the regular Chairperson shall be duly recorded in the minutes.			No such incidence arose in the reporting period
<b>1.5</b>	<b>The Directors' Report to Shareholders</b>			
1(5)(i)	The Board of the company shall include the following additional statements or disclosures in the Directors' Report prepared under section 184 of the Companies Act, 1994 (Act No. XVIII of 1994): An industry outlook and possible future developments in the industry;	✓		Included in Directors' Report.
1(5)(ii)	The segment-wise or product-wise performance;	✓		Do
1(5)(iii)	Risks and concerns including internal and external risk factors, threat to sustainability and negative impact on environment, if any;	✓		Do
1(5)(iv)	A discussion on Cost of Goods sold, Gross Profit Margin and Net Profit Margin, where applicable;	✓		Do
1(5)(v)	A discussion on continuity of any extraordinary activities and their implications (gain or loss);	✓		Do
1(5)(vi)	A detailed discussion on related party transactions along with a statement showing amount, nature of related party, nature of transactions and basis of transactions of all related party transactions;	✓		Do
1(5)(vii)	A statement of utilization of proceeds raised through public issues, rights issues and/or any other instruments;			Not Applicable
1(5)(viii)	An explanation if the financial results deteriorate after the company goes for Initial Public Offering (IPO), Repeat Public Offering (RPO), Rights Share Offer, Direct Listing, etc.;			Not Applicable

Condition No.	Title	Compliance Status (Put ✓ in the appropriate column)		Remarks (if any)
		Complied	Not Complied	
1(5)(ix)	An explanation on any significant variance that occurs between Quarterly Financial performances and Annual Financial Statements;	✓		Significance Variance, If any, were explained.
1(5)(x)	A statement of remuneration paid to the directors including independent directors;	✓		Included in Directors' Report and Audited Financial Statements.
1(5)(xi)	A statement that the financial statements prepared by the management of the issuer company present fairly its state of affairs, the result of its operations, cash flows and changes in equity;	✓		Do
1(5)(xii)	A statement that proper books of account of the issuer company have been maintained;	✓		Do
1(5)(xiii)	A statement that appropriate accounting policies have been consistently applied in preparation of the financial statements and that the accounting estimates are based on reasonable and prudent judgment;	✓		Do
1(5)(xiv)	A statement that International Accounting Standards (IAS) or International Financial Reporting Standards (IFRS), as applicable in Bangladesh, have been followed in preparation of the financial statements and any departure there from has been adequately disclosed;	✓		Do
1(5)(xv)	A statement that the system of internal control is sound in design and has been effectively implemented and monitored;	✓		Do
1(5)(xvi)	A statement that minority shareholders have been protected from abusive actions by, or in the interest of, controlling shareholders acting either directly or indirectly and have effective means of redress;	✓		Do
1(5)(xvii)	A statement that there is no significant doubt upon the issuer company's ability to continue as a going concern, if the issuer company is not considered to be a going concern, the fact along with reasons there of shall be disclosed;	✓		Do
1(5)(xviii)	An explanation that significant deviations from the last year's operating results of the issuer company shall be highlighted and the reasons thereof shall be explained;	✓		Do
1(5)(xix)	A statement where key operating and financial data of at least preceding 5 (five) years shall be summarized;	✓		Included in Directors' Report
1(5)(xx)	An explanation on the reasons if the issuer company has not declared dividend (cash or stock) for the year;			Not Applicable. (Board of Directors has recommended 10% cash dividend)
1(5)(xxi)	Board's statement to the effect that no bonus share or stock dividend has been or shall be declared as interim dividend;	✓		Included in the Directors' Report.
1(5)(xxii)	The total number of Board meetings held during the year and attendance by each director;	✓		4 (four) meetings held during the year 2024-2025
1.5(xxiii)(a)	A report on the pattern of shareholding disclosing the aggregate number of shares (along with name-wise details where stated below) held by: Parent or Subsidiary or Associated Companies and other related parties (name-wise details);	✓		Included in the Directors' Report.
1.5(xxiii)(b)	Directors, Chief Executive Officer, Company Secretary, Chief Financial Officer, Head of Internal Audit and Compliance and their spouses and minor children (name-wise details);	✓		Do
1.5(xxiii)(c)	Executives; and	✓		Do
1(5)(xxiii)(d)	Shareholders holding ten percent (10%) or more voting interest in the company (name-wise details);	✓		Do
1(5)(xxiv)(a)	In case of the appointment or reappointment of a director, a disclosure on the following information to the shareholders: A brief resume of the director;	✓		Presented on Board of Directors' Biography section in Annual Report.
1(5)(xxiv)(b)	Nature of his or her expertise in specific functional areas; and	✓		Do
1(5)(xxiv)(c)	Names of companies in which the person also holds the directorship and the membership of committees of the Board;	✓		Do
1(5)(xxv)(a)	A Management's Discussion and Analysis signed by CEO or MD presenting detailed analysis of the company's position and operations along with a brief discussion of changes in the financial statements, among others, focusing on: Accounting policies and estimation for preparation of financial statements;	✓		Included in the Annual Report.
1(5)(xxv)(b)	Changes in accounting policies and estimation, if any, clearly describing the effect on financial performance or results and financial position as well as cash flows in absolute figure for such changes;	✓		Do

Condition No.	Title	Compliance Status (Put ✓ in the appropriate column)		Remarks (if any)
		Complied	Not Complied	
1(5)(xxv)(c)	Comparative analysis (including effects of inflation) of financial performance or results and financial position as well as cash flows for current financial year with immediate preceding five years explaining reasons thereof;	✓		Do
1(5)(xxv)(d)	Compare such financial performance or results and financial position as well as cash flows with the peer industry scenario;	✓		Not Applicable
1(5)(xxv)(e)	Briefly explain the financial and economic scenario of the country and the globe;	✓		Included in the Director's Report
1(5)(xxv)(f)	Risks and concerns issues related to the financial statements, explaining such risk and concerns mitigation plan of the company; and	✓		Do
1(5)(xxv)(g)	Future plan or projection or forecast for company's operation, performance and financial position, with justification thereof, i.e., actual position shall be explained to the shareholders in the next AGM;	✓		Do
1(5)(xxvi)	Declaration or certification by the CEO and the CFO to the Board as required under condition No. 3(3) shall be disclosed as per Annexure-A;	✓		Included in the Annual Report
1(5)(xxvii)	The report as well as certificate regarding compliance of conditions of this Code as required under condition No. 9 shall be disclosed as per Annexure-B and Annexure-C; and	✓		Included in the Annual Report
1(5)(xxviii)	The Directors' report to the shareholders does not require to include the business strategy or technical specification related to products or services, which have business confidentiality.	✓		Do
1(6)	Meetings of the Board of Directors: The company shall conduct its Board meetings and record the minutes of the meetings as well as keep required books and records in line with the provisions of the relevant Bangladesh Secretarial Standards (BSS) as adopted by the Institute of Chartered Secretaries of Bangladesh (ICSB) in so far as those standards are not inconsistent with any condition of this Code.	✓		In Practice
<b>1.7</b>	<b>Code of Conduct for the Chairperson, other Board members and Chief Executive Officer</b>			
1(7)(a)	The Board shall lay down a code of conduct, based on the recommendation of the Nomination and Remuneration Committee (NRC) at condition No. 6, for the Chairperson of the Board, other board members and Chief Executive Officer of the company;	✓		
1(7)(b)	The code of conduct as determined by the NRC shall be posted on the website of the company including, among others, prudent conduct and behavior; confidentiality; conflict of interest; compliance with laws, rules and regulations; prohibition of insider trading; relationship with environment, employees, customers and suppliers; and independency.	✓		
<b>2.0</b>	<b>Governance of Board of Directors of Subsidiary Company</b>			
2(a)	Provisions relating to the composition of the Board of the holding company shall be made applicable to the composition of the Board of the subsidiary company;			Not Applicable
2(b)	At least 1 (one) independent director on the Board of the holding company shall be a director on the Board of the subsidiary company;			Not Applicable
2(c)	The minutes of the Board meeting of the subsidiary company shall be placed for review at the following Board meeting of the holding company;			Not Applicable
2(d)	The minutes of the respective Board meeting of the holding company shall state that they have reviewed the affairs of the subsidiary company also;			Not Applicable
2(e)	The Audit Committee of the holding company shall also review the financial statements, in particular the investments made by the subsidiary company.			Not Applicable
<b>3.0</b>	<b>Managing Director (MD) or Chief Executive Officer (CEO), Chief Financial Officer (CFO), Head of Internal Audit and Compliance (HIAC) and Company Secretary (CS).</b>			
3(1)(a)	Appointment: The Board shall appoint a Managing Director (MD) or Chief Executive Officer (CEO), a Company Secretary (CS), a Chief Financial Officer (CFO) and a Head of Internal Audit and Compliance (HIAC);	✓		In Practice
3(1)(b)	The positions of the Managing Director (MD) or Chief Executive Officer (CEO), Company Secretary (CS), Chief Financial Officer (CFO) and Head of Internal Audit and Compliance (HIAC) shall be filled by different individuals;	✓		

Condition No.	Title	Compliance Status (Put ✓ in the appropriate column)		Remarks (if any)
		Complied	Not Complied	
3(1)(c)	The MD or CEO, CS, CFO and HIAC of a listed company shall not hold any executive position in any other company at the same time: Provided that CFO or CS of any listed company may be appointed for the same position in any other listed or non-listed company under the same group for reduction of cost or for technical expertise, with prior approval of the Commission: Provided further that the remuneration and perquisites of the said CFO or CS shall be shared by appointing companies proportionately;	✓		
3(1)(d)	The Board shall clearly define respective roles, responsibilities and duties of the CFO, the HIAC and the CS;	✓		The Board clearly defined roles and responsibilities of the CFO, the HIAC and the CS.
3(1)(e)	The MD or CEO, CS, CFO and HIAC shall not be removed from their position without approval of the Board as well as immediate dissemination to the Commission and stock exchange(s).			No such incidence arose in the reporting Period
3(2)	Requirement to attend Board of Directors' Meetings: The MD or CEO, CS, CFO and HIAC of the company shall attend the meetings of the Board: Provided that the CS, CFO and/or the HIAC shall not attend such part of a meeting of the Board which involves consideration of an agenda item relating to their personal matters.	✓		In Practice
<b>3.3</b>	<b>Duties of Managing Director (MD) or Chief Executive Officer (CEO) and Chief Financial Officer (CFO)</b>			
3(3)(a)(i)	The MD or CEO and CFO shall certify to the Board that they have reviewed financial statements for the year and that to the best of their knowledge and belief: These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading; and	✓		
3(3)(a)(ii)	These statements together present a true and fair view of the company's affairs and are in compliance with existing accounting standards and applicable laws;	✓		
3(3)(b)	The MD or CEO and CFO shall also certify that there are, to the best of knowledge and belief, no transactions entered into by the company during the year which are fraudulent, illegal or in violation of the code of conduct for the company's Board or its members;	✓		
3(3)(c)	The certification of the MD or CEO and CFO shall be disclosed in the Annual Report.	✓		
<b>4.0</b>	<b>Board of Directors' Committee.</b>			
4(i)	For ensuring good governance in the company, the Board shall have at least following sub-committees: Audit Committee; and	✓		The committee comprises 1 (one) BSEC's pre-approved ID as a Board member and 2(two) Board appointed Non-Executive but not yet applied for BSEC approval, which is under process.
4(ii)	Nomination and Remuneration Committee.	✓		Do
<b>5.0</b>	<b>Audit Committee</b>			
5(1)(a)	Responsibility to the Board of Directors: The company shall have an Audit Committee as a sub-committee of the Board;	✓		In Practice
5(1)(b)	The Audit Committee shall assist the Board in ensuring that the financial statements reflect true and fair view of the state of affairs of the company and in ensuring a good monitoring system within the business;	✓		Do
5(1)(c)	The Audit Committee shall be responsible to the Board; the duties of the Audit Committee shall be clearly set forth in writing.	✓		Do
5(2)(a)	<b>Constitution of the Audit Committee:</b> The Audit Committee shall be composed of at least 3 (three) members;		✓	The Committee comprises 1(One) BSEC's Pre-approved ID as a Board Member. 1(one) Independent Director and 2(Two) Non-Executive Director appointed by Board but not yet applied for BSEC approval, which is under process.

Condition No.	Title	Compliance Status (Put ✓ in the appropriate column)		Remarks (if any)
		Complied	Not Complied	
5(2)(b)	The Board shall appoint members of the Audit Committee who shall be non-executive directors of the company excepting Chairperson of the Board and shall include at least 1 (one) independent director;		✓	Do
5(2)(c)	All members of the audit committee should be "financially literate" and at least 1 (one) member shall have accounting or related financial management background and 10 (ten) years of such experience;	✓		Do
5(2)(d)	When the term of service of any Committee member expires or there is any circumstance causing any Committee member to be unable to hold office before expiration of the term of service, thus making the number of the Committee members to be lower than the prescribed number of 3 (three) persons, the Board shall appoint the new Committee member to fill up the vacancy immediately or not later than 60 (sixty) days from the date of vacancy in the Committee to ensure continuity of the performance of work of the Audit Committee;			No such vacancy arose in the reporting Period
5(2)(e)	The company secretary shall act as the secretary of the Committee;	✓		In Practice
5(2)(f)	The quorum of the Audit Committee meeting shall not constitute without at least 1 (one) independent director.	✓		In Practice
5(3)(a)	Chairperson of the Audit Committee: The Board shall select 1 (one) member of the Audit Committee to be Chairperson of the Audit Committee, who shall be an independent director;	✓		Do
5(3)(b)	In the absence of the Chairperson of the Audit Committee, the remaining members may elect one of themselves as Chairperson for that particular meeting, in that case there shall be no problem of constituting a quorum as required under condition No. 5(4)(b) and the reason of absence of the regular Chairperson shall be duly recorded in the minutes.			Do
5(3)(c)	Chairperson of the Audit Committee shall remain present in the Annual General Meeting (AGM): Provided that in absence of Chairperson of the Audit Committee, any other member from the Audit Committee shall be selected to be present in the annual general meeting (AGM) and reason for absence of the Chairperson of the Audit Committee shall be recorded in the minutes of the AGM.	✓		Do
5(4)(a)	Meeting of the Audit Committee: The Audit Committee shall conduct at least its four meetings in a financial year: Provided that any emergency meeting in addition to regular meeting may be convened at the request of any one of the members of the Committee;	✓		Do
5(4)(b)	The quorum of the meeting of the Audit Committee shall be constituted in presence of either two members or two-third of the members of the Audit Committee, whichever is higher, where presence of an independent director is a must.	✓		Do
5(5)(a)	Role of Audit Committee The Audit Committee shall: Oversee the financial reporting process;	✓		Do
5(5)(b)	Monitor choice of accounting policies and principles;	✓		Do
5(5)(c)	Monitor Internal Audit and Compliance process to ensure that it is adequately resourced, including approval of the Internal Audit and Compliance Plan and review of the Internal Audit and Compliance Report;	✓		Do
5(5)(d)	Oversee hiring and performance of external auditors;	✓		Do
5(5)(e)	Hold meeting with the external or statutory auditors for review of the annual financial statements before submission to the Board for approval or adoption;	✓		Do
5(5)(f)	Review along with the management, the annual financial statements before submission to the Board for approval;	✓		Do
5(5)(g)	Review along with the management, the quarterly and half yearly financial statements before submission to the Board for approval;	✓		Do
5(5)(h)	Review the adequacy of internal audit function;	✓		Do
5(5)(i)	Review the Management's Discussion and Analysis before disclosing in the Annual Report;	✓		Do
5(5)(j)	Review statement of all related party transactions submitted by the management;	✓		Do
5(5)(k)	Review Management Letters or Letter of Internal Control weakness issued by statutory auditors;	✓		Do

Condition No.	Title	Compliance Status (Put ✓ in the appropriate column)		Remarks (if any)
		Complied	Not Complied	
5(5)(l)	Oversee the determination of audit fees based on scope and magnitude, level of expertise deployed and time required for effective audit and evaluate the performance of external auditors; And	✓		Do
5(5)(m)	Oversee whether the proceeds raised through Initial Public Offering (IPO) or Repeat Public Offering (RPO) or Rights Share Offer have been utilized as per the purposes stated in relevant offer document or prospectus approved by the Commission: Provided that the management shall disclose to the Audit Committee about the uses or applications of the proceeds by major category (capital expenditure, sales and marketing expenses, working capital, etc.), on a quarterly basis, as a part of their quarterly declaration of financial results: Provided further that on an annual basis, the company shall prepare a statement of the proceeds utilized for the purposes other than those stated in the offer document or prospectus for publication in the Annual Report along with the comments of the Audit Committee.			Do
<b>5.6</b>	<b>Reporting of the Audit Committee</b>			
5(6)(a)(i)	Reporting to the Board of Directors: The Audit Committee shall report on its activities to the Board;	✓		Do
5(6)(a)(ii)(a)	The Audit Committee shall immediately report to the Board on the following findings, if any: Report on conflicts of interests;			Do
5(6)(a)(ii)(b)	Suspected or presumed fraud or irregularity or material defect identified in the internal audit and compliance process or in the financial statements;	✓		Do
5(6)(a)(ii)(c)	Suspected infringement of laws, regulatory compliances including securities related laws, rules and regulations; and	✓		Do
5(6)(a)(ii)(d)	Any other matter which the Audit Committee deems necessary shall be disclosed to the Board immediately;	✓		Do
5(6)(b)	<b>Reporting to the Authorities:</b> If the Audit Committee has reported to the Board about anything which has material impact on the financial condition and results of operation and has discussed with the Board and the management that any rectification is necessary and if the Audit Committee finds that such rectification has been unreasonably ignored, the Audit Committee shall report such finding to the Commission, upon reporting of such matters to the Board for three times or completion of a period of 6 (six) months from the date of first reporting to the Board, whichever is earlier.	✓		Do
5(7)	Reporting to the Shareholders and General Investors: Report on activities carried out by the Audit Committee, including any report made to the Board under condition No. 5(6)(a)(ii) above during the year, shall be signed by the Chairperson of the Audit Committee and disclosed in the annual report of the issuer company.	✓		Do
<b>6.0</b>	<b>Nomination and Remuneration Committee (NRC)</b>			
6(1)(a)	<b>Responsibility to the Board of Directors:</b> The company shall have a Nomination and Remuneration Committee (NRC) as a sub-committee of the Board;	✓		The Committee comprises 1(One) BSEC's Pre-approved ID as a Board Member. 1(one) Independent Director and 2(Two) Non-Executive Director appointed by Board but not yet applied for BSEC approval, which is under process.
6(1)(b)	The NRC shall assist the Board in formulation of the nomination criteria or policy for determining qualifications, positive attributes, experiences and independence of directors and top level executive as well as a policy for formal process of considering remuneration of directors, top level executive;	✓		Do
6(1)(c)	The Terms of Reference (ToR) of the NRC shall be clearly set forth in writing covering the areas stated at the condition No. 6(5) (b).	✓		DO

Condition No.	Title	Compliance Status (Put ✓ in the appropriate column)		Remarks (if any)
		Complied	Not Complied	
6(2)(a)	<b>Constitution of the NRC:</b> The Committee shall comprise of at least three members including an independent director;		✓	The Committee comprises 1(One) BSEC's Pre-approved ID as a Board Member. 1(one) Independent Director and 2(Two) Non-Executive Director appointed by Board but not yet applied for BSEC approval, which is under process.
6(2)(b)	At least 02 (two) members of the Committee shall be non-executive directors;		✓	Do
6(2)(c)	Members of the Committee shall be nominated and appointed by the Board;	✓		Do
6(2)(d)	The Board shall have authority to remove and appoint any member of the Committee;	✓		Do
6(2)(e)	In case of death, resignation, disqualification, or removal of any member of the Committee or in any other cases of vacancies, the board shall fill the vacancy within 180 (one hundred eighty) days of occurring such vacancy in the Committee;			No such vacancy arose in the reporting period
6(2)(f)	The Chairperson of the Committee may appoint or co-opt any external expert and/or member(s) of staff to the Committee as advisor who shall be non-voting member, if the Chairperson feels that advice or suggestion from such external expert and/or member(s) of staff shall be required or valuable for the Committee;			No such appointment/ co-opt required in the reporting period
6(2)(g)	The company secretary shall act as the secretary of the Committee;	✓		In Practice
6(2)(h)	The quorum of the NRC meeting shall not constitute without attendance of at least an independent director;	✓		Do
6(2)(i)	No member of the NRC shall receive, either directly or indirectly, any remuneration for any advisory or consultancy role or otherwise, other than Director's fees or honorarium from the company.	✓		Do
6(3)(a)	Chairperson of the NRC: The Board shall select 1 (one) member of the NRC to be Chairperson of the Committee, who shall be an independent director;	✓		Chairperson of the NRC is an Independent Director
6(3)(b)	In the absence of the Chairperson of the NRC, the remaining members may elect one of themselves as Chairperson for that particular meeting, the reason of absence of the regular Chairperson shall be duly recorded in the minutes;			No such incidence arose in the reporting period
6(3)(c)	The Chairperson of the NRC shall attend the annual general meeting (AGM) to answer the queries of the shareholders: Provided that in absence of Chairperson of the NRC, any other member from the NRC shall be selected to be present in the annual general meeting (AGM) for answering the shareholder's queries and reason for absence of the Chairperson of the NRC shall be recorded in the minutes of the AGM.	✓		The Chairperson of the NRC attended at the 42th AGM held on 26 December 2024
6(4)(a)	Meeting of the NRC: The NRC shall conduct at least one meeting in a financial year;	✓		There were 1 (One) meetings held during the reporting period
6(4)(b)	The Chairperson of the NRC may convene any emergency meeting upon request by any member of the NRC;			No such incidence arose in the reporting period
6(4)(c)	The quorum of the meeting of the NRC shall be constituted in presence of either two members or two third of the members of the Committee, whichever is higher, where presence of an independent director is must as required under condition No. 6(2)(h);	✓		In Practice
6(4)(d)	The proceedings of each meeting of the NRC shall duly be recorded in the minutes and such minutes shall be confirmed in the next meeting of the NRC.	✓		Do
6(5)(a)	<b>Role of the NRC:</b> NRC shall be independent and responsible or accountable to the Board and to the Shareholders	✓		Do
6(5)(b)(i)(a)	Formulating the criteria for determining qualifications, positive attributes and independence of a director and recommend a policy to the Board, relating to the remuneration of the directors, top level executive, considering the following: The level and composition of remuneration is reasonable and sufficient to attract, retain and motivate suitable directors to run the company successfully;	✓		Do
6(5)(b)(i)(b)	The relationship of remuneration to performance is clear and meets appropriate performance benchmarks; and	✓		Do

Condition No.	Title	Compliance Status (Put ✓ in the appropriate column)		Remarks (if any)
		Complied	Not Complied	
6(5)(b)(i)(c)	Remuneration to directors, top level executive involves a balance between fixed and incentive pay reflecting short and long-term performance objectives appropriate to the working of the company and its goals;	✓		Do
6(5)(b)(ii)	Devising a policy on Board's diversity taking into consideration age, gender, experience, ethnicity, educational background and nationality;	✓		Do
6(5)(b)(iii)	Identifying persons who are qualified to become directors and who may be appointed in top level executive position in accordance with the criteria laid down, and recommend their appointment and removal to the Board;	✓		Do
6(5)(b)(iv)	Formulating the criteria for evaluation of performance of independent directors and the Board;	✓		Do
6(5)(b)(v)	Identifying the company's needs for employees at different levels and determine their selection, transfer or replacement and promotion criteria; and	✓		Do
6(5)(b)(vi)	Developing, recommending and reviewing annually the company's human resources and training policies;	✓		Do
6(5)(c)	The company shall disclose the nomination and remuneration policy and the evaluation criteria and activities of NRC during the year at a glance in its annual report.	✓		Disclosed in the NRC Report annexed to the Annual Report
<b>7.0</b>	<b>External or Statutory Auditors</b>			
7(1)(i)	The issuer company shall not engage its external or statutory auditors to perform the following services of the company, namely:- Appraisal or valuation services or fairness opinions;	✓		During the reporting period, the Company did not engage its statutory auditors to perform as such
7(1)(ii)	Financial information systems design and implementation;	✓		Do
7(1)(iii)	Book-keeping or other services related to the accounting records or financial statements;	✓		Do
7(1)(iv)	Broker-dealer services;	✓		Do
7(1)(v)	Actuarial services;	✓		Do
7(1)(vi)	Internal audit services or special audit services;	✓		Do
7(1)(vii)	Any service that the Audit Committee determines;	✓		Do
7(1)(viii)	Audit or certification services on compliance of corporate governance; and	✓		Do
7(1)(ix)	Any other service that creates conflict of interest.	✓		Do
7(2)	No partner or employees of the external audit firms shall possess any share of the company they audit at least during the tenure of their audit assignment of that company; his or her family members also shall not hold any shares in the said company: Provided that spouse, son, daughter, father, mother, brother, sister, son-in-law and daughter-in-law shall be considered as family members.	✓		As declared by the statutory auditors
7(3)	Representative of external or statutory auditors shall remain present in the Shareholders' Meeting (Annual General Meeting or Extraordinary General Meeting) to answer the queries of the shareholders.	✓		Representative of statutory auditors attended at the 42th AGM held on 26 December 2024.
<b>8.0</b>	<b>Maintaining a website by the Company.</b>			
8(1)	The company shall have an official website linked with the website of the stock exchange.	✓		In Practice
8(2)	The company shall keep the website functional from the date of listing.	✓		In Practice
8(3)	The company shall make available the detailed disclosures on its website as required under the listing regulations of the concerned stock exchange(s).	✓		In Practice
<b>9.0</b>	<b>Reporting and Compliance of Corporate Governance.</b>			
9(1)	The company shall obtain a certificate from a practicing Professional Accountant or Secretary (Chartered Accountant or Cost and Management Accountant or Chartered Secretary) other than its statutory auditors or audit firm on yearly basis regarding compliance of conditions of Corporate Governance Code of the Commission and shall such certificate shall be disclosed in the Annual Report.	✓		The Company obtained the certificate from MABS & J Partners, Chartered Accountants and such certificate is presented in this Annual Report
9(2)	The professional who will provide the certificate on compliance of this Corporate Governance Code shall be appointed by the shareholders in the annual general meeting.	✓		In Practice
9(3)	The directors of the company shall state, in accordance with the Annexure-C attached, in the directors' report whether the company has complied with these conditions or not.	✓		



## WATA CHEMICALS LIMITED Declaration by CEO and CFO TO THE BOARD

Date: 06 November, 2025

The Board of Directors,  
WATA Chemicals Limited  
Registered Office: 17/B, Monipuripara,  
Sangshad Avenue, Dhaka-1215.

Subject: Declaration on Financial Statements for the year ended on 30 June 2025.

Dear Sirs,

Pursuant to the condition No.1 (5)(xxvi) imposed vide the Commission's Notification No. BSEC/CMRRC-D/2006-158/207/Admin/80 Dated 3 June 2018 under section 2CC of the Securities and Exchange Ordinance, 1969, we do hereby declare that:

- 1) The Financial Statements of WATA Chemicals Limited for the year ended on 30 June 2025 have been prepared in compliance with International Accounting Standards (IAS) or International Financial Reporting Standards (IFRS), as applicable in Bangladesh and any departure therefrom has been adequately disclosed;
- 2) The estimates and judgments related to the financial statements were made on a prudent and reasonable basis, in order for the financial statements to reveal a true and fair view;
- 3) The form and substance of transactions and the Company's state of affairs have been reasonably and fairly presented in its financial statements;
- 4) To ensure above, the Company has taken proper and adequate care in installing a system of internal control and maintenance of accounting records;
- 5) Our internal auditors have conducted periodic audits to provide reasonable assurance that the established policies and procedures of the Company were consistently followed; and
- 6) The management's use of the going concern basis of accounting in preparing the financial statements is appropriate and there exists no material uncertainty related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. In this regard, we also certify that: -
  - (i) We have reviewed the financial statements for the year ended on 30 June 2025 and that to the best of our knowledge and belief:
    - (a) These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
    - (b) These statements collectively present a true and fair view of the Company's affairs and are in compliance with existing accounting standards and applicable laws.
  - (ii) There are, to the best of knowledge and belief, no transaction entered into by the Company during the year which is fraudulent, illegal or in violation of the code of conduct for the company's Board of Directors or its members.

Sincerely yours,

(MD. NAZRUL ISLAM)  
Chief Executive Officer (CEO)

(MD. ALI AHSAN)  
Chief Financial Officer (CFO)

# CONTENTS OF AUDIT REPORT AUDITOR'S AND FINANCIAL STATEMENTS

42-46

AUDITOR'S REPORT

48

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

50

STATEMENT OF CASH FLOWS

47

STATEMENT OF CHANGES IN EQUITY

49

NOTES AND SCHEDULES

51-103





## INDEPENDENT AUDITOR'S REPORT

### TO THE SHARE HOLDERS OF WATA CHEMICALS LIMITED

#### REPORT ON THE AUDIT OF THE FINANCIAL STATEMENTS

##### QUALIFIED OPINION

We have audited the accompanying financial statements of WATA Chemicals Limited (the Company), which comprise the statement of financial position as at 30 June 2025, and statement of Profit or Loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, except for the effects of the matters described in the Basis for Qualified Opinion section of our report, the accompanying financial statements present fairly, in all material respects, the financial position of WATA Chemicals Limited as at 30 June 2025, and of its financial performance and its cash flows for the year then ended in accordance with International Financial Reporting Standards (IFRSs), the Companies Act 1994, the Securities and Exchange Rules 2020 as amended up to date and other applicable laws and regulations.

##### BASIS FOR QUALIFIED OPINION

1. No depreciation was charged on LABSA plant and BCP plant. The management reported that these plants are not in use since 2008. According to IAS 16 (paragraph 55), a company should not cease the depreciation when the assets become idle or is retired from active use unless the asset is fully depreciated. As a result, depreciation was undercharged by Tk. 4,415,006 for this year.
2. The company has revalued its Plant & Machinery and Factory Building in 2008 but has not transferred depreciation on revaluation from Revaluation reserves to Retained earnings for 04 (four) years from 2008 to 2011. As such consistency was not maintained as per paragraph 34 of IAS 16 "Property, Plant & Equipment". Therefore, retained earnings has been understated and Revaluation reserve has been overstated to the same extent. Moreover, the company has not maintained fixed asset register properly.
3. The company has utilized the Workers Profit Participation Fund (WPPF) as an internal source of financing but has neglected to provide interest for such usage, contravening section 240(3) of the Labor Act 2006, as amended in 2013. Notably, an amount of Tk. 48,597,905 has been categorized under "Workers Profit Participation Fund" as a current liability, without any corresponding disbursement as employees' benefits to the workers, although the company has executed Trust Deeds for the same. This discrepancy points to a transgression of the provisions outlined in the Labor Act 2006, section 242(1), as amended in 2013.
4. While checking current tax provision we found that the provision was not calculated properly which leads to shortfall of provision.
5. During the year the company has received BDT 107,950,000 from its directors as loan using Banking Channel to repay Company's bank loan liability and subsequently repaid BDT 210,165,336 to them. While checking we observed that substantial part of amount of repayments were made using cash cheques.

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) together with the ethical requirements that are relevant to our audit of the financial statements in jurisdictions, and we have fulfilled our other ethical responsibilities in accordance with these requirements and with the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion.

**HEAD OFFICE:** RUPALI BIMA BHABAN, 7, RAJUK AVENUE (5TH & 6TH FLOOR), MOTIJHEEL, DHAKA-1000. **TEL:** 47122785, 223385136, 47122824

**Fax:** 880-2-47122824, **E-mail:** info@kwsrbd.com, kwsr@dhaka.net, **Web:** www.kwsrbd.com

**BRANCH OFFICE:** FARUK CHAMBER (9TH FLOOR), 1403 SK. MUJIB ROAD, AGRABAD C/A, DOUBLE MOORING, CHITTAGONG, BANGLADESH.

**Tel:** 02-333320056, **E-mail:** kwsrctg@gmail.com

**EMPHASIS OF MATTERS**

We draw attention to the following:

- a. Note 32.00, "Earnings Per Share," within the financial statements elucidates the rationale behind the slight increase in Earnings Per Share (EPS) from BDT 0.67 (2023-24) in the preceding year to BDT 0.74 (2024-25) in the current year. In addition, as indicated in Note 41.00, there is a noteworthy increase in Net Operating Cash Flow Per Share (NOCFPS), rising from BDT 16.83 to BDT 19.93, mainly due to higher collection of sales and accounts receivables than payments.
- b. Note 50.00, "Contingent Liabilities," found in the notes accompanying the financial statements. It discloses that the Commissioner of Customs Excise and VAT Directorate has raised a claim of Tk. 41,427,896 against the company due to a VAT audit objection. Subsequently, the company has lodged an appeal with the Appellate Tribunal following the payment of Tk. 4,142,790, equivalent to 10% of the claimed amount. As of now, the appeal remains pending in the Appellate Tribunal. Another demand claimed by Customs Excise & Vat Commissionerate, Dhaka by cancelling rebate for Tk. 22,81,103 and imposed fine for Tk. 45,62,206/- as because non-submission of price declaration in time. Against this claim a writ petition has been filed on payment of Tk. 456,220 before the Hon'ble High Court Division. Hon'ble Justice stayed the order of claim and the writ petition now pending for hearing.
- c. Note 6.00, "Trade Receivables," where the company has disclosed that the impact of expected credit loss, in accordance with IFRS 9, has not been reflected in the financial statements.
- d. In accordance with Section 99 of the Labor Act 2006, as amended in 2013, it is incumbent upon establishments employing a minimum of 100 permanent workers to institute group insurance in accordance with the prescribed regulations. Regrettably, the company has yet to introduce group insurance for its permanent employees, despite employing more than 100 permanent personnel. This points to a non-compliance with the provisions set forth in Section 99 of the Labor Act 2006, as amended in 2013.
- e. Note 1.17 where the company has disclosed in respect of transactions which were made using cash channels, including the purchase of land and others, we are not aware of any consequences associated with the cash transactions.
- f. We draw attention to Note 29.00, where the company has disclosed the finance cost, which shows a notable increase in the company's finance expenses for the last 3 years.

Our opinion is not modified in respect of these above matters.

**KEY AUDIT MATTERS**

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

We have fulfilled the responsibilities described in the Auditors' Responsibilities of audit of the financial statements section of our report, including in relation to these matters. Accordingly, our audit included the performance of procedures designed to respond to our assessment of the risk of material misstatements of the financial statements. The results of our audit procedures, including the procedures performed to address the matters below, provide the basis for our audit opinion on the accompanying financial statements.

We have determined the following key audit matters to communicate in our report.

**REVENUE**

**THE KEY AUDIT MATTER**

The company reported revenue net of VAT of Tk. 813,487,372 including Revenue from Services (Contract Manufacturing), reflecting a slight increase in the preceding year to current year. But there is a significant decline in revenue net of VAT from Tk. 1,010,976,301 (2022-23) in the preceding year to Tk. 813,487,372 (2024-25) in the current year due to reduced customer demand, particularly for Sulphuric Acid, Alum Sulphate, and LABSA. Revenue recognition for WATA is considered complex due to various contracts with local customers and the government for different products.

There is also a risk that revenue may be overstated due to fraud through manipulation of the invoices, discounts, incentives and rebates recognized resulting from the pressure of management may feel to achieve performance targets. Thus, we considered this as key audit matter.

Please refer to Note 26.00 "Revenue" of the notes to the financial statements for relevant details.

How the scope of our audit responded to the key audit matter:

We have reviewed the company's revenue recognition policies, accounting guidelines and disclosures to assess conformity with IFRS 15 "Revenue from Contracts with Customers". We have tested relevant internal control used to ensure the completeness, accuracy and timing of revenue recognized including revenue during the year end to ensure cut off has been properly maintained. We have applied analytical and substantive procedures to establish, whether any revenue had been recognized where no corresponding accounts receivable or proceeds have been recorded in the general ledger. We have collected balance confirmation on some parties on sample basis.

Trade Receivable

The Key Audit Matter

Trade receivable BDT 256,380,058 being about 10.12% of the total assets of the Company is a material item to the financial statements.

There is a significant risk regarding recoverability of the amounts and misstatement of the items. As such, management is required to make judgments in determining whether accounts receivable are being appropriately valued and also need to make sufficient provision for aged accounts receivable, if required.

Please refer Note 6 "Trade Receivables" of notes to the financial statements.

How the scope of our audit responded to the key audit matter:

- Tested the operating effectiveness of key controls over accounts receivable.
- Being a part of auditor's responsibility as regarding external confirmation as per ISA 505, we requested for external confirmation.
- Tested on a sample basis the value disclosed according to the reply obtained.

Assessed whether appropriate provisions have been recognized for aged accounts receivable, if required and evaluating management's basis for determining the recoverability.

Taxation & VAT

The key Audit Matter

The Statement of Profit & Loss and Other Comprehensive Income of the company shows amount of Tk. 11,149,343 as tax charged on current year's profit before tax. In the last two years the company has submitted its income tax return under Income Tax Act 2023. Assessment orders since Assessment year 2022-2023, 2023-2024 & 2024-25 are yet to be finalized for which additional tax charges may be imposed. Moreover, the company has tax & VAT positions including matters under dispute, which involve significant judgment to determine the possible outcome of these disputes.

Given the company's exposure to complex tax issues, the high level of management judgment in estimating the amounts provision for tax and involvement with regulatory authorities, taxation was considered to be a key audit matter.

Please refer to Note 23.00 "Provision for Taxation", Note 31.00 "Income Tax Expenses" and Note 15.00 "Deferred Tax Liability" to the financial statements for relevant disclosures regarding calculation and disclosure of taxation.

How the scope of our audit responded to the key audit matter:

We particularly focused on the impact of changes in tax regulations for provisions of the latest Finance Act. To assess whether the tax provision was appropriately recognized, we conducted interviews with the company's tax personnel in order to assess the taxable income of the company. We re-performed the calculations made by the management regarding tax liabilities to ensure compliance with the provisions of the Income Tax Act 2023 and checked the arithmetical accuracy of the calculations. We reviewed the latest returns and assessment orders and confirmed whether any adjustments were needed in the provisions. We also carefully reviewed for any contingent liabilities to be included in the financial statements in this regard.

We also obtained an understanding, evaluated the design and tested the operational effectiveness of the Company's key controls over the recognition and measurement of deferred tax liabilities and the assumptions used thereon. We assessed key assumptions, controls, recognition and measurement of deferred tax assets. We also assessed the appropriateness of presentation of disclosures against IAS 12 "Income Tax".

#### Other Information

Management is responsible for the other information. The other information comprises all of the information other than the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

When we read the annual report, if we conclude that there is a material misstatement therein, we are required to communicate the matter to the board of directors of the Company.

#### Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with IFRSs, the Companies Act 1994, the Securities and Exchange Rules 2020 as amended up to date and other applicable laws and regulations and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Wata Chemicals Limited ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate WATA Chemicals Limited or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

#### Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management but not for the purpose expressing an opinion on the effectiveness of the company's internal control.

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the company's financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Company to express an opinion on the financial statements. We are responsible for the direction, supervision and performance of the company audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.


From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

#### Report on other Legal and Regulatory Requirements

In accordance with the Companies Act 1994, the Securities and Exchange Rules 2020 as amended up to date and other applicable laws and regulations, we also report the following:

- a) we have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit and made due verification thereof except those mentioned in the basis for qualified opinion para of our report;
- b) in our opinion, proper books of accounts as required by law have been kept by the company so far as it appeared from our examination of these books except those mentioned in the basis for qualified opinion para of our report;
- c) the statements of financial position and statements of profit or loss and other comprehensive income dealt with by the report are in agreement with the books of accounts and returns except those mentioned in the basis for qualified opinion para of our report; and
- d) The expenditure incurred and payments made were for the purposes of the company's business.

Dated; Dhaka  
November 06, 2025

  
Faruk Ahmed FCA  
ICAB Enrolment No: 1591  
Partner  
Khan Wahab Shafique Rahman & Co.  
Chartered Accountant  
Firm Registration No.: 11970 E.P.  
DVC : 2511061591AS356696

**WATA CHEMICALS LIMITED**  
**STATEMENT OF FINANCIAL POSITION**  
**AS AT 30TH JUNE, 2025**

Particulars	Notes	Amount in Taka		
		30-Jun-25	30-Jun-24	
<b>ASSETS</b>				
<b>NON-CURRENT ASSETS</b>				
Property, Plant and Equipment (PPE)	2.00	1,887,049,090	1,811,998,909	
Capital Work-in-Progress (CWIP)-BMRE	3.00	786,770,083	815,910,571	
Right-of-Use (ROU) Asset	4.00	1,097,198,536	992,237,747	
		3,080,471	3,850,591	
<b>CURRENT ASSETS</b>				
Inventories	5.00	646,754,756	881,902,894	
Trade Receivables	6.00	65,127,286	171,420,154	
Advance Income Tax	7.00	256,380,058	442,047,628	
Advances, Prepayments & Deposits	8.00	162,998,394	118,352,190	
Cash & Cash Equivalents	9.00	128,681,587	114,617,397	
		33,567,431	35,465,524	
<b>TOTAL ASSETS</b>		<b>2,533,803,846</b>	<b>2,693,901,803</b>	
<b>SHAREHOLDER'S EQUITY &amp; LIABILITIES</b>				
<b>SHAREHOLDER'S EQUITY</b>				
Share Capital	10.00	905,444,456	913,133,509	
Share Premium	11.00	148,226,180	148,226,180	
Revaluation Reserve	12.00	32,400,000	32,400,000	
Retained Earnings	13.00	373,248,416	378,379,820	
		351,569,860	354,127,509	
<b>LIABILITIES</b>				
<b>NON-CURRENT LIABILITIES</b>				
Long Term Loan	14.00	441,092,911	522,218,011	
Deferred Tax Liability	15.00	397,545,633	475,374,113	
Lease Liability	16.00	40,922,523	43,819,035	
		2,624,755	3,024,864	
<b>CURRENT LIABILITIES</b>				
Bank Overdraft & Loans	17.00	1,187,266,480	1,258,550,283	
Current Portion of Long Term Loan	18.00	900,363,620	872,582,341	
Short term Loan (Unsecured)	19.00	103,884,964	116,930,416	
Lease Liability	20.00	74,385,922	176,601,258	
Trade Payables	21.00	850,110	779,918	
Liabilities for Expenses	22.00	1,344,394	987,401	
Workers Profit Participation Fund & Welfare Fund	23.00	18,851,204	14,922,828	
Provision for Taxation	24.00	48,597,905	47,690,608	
Unclaimed Dividend Account		35,816,440	24,872,073	
		3,171,920	3,183,442	
<b>TOTAL LIABILITIES</b>		<b>1,628,359,390</b>	<b>1,780,768,294</b>	
<b>TOTAL SHAREHOLDER'S EQUITY &amp; LIABILITIES</b>		<b>2,533,803,846</b>	<b>2,693,901,803</b>	
<b>Net Assets Value (NAV) Per Share in Taka</b>	25.00	61.09	61.60	

The annexed notes **1 to 53** and schedule **1 to 10** from an integral part of these financial statements.



Md. Nurul Huda  
Chairman



Md. Nazrul Islam  
Managing Director



A.H.M. Abdullah  
Director



Md. Ali Ahsan  
Chief Finance Officer



Shamsul Huq  
Company Secretary

Subject to our separate report of even date.

Dated: Dhaka  
November 06, 2025



Faruk Ahmed FCA  
ICAB Enrolment No: 1591  
Partner


Khan Wahab Shafique Rahman & Co.  
Chartered Accountant  
Firm Registration No.: 11970 E.P.  
DVC : 2511061591AS356696


**WATA CHEMICALS LIMITED**  
**STATEMENT OF PROFIT OR LOSS & OTHER COMPREHENSIVE INCOME**  
**FOR THE YEAR ENDED 30TH JUNE, 2025**

Particulars	Notes	Amount in Taka	
		2024-2025	2023-2024
Revenue (Net of VAT)	26.00	813,487,372	713,392,353
Cost of Sales	27.00	(572,724,085)	(494,495,799)
<b>Gross Profit</b>		<b>240,763,287</b>	<b>218,896,554</b>
Administrative, Selling and Distribution Expenses	28.00	(38,322,490)	(45,066,463)
<b>Operating Profit</b>		<b>202,440,797</b>	<b>173,830,091</b>
Finance Expenses	29.00	(187,885,642)	(160,704,849)
Non Operating Income	30.00	4,498,086	6,790,812
<b>Profit before contribution to WPPF &amp; Welfare Fund</b>		<b>19,053,241</b>	<b>19,916,055</b>
Contribution to WPPF & Welfare Fund		(907,297)	(948,384)
<b>Profit before Tax</b>		<b>18,145,944</b>	<b>18,967,671</b>
<b>Income Tax Expenses</b>	31.00	(7,105,352)	(9,106,657)
<b>Profit after Tax</b>		<b>11,040,592</b>	<b>9,861,014</b>
<b>Other Comprehensive Income / Expenses</b>			
Deferred Tax on Revaluation of PPE		(942,503)	(1,028,278)
<b>Total Comprehensive Income</b>		<b>10,098,089</b>	<b>8,832,736</b>
<b>Earning Per Share (EPS) in Taka</b>	32.00	<b>0.74</b>	<b>0.67</b>


The annexed notes **1 to 53** and schedule **1 to 10** from an integral part of these financial statements.

  
**Md. Nurul Huda**  
Chairman

  
**Md. Nazrul Islam**  
Managing Director

  
**A.H.M. Abdullah**  
Director

  
**Md. Ali Ahsan**  
Chief Finance Officer

  
**Shamsul Huq**  
Company Secretary

Subject to our separate report of even date.

Dated: Dhaka  
November 06, 2025

  
**Faruk Ahmed FCA**  
ICAB Enrolment No: 1591  
Partner  
Khan Wahab Shafique Rahman & Co.  
Chartered Accountant  
Firm Registration No.: 11970 E.P.  
DVC : 2511061591AS356696

**WATA CHEMICALS LIMITED**  
**STATEMENT OF CHANGES IN EQUITY**  
**FOR THE YEAR ENDED 30TH JUNE, 2025**

Particulars	Amount in Taka				
	Share Capital	Share Premium	Revaluation Reserve	Retained Earning	Total
<b>Balance as at 01 July 2024</b>	<b>148,226,180</b>	<b>32,400,000</b>	<b>378,379,821</b>	<b>354,127,509</b>	<b>913,133,509</b>
Profit after Tax during the period	-	-	-	11,040,592	11,040,592
Cash dividend for the year 23-24	-	-	-	(17,787,142)	(17,787,142)
Adj. of Realized Depreciation on Revaluation	-	-	(4,188,901)	4,188,901	-
Deferred Tax on Revaluation transferred to Revaluation Reserve	-	-	(942,503)	-	(942,503)
<b>Balance as at 30th June'2025</b>	<b>148,226,180</b>	<b>32,400,000</b>	<b>373,248,416</b>	<b>351,569,860</b>	<b>905,444,456</b>

**STATEMENT OF CHANGES IN EQUITY**  
**FOR THE PERIOD ENDED 30TH JUNE, 2024**

Particulars	Amount in Taka				
	Share Capital	Share Premium	Revaluation Reserve	Retained Earning	Total
<b>Balance as at 01 July 2023</b>	<b>148,226,180</b>	<b>32,400,000</b>	<b>383,978,224</b>	<b>361,930,296</b>	<b>926,534,701</b>
Profit after Tax during the period	-	-	-	9,861,014	9,861,014
Cash dividend for the year 22-23	-	-	-	(22,233,927)	(22,233,927)
Adj. of Realized Depreciation on Revaluation	-	-	(4,570,126)	4,570,126	-
Deferred Tax on Revaluation transferred to Revaluation Reserve	-	-	(1,028,278)	-	(1,028,278)
<b>Balance as at 30th June'2024</b>	<b>148,226,180</b>	<b>32,400,000</b>	<b>378,379,821</b>	<b>354,127,509</b>	<b>913,133,509</b>

The annexed notes 1 to 53 and schedule 1 to 10 from an integral part of these financial statements.



Md. Nurul Huda  
Chairman



Md. Nazrul Islam  
Managing Director



A.H.M. Abdullah  
Director



Md. Ali Ahsan  
Chief Finance Officer



Shamsul Huq  
Company Secretary

Subject to our separate report of even date.

Dated: Dhaka  
November 06, 2025



Faruk Ahmed FCA  
ICAB Enrolment No: 1591  
Partner

Khan Wahab Shafique Rahman & Co.  
Chartered Accountant  
Firm Registration No.: 11970 E.P.  
DVC : 2511061591AS356696

**WATA CHEMICALS LIMITED**  
**STATEMENT OF CASH FLOWS**  
**FOR THE YEAR ENDED 30TH JUNE, 2025**

Particulars	Notes	Amount in Taka	
		2024-2025	2023-2024
<b>Cash Flows from Operating Activities:</b>			
Cash receipts from Customers and others	33.00	1,114,297,603	1,067,325,274
Cash paid to Suppliers and others	34.00	(362,853,788)	(336,886,323)
Cash paid to employees and for expenses	35.00	(287,103,386)	(302,373,161)
Cash paid for VAT & Tax	36.00	(168,875,375)	(178,561,663)
<b>Net Cash (used in)/generated from Operating Activities (A)</b>		<b>295,465,055</b>	<b>249,504,125</b>
<b>Cash Flows from Investing Activities:</b>			
Acquisition of Fixed Assets	37.00	(113,376,794)	(26,226,819)
Paid of Lease Liability	37.00	(400,109)	(1,229,918)
<b>Net Cash (used in)/generated from Investing Activities (B)</b>		<b>(113,776,902)</b>	<b>(27,456,737)</b>
<b>Cash Flows from Financing Activities:</b>			
Loan Received	38.00	207,932,132	122,878,139
Loan Repayment	39.00	(373,240,122)	(293,734,943)
Dividend Paid	40.00	(18,278,256)	(21,885,882)
<b>Net Cash (used in)/generated from financing activities ( C)</b>		<b>(183,586,246)</b>	<b>(192,742,686)</b>
<b>Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)</b>		<b>(1,898,093)</b>	<b>29,304,703</b>
Effect of movements in exchange rate on cash held		-	-
Opening Cash & Cash Equivalents		35,465,524	6,160,822
<b>Closing Cash &amp; Cash Equivalent at Reporting Date</b>		<b>33,567,431</b>	<b>35,465,524</b>
<b>Closing Cash &amp; Cash Equivalent at Reporting Date (as per Statement of Financial Position)</b>		<b>33,567,431</b>	<b>35,465,524</b>
<b>Net Operating Cash Flow Per Share (NOCFPS) in Taka</b>	41.00	19.93	16.83

The annexed notes **1 to 53** and schedule **1 to 10** from an integral part of these financial statements.



Md. Nurul Huda  
Chairman



Md. Nazrul Islam  
Managing Director



A.H.M. Abdullah  
Director



Md. Ali Ahsan  
Chief Finance Officer



Shamsul Huq  
Company Secretary

Subject to our separate report of even date.



Faruk Ahmed FCA  
ICAB Enrolment No: 1591

Partner

Khan Wahab Shafique Rahman & Co.  
Chartered Accountant  
Firm Registration No.: 11970 E.P.  
DVC : 2511061591AS356696

Dated: Dhaka  
November 06, 2025

**WATA CHEMICALS LIMITED**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**AS AT AND FOR THE YEAR ENDED 30TH JUNE' 2025**

**1.00.00 Reporting Entity**

**1.01.00 Company Profile**

"WATA CHEMICALS LIMITED" hereinafter referred as to the Company was incorporated in Bangladesh on August 19, 1981 under Companies Act, 1913 (Subsequently amended in 1994). Its shares are listed with Dhaka Stock Exchange Limited since 1992 & Chittagong Stock Exchange Limited since 1997.

The registered office of the company is at 17/B, Monipuripara (3rd Floor), Sangshad Avenue, Dhaka-1215. Its factory is situated at Murapara, Rupgonj, Narayangonj, Bangladesh.

**1.02.00 Nature of Business**

The Company produces Alum, Zinc Sulphate, Magnesium Sulphate, Sulphuric Acid, Basic Chrome Powder (BCP) and Linear Alkyl Benzene Sulphonic Acid (LABSA) for 100% local consumption.

**1.03.00 Basis of Preparation of the Financial Statements**

**1.03.01 Statement of Compliance**

In accordance with the requirement of the gazette notification issued by The Financial Reporting Council (FRC) on 22 November 2020, the financial statements have been prepared in accordance with International Financial Reporting Standards (IFRSs)

The Company also complied with the requirements of following laws and regulations from various Government bodies:

- i. Bangladesh Securities and Exchange Rules 1987 ( as amended upto date).
- ii. The Companies Act, 1994;
- iii. The Income Tax Act, 2023; and
- iv. The Value Added Tax and Supplementary Duty Act, 2012.
- v. Regulations of Financial Reporting Councils (FRC).

The title and format of this financial statements follow the requirements of IFRSs which are to some extent different from the requirement of the Companies Act, 1994. However, such differences are not material and in the view of management, IFRS format gives a better presentation to the shareholders.

According to the International Accounting Standards (IAS)-1 "Presentation of Financial Statements" the complete set of Financial Statements includes the following components":

- i. Statements of Financial Position as at **30th June 2025**
- ii. Statement of Profit or Loss and Other Comprehensive Income for the year ended **30th June 2025**
- iii. Statement of Changes in Equity for the year ended **30th June 2025**
- iv. Statement of Cash Flows for the year ended **30th June 2025**
- v. Notes to the Financial Statements and Other Explanatory Information

**1.03.02 Authorisation for Issue**

This financial statement is authorised for issue by the Board of Directors in its Board of Directors meeting for the year 2024-2025 held on **06 November 2025**.

**1.03.03 Reporting Period**

These financial statements of the Company covers from **01 July'2024 to 30 June'2025**.

**1.03.04 Comparative and Reclassification**

Comparative information has been disclosed for all numerical, narrative and descriptive information where it is relevant for understanding of the current period financial statements. Comparative figures have been rearranged/reclassified wherever considered necessary, to ensure better comparability with the current period financial statements and to comply with relevant IFRSs.

**1.03.05 Functional and Presentation Currency**

This financial statements are presented in Bangladeshi Taka (Taka/TK/BDT) which is the Company's functional and presentation currency. All amounts have been rounded off to the nearest integer.

**1.03.06 Use of judgements and estimates**

In preparing this financial statement, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to estimates are recognised prospectively.

**a) Judgements**

Information about judgements related to lessee accounting under IFRS 16 made in applying accounting policies that have the most significant effects on the amounts recognised in the financial statements is described in note 4.

**b) Assumptions, Estimation and Uncertainties**

Information about assumptions and estimation uncertainties at **30th June'2025** that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities in the next financial year is included in the following notes:

Note 02: Property, Plant and equipment

Note 05: Inventory

Note 23: Provision for Taxation/Current Tax Liabilities

Note 15: Deferred Tax Liabilities

Note 50: Contingent Liabilities

**1.04.00 Basis of Measurement**

Measurement is the process of determining the monetary amounts at which the elements of the financial statements are to be recognized and carried in the financial statements. The measurement basis adopted by the Company is historical cost except for plant & machinery & equipment, building, land & land development and other assets which are stated in accordance with the policies mentioned in the respective notes.

**1.05.00 Going Concern**

When preparing financial statements, management makes an assessment of the Company's ability to continue as a going concern. The Company prepares financial statements on a going concern basis. In spite of working capital constant, the Company has adequate resources to continue in operation for the foreseeable future. For this reasons the directors continue to adopt going concern basis in preparing the financial statements.

**1.06.00 Accrual Basis of Accounting**

The Company prepares its financial statements, except for cash flow information, using the accrual basis of accounting. Since the accrual basis of accounting is used, the Company recognizes items as assets, liabilities, equity, income and expenses (the elements of financial statements) when they satisfy the definitions and recognition criteria for those elements in the Framework.

**1.07.00 Materiality and Aggregation**

The Company presents separately each material class of similar items. The Company presents separately items of a dissimilar nature or function unless they are immaterial. Financial statements result from processing large numbers of transactions or other events that are aggregated into classes according to their nature or function.

**1.08.00 Statement of Cash Flows**

Cash Flow Statement is prepared in accordance with IAS 7-"Statement of Cash Flows". The Statement shows the structure of changes in cash and cash equivalents during the financial year. Statement of Cash Flows is prepared principally in accordance with IAS-7 "Cash Flow Statement" and the cash flow from the operating activities have been presented under direct method, paragraph 19 of IAS-7 which provides that "Enterprises are Encouraged to Report Cash Flow from Operating Activities Using the Direct Method".

**1.09.00 Statement of Changes in Equity**

Statement of Changes in Equity has been prepared in accordance with IAS 1 -"Presentation of Financial Statements".

**1.10.00 Changes in Accounting Policies**

The company changes its accounting policy only if the change is required by a IFRS or results in the financial statements providing reliable and more relevant information about the effects of transactions, other events or conditions on the company financial position, financial performance or cash flows. Changes in accounting policies is made through retrospective application by adjusting opening balance of each affected components of equity i.e. as if new policy has always been applied.

**1.11.00 Changes in Accounting Estimates**

Estimates arise because of uncertainties inherent within them, judgment is required but this does not undermine reliability. Effect of changes of accounting estimates is included in the statement of profit or loss and other comprehensive income account. The preparation of the financial statements are in conformity with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgment in the process of applying the Company's accounting policies.

**1.12.00 Segment Reporting**

No segmental reporting is applicable for the company as required by IFRS 8: "Operating Segments" as the company operates in a single industry segment and within a single geographical territory.

**1.13.00 Summary of Significant Accounting Policies**

Accounting policies are determined by applying the relevant IFRS. Where there is no available guidelines of IFRS, management uses its judgment in developing and applying an accounting policy that results in information that is relevant and reliable. The company selects and applies its accounting policies for a period consistently for similar transactions, other events and conditions, unless a IFRS or specifically requires or permits categorization of items for which different policies may be appropriate. The accounting policies set out below have been applied consistently in all material respects to all periods presented in these financial statements.

**1.14.00 Foreign Currency Transaction**

Transactions in foreign currencies are translated to the respective functional currency (BDT) of the company at exchange rates at the date of the transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are retranslated to the functional currency at the exchange rates ruling at the statement of financial position date. Non-monetary assets and liabilities denominated in foreign currencies, stated at historical cost, are translated into (BDT) at the exchange rate ruling at the date of transaction. Foreign exchange differences arising on translation are recognised in profit or loss.

**1.15.00 Revenue Recognition**

The core principle of IFRS 15 is that an entity will recognise revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This core principle is delivered in a five-step model framework as follows;

- i. Identify the contract(s) with a customer
- ii. Identify the performance obligations in the contract
- iii. Determine the transaction price
- iv. Allocate the transaction price to the performance obligations in the contract
- v. Recognise revenue when (or as) the entity satisfies a performance obligation. However, the company has complied with the applicable requirements of IFRS 15 in recognizing revenue.

Moreover, the entity assesses whether it transfers control over time by following prescribed criteria for satisfying performance obligation. If none of the criteria is met then the entity recognizes revenue at point of time at which it transfers control of the goods to the customer.

Revenue is measured net of value added tax, trade discount, returns and allowances (if any). In case of cash delivery, revenue is recognised when delivery is made and cash is received by the Company

## **1.16.00 Financial Instruments**

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

### **Recognition and Initial Measurement**

Trade receivables and debt securities issued are initially recognised when they are originated. All other financial assets and financial liabilities are initially recognised when the Company becomes a party to the contractual provisions of the instrument.

A financial asset (unless it is a trade receivable without a significant financing component) or financial liability is initially measured at fair value plus, for an item not at Fair value through profit or loss (FVTPL), transaction costs that are directly attributable to its acquisition or issue. A trade receivable without a significant financing component is initially measured at the transaction price.

### **Classification and Subsequent Measurement**

#### **Financial Assets**

On initial recognition, a financial asset is classified as measured at:

- Amortised Cost;
- FVOCI – debt investment; and
- FVOCI – Equity Investment; or FVTPL.

#### **Financial liability**

All financial liabilities are recognised initially on the transaction date at which the Company becomes a party to the contractual provisions of the liability. The Company derecognises a financial liability when its contractual obligations are discharged or cancelled or expired. Financial liabilities include trade and other payables etc.

## **1.17.00 Cash and Cash Equivalents**

Cash and cash equivalents include notes and coins in hand and at bank, which are not ordinarily susceptible to change in value. For the purpose of Balance Sheet and Cash Flow Statement, Cash in Hand and Bank balances represent cash and cash equivalents considering the IAS-1 "Presentation of Financial Statements" and IAS-7 "Cash Flow Statement", which provide that Cash and Cash equivalents are readily convertible to known amounts of Cash and are subject to an insignificant risk of changes in value and are not restricted as to use.

The company has made some transactions through cash for various head of accounts due to some vendors/parties not interested to cheque transactions, sometimes have to purchase various materials within the deadline date, otherwise price will be increased etc.

## **1.18.00 Non-current Assets [Property, Plant & Equipment and Intangibles]**

### **1.18.01 Recognition**

The cost of an item of property, plant and equipment is recognized as an asset if, and only if, it is probable that future economic benefits will flow to the Company and the cost of the item can be measured reliably.

### **1.18.02 Measurement at Recognition**

An item of property, plant and equipment that qualifies for recognition as an asset is measured at its cost. The cost of an item of property, plant and equipment is the cash price equivalent at the recognition date. The cost of a self-constructed asset is determined using the same principles as for an acquired asset.

### **1.18.03 Elements of Costs and Subsequent Costs**

Cost includes purchase price (including import duties and non-refundable purchase taxes), directly attributable costs to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by the management and the initial estimate of the cost of dismantling and removing the item and restoring the site on which it is located. Costs of day to day servicing (repairs and maintenance) are recognized as expenditure as incurred. Replacement parts are capitalized, provided the original cost of the items they replace is derecognized.

### **1.18.04 Measurement of Property, Plant & Equipment after Recognition**

#### **Cost model**

After recognition as an asset, an item of property, plant and equipment shall be carried at its cost less any accumulated depreciation.

#### **Revaluation model**

The revaluation model requires an asset, after initial recognition, to be measured at a revalued amount, which is its fair value less subsequent accumulated depreciation.

Where an asset's carrying amount is increased as a result of a revaluation, the increase is recognized in equity under the heading of revaluation reserve. However, the increase is recognized in statement of profit or loss and other comprehensive income to the extent that it reverses a revaluation decrease of the same asset previously recognized in statement of profit or loss and other comprehensive income.

Where an asset's carrying amount is decreased as a result of a revaluation, the decrease is recognized in statement of profit or loss and other comprehensive income. However, the decrease is recognized in equity to the extent of any credit balance existing in the revaluation reserve in respect of that asset. The decrease recognized in equity reduces the amount accumulated under the heading of revaluation reserve.

The revaluation reserve included in equity in respect of an item of property, plant and equipment is transferred directly to retained earnings when the asset is derecognized. However, some of the surplus is transferred as the asset is used by the Company. In such a case, the amount of the revaluation reserve transferred would be the difference between depreciation based on the revalued carrying amount of the asset and depreciation based on the asset's original cost.

### **1.18.05 Derecognition of Property, Plant and Equipment**

The carrying amount of an item of property, plant and equipment is derecognized on disposal or when no future economic benefits are expected from its use or disposal. The gain or loss arising from the derecognition of an item of property, plant and equipment is included as other income in statement of profit or loss and other comprehensive income when the item is derecognized.

#### 1.18.06 Impairment of Assets

Entity applies periodic review to ensure that its assets are carried at no more than their recoverable amount. Which is hunger of an asset's or Cash generating unit's fair value less costs to sell and its value in use as prescribed in IAS36 "Impairment of Assets". However, the company has measured the carrying amount of non-financial assets considering possible impairment of assets and performed the impairment testing of assets under the scope of International Accounting Standards (IAS) 36 at the reporting date. In conducting asset impairment testing, the company has considered all the non-current assets under the scope of Impairment as single cash generating unit and Value in Use has been considered as its recoverable value. However, no impairment loss has been made on such assets in its financial statements for the year ended 30 June 2025 as the carrying amount of assets or its cash-generating unit did not exceed its recoverable amount.

#### 1.18.07 Depreciation

The depreciation charge for each period is recognized in statement of profit or loss and other comprehensive income unless it is included in the carrying amount of another asset. Depreciation of an asset begins when it is installed and available for use, i.e. when it is in the location and condition necessary for it to be capable of operating in the manner intended by management. Depreciation of an asset ceases at the earlier of the date that the asset is classified as held for sale and the date that the asset is derecognized. Depreciation has been charged using Reducing Balance Method (RBM) on additions from the date of acquisition, when the related assets are put into use and no depreciation is charged on assets disposed of during the year. Expenditure for maintenance and repairs are expensed, major replacements, renewals and betterment are capitalized.

Depreciation is calculated based on the cost/revalued amount of items of fixed assets [property, plant & equipment] less their estimated residual values using reducing balance method (RBM) over their useful lives and recognized in profit and loss. Land is not depreciated. Rates of depreciation considering the useful life of respective assets are as follows:

Particulars	Rate
Plant & Machinery	10%
Factory Building	5%
Boundary Wall	15%
Motor Vehicles and Bi-cycle	10%
Furniture & Fixtures	10%
Office Equipments	10%
Laboratory Equipments	15%
Computer & Software	10%
Generator	10%

Depreciation has been charged to Statement of Profit or Loss and other Comprehensive Income consistently.

#### 1.19.00 Valuation of Inventories

Inventories are assets held for sale in the ordinary course of business, in the process of production for such sale or in the form of materials or supplies to be consumed in the production process. Inventories are stated at the lower of cost or net realizable value in compliance to the requirements of Para 10 of IAS-2. Costs including an appropriate portion of fixed and variable overhead expenses are assigned inventories by the method most appropriate to the particular class of inventory. Net realizable value represents the estimated selling price for the inventories less all estimated cost of completion and cost necessary to make the sale. Item wise valuation is as follows:

Category of Inventories	Basis of Valuation
Raw & Packing Materials	At Weighted average cost
Work-in Progress	At Weighted average cost
Finished Goods	At Weighted average cost

#### 1.20.00 Other Provisions, Accruals and Contingencies

##### 1.20.01 Recognition of Provisions, Accruals and Contingencies

A provision is recognized when the Company has a present obligation (legal or constructive) as a result of a past event; it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation; a reliable estimate can be made of the amount of the obligation. Accruals are liabilities to pay for goods or services that have been received or supplied but have not been paid, invoiced or formally agreed with the supplier, including amount due to employees.

##### 1.20.02 Measurement of Provision

The amount recognized as a provision is the best estimate of the expenditure required to settle the present obligation at the end of the reporting period.

##### 1.21.00 Workers' Profit Participation Fund (WPPF) & Welfare Fund

As per Bangladesh Labour Law, 2006 as amended in 2013 all companies fall within the scope of WPPF (which includes Company) are required to provide 5% of its profit after charging such expense to their eligible employees within the stipulated time. As required by Law, the Company has maintained WPPF and kept sufficient provision against profit participation fund.

#### 1.22.00 Taxation

The tax expense for the period comprises current tax and deferred tax. Tax is recognized in the statement of profit or loss and other comprehensive income, except in the case it relates to items recognized directly in equity.

##### 1.22.01 Current Tax

Current tax is the expected tax payable on the taxable income for the year, using tax rates enacted or substantially enacted at the reporting date and any adjustment to the tax payable in respect of previous years. Provision for current income tax has been made on taxable income of the company as per following rates: The Company is "Publicly Traded Company" as per the Finance Act, 2023 and the rate of Minimum tax applicable is 1.00%.

Type of Income	2024-2025	2023-2024
Business income	22.50%	22.50%
Capital gain	10% to 15%	10% to 15%
Minimum Tax U/s 163 of ITA, 2023	1.00%	0.60%

## 1.22.02 Deferred Tax

Deferred tax is recognized on differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit and are accounted for using the Statement of Financial Position as liability method. Deferred tax liabilities are generally recognized for all taxable temporary differences and deferred tax assets are generally recognized for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilized.

### Principles of Recognition

Deferred tax is recognized as income or an expense amount within the tax charge, and included in the net profit or loss for the period. Deferred tax relating to items dealt with directly in equity is recognized directly in equity.

## 1.23.00 Share Capital and Reserves

### 1.23.01 Capital

#### Authorized Capital

Authorized Capital is the maximum amount of share capital that the Company is authorized to raise as per its Memorandum and Articles of Association.

#### Paid-up Capital

Paid-up Capital represents total amount of shareholders' capital that has been paid in full by the shareholders. Shareholders are entitled to receive dividend as approved from time to time in the Annual General Meeting.

### 1.23.02 Share Premium

Premium received amounting of Tk. 32,400,000 as against 162,000 ordinary share of Tk. 200 each of the share in the year 1995.

The Share Premium shall be utilized in accordance with provisions of the Companies Act, 1994 and as directed by the Securities and Exchange Commission in this respect. The section 57 of the Companies Act, 1994 provides that the Company may apply the Share Premium Account as follows:

- i. in paying up un-issued shares of the Company to be issued to members of the Company as fully paid bonus shares;
- ii. in amortized off the preliminary expenses of the Company;
- iii. in amortized off the expenses or the commission paid or discount allowed on any issue of shares or debentures of the Company; and
- iv. in providing for the premium payable on the redemption of any redeemable preference shares or of any debenture of the Company.

### 1.23.03 Assets Revaluation Reserve

This represents the difference between the book value and the re-valued amount of Building and other Construction and Plant & Machineries of the Company as assessed by professional valuers in the year 2008. The reserve is not distributable.

## 1.24.00 Expenses

### 1.24.01 Management and Other Expenses

Expenses incurred by the Company are recognized on an accrual basis.

## 1.25.00 Earnings Per Share (EPS)

### Measurement

The Company calculates basic earnings per share amounts for profit or loss attributable to ordinary equity holders of the parent entity. Basic earnings per share is calculated by dividing profit or loss attributable to ordinary equity holders of the parent entity (the numerator) by the weighted average number of ordinary shares outstanding (the denominator) during the period.

### Presentation

The Company presents in the statement of profit or loss and comprehensive income earnings per share. The Company present earnings per share with equal prominence for all periods presented. The Company presents earnings per share, even if the amounts are negative (i.e. a loss per share).

## 1.26.00 Employee Benefits

According to para-05 of IAS 19, employee benefits are given below :

#### a) Short-term Employee Benefits

- i) Paid Wages, Salaries and no Social Security Contributions;
- ii) Paid 20 (Twenty) days Annual (Casual Leave), 14 (Fourteen) days Medical (Sick Leave), 06 (Six) days Earn Leave, 120 (One Hundred Twenty) days Maternity Leave and General Holidays as per Govt declaration;
- iii) Paid Festival Bonuses and 05 (Five) percent WPPF (Workers Profit Participation Fund) as profit-sharing; and
- iv) No non-monetary benefit for current employees except lunch facility and accidental medical facilities at work station.

#### b) Post-employment Benefits

- i) No retirement benefit; and
- ii) No other post employment benefits such as post-employment life insurance and post-employment medical care.

#### c) Other Long-term Employee Benefits, such as the followings

- i) No long-term paid absences such as long-service leave or sabbatical leave;
- ii) No jubilee or other long-service benefits; and
- iii) No long-term disability benefits; and

#### d) Termination Benefits

No termination benefits but paid onetime financial benefit due to death of any employee on the basis of financial condition of employee but not less than 06 (six) months salary avail in the last month.

#### 1.27.00 Leases

Implementation of IFRS 16 and its relevant assumptions and disclosures IFRS 16: "Leases" has come into force on 1 January 2019, as adopted by the Institute of Chartered Accountants of Bangladesh (ICAB) then in Bangladesh. Wata Chemicals Limited applied IFRS 16 where the Company measured the lease liability at the present value of the remaining lease payments, discounted it using incremental borrowing rate at the date of initial application, and recognised a right-of-use asset at the date of the initial application on a lease by lease basis.

##### Right-of-use assets

The Company recognises right-of-use assets at the date of initial application of IFRS 16. Right-of-use assets are measured at cost, less any accumulated depreciation. Right-of-use asset is depreciated on a straight-line basis over the lease term. The right-of-use asset is presented under property, plant and equipment.

##### Lease liabilities

At the commencement date of the lease, the Company recognises lease liability measured at the present value of lease payments to be made over the lease term using incremental borrowing rate of 9% at the date of initial application. Lease liability is measured by increasing the carrying amount to reflect interest on the lease liability, reducing the carrying amount to reflect the lease payments.

Interest on the lease liability in each period during the lease term shall be the amount that produces a constant periodic rate of interest on the remaining balance of the lease liability.

However, the Company has only lease agreement for rental its Head Office with the Landlord for 10 years with effect from 01 July 2019 has been considered for lease as IFRS 16 and recognized in the financial statements accordingly.

#### 1.28.00 Compliance with Financial Reporting Standards as Applicable in Bangladesh

The Companies complied, as per Para 12 of Securities & Exchange Rule 1987(as ammended upto date), with the following International Accounting Standards (IASs) as adopted by The Institute of Chartered Accountants of Bangladesh (ICAB) then in Bangladesh in preparing the financial statements of the Company subject to departure where we have followed :

SN	Standard Number	Title of Standards	Compliance Status
01	IAS 01	Presentation of Financial Statements	Complied
02	IAS 02	Inventories	Complied
03	IAS 07	Statement of Cash Flows	Complied
04	IAS 08	Accounting Policies, Changes in Accounting Estimates and Errors	Complied
05	IAS 10	Events after the Reporting Period	Complied
06	IAS 12	Income Taxes	Complied
07	IAS 16	Property, Plant & Equipment	Complied
08	IAS 19	Employee Benefits	Complied
09	IAS 23	Borrowing Costs	Complied
10	IAS 24	Related Party Disclosures	Complied
11	IAS 33	Earnings per Share	Complied
12	IAS 36	Impairment of Assets	Complied
13	IAS 37	Provisions, Contingent Liabilities and Contingent Assets	Complied
14	IFRS 9	Financial Instruments	Complied
15	IFRS 15	Revenue from Contracts with Customers	Complied
16	IFRS 16	Leases	Complied

#### 1.29.00 Standards issued but not yet effective

In January 2018, the Institute of Chartered Accountants of Bangladesh (ICAB) has adopted International Financial Reporting Standards issued by the International Accounting Standards Board as IFRSs. As the ICAB previously adopted such standards as Bangladesh Financial Reporting Standards without any modification, this adoption does not have any impact on the financial statements of the Company.

A number of new standards are effective for annual periods beginning after 1 April 2020 and earlier application is permitted; however, the Company has not early adopted the new or amended standards in preparing this financial statements.

The following amended standards and interpretations are effective form 1 April 2020.

- Amendments To References To Conceptual Framework in IFRS Standards.
- IFRS 17: Insurance Contracts.
- IAS 01 and IAS 08: Definition of Material
- IAS 01: Classification of Liabilities as Current or Non-current
- IAS 16: Proceeds before Intended Use
- IAS 37: Costs of Fulfilling a Contract
- IFRS 9: Fees in the '10 per cent' test for derecognition of financial liabilities
- IAS 41: Taxation in fair value measurements
- IAS 08: Definition of Accounting Estimates

		Amount in Taka	
		30-Jun-25	30-Jun-24
<b>2.00</b>	<b>Property, Plant &amp; Equipment (PPE)</b>		
	<b>At Cost / Revalued:</b>		
	Opening Balance	1,404,758,159	1,403,911,559
	Add: Addition during the year	8,416,005	846,600
	Less: Disposal during the year	-	-
		<b>1,413,174,164</b>	<b>1,404,758,159</b>
	<b>Depreciation:</b>		
	Opening Balance	588,847,588	547,704,263
	Add: Depreciation charged during the year	37,556,493	41,143,325
	Less: Disposal during the year	-	-
		<b>626,404,081</b>	<b>588,847,588</b>
	<b>Written Down Value as on Closing Date</b>	<b>786,770,083</b>	<b>815,910,571</b>
<b>3.00</b>	<b>Capital Work-In-Progress (CWIP)-BMRE</b>		
	<b>Opening Balance</b>	992,237,747	966,857,528
	Add: Addition during the year	104,960,789	25,380,219
	Less: Adjustment / Transfer to Non-current Assets	1,097,198,536	992,237,747
	<b>Closing Balance</b>	<b>1,097,198,536</b>	<b>992,237,747</b>
	<b>N.B.</b> i) It is to be noted that BMRE Project cost will be capitalized after successfully completion of test Production in compliance with the relevant IAS/IFRS. This year, a machine with an LC value of Tk. 93,435,613.62 was transferred from "Asset in Transit" to "Capital Work in Progress" (CWIP). The machinery, along with other assets in CWIP, will remain there until the project's completion, after which depreciation will be applied. ii) It is mentionable that some portion of addition in Capital Work-In-Progress (CWIP) were made through cash channel due to purchase of some spare parts etc through local shops/stores.		
<b>4.00</b>	<b>Right-of-Use (ROU) Asset</b>		
	<b>Cost</b>		
	Opening Balance	7,701,189	7,701,189
	Add: Addition during the year	-	-
		<b>7,701,189</b>	<b>7,701,189</b>
	<b>Depreciation</b>		
	Opening Balance	3,850,598	3,080,478
	Add: Depreciation charged during the year	770,120	770,120
		<b>4,620,718</b>	<b>3,850,598</b>
	<b>Written Down Value as on closing Date</b>	<b>3,080,471</b>	<b>3,850,591</b>
<b>5.00</b>	<b>Inventories</b>		
	Raw Materials Stock	10,439,475	97,442,751
	Finished Goods Stock	19,421,204	14,316,264
	Materials-In-Transit	Note: 5.01	24,047,528
	Stores & Spares	Note: 27.02	11,219,078
	Raw Materials (M. Ton)	65,127,286	171,420,154
	Finished Goods (M. Ton)	352.710	3,638.383
	<b>Total (M. Tons)</b>	<b>979.880</b>	<b>4,697.828</b>
<b>5.01</b>	<b>Materials-In-Transit</b>		
	LC Margin Account	20,628,727	54,854,226
	Lc No - 120224010302 ( 2000 MT Sulphur)	-	217,549
	Lc No - 120224010316 ( 1500 MT Sulphur)	-	72,139
	LC-120225010135 (500 MT Hydrate \$400) -Sibl-at Sig	66,247	-
	LC- AGB-000125010041(Bentonite Powder 40mt \$ 365 US	2,056,042	-
	LC-AGB-000125010054 (2000 MT Sulphur @250) At Sight	592,520	-
	LC-AGB-000125010113 (990 MT Sulphur \$320) at Sight	142,562	-
	LC-AGB-000125010117(2080 MT Sulphur @340) at Sight	272,652	-
	Lc-No-120225010163-SIBL-(200 MT Lab @ \$1510) Sight	288,777	-
		<b>24,047,528</b>	<b>55,143,914</b>
<b>6.00</b>	<b>Trade Receivables</b>		
	<b>Opening Balance</b>	442,047,628	638,848,050
	Add: Sales during the year	935,516,031	824,452,515
		<b>1,377,563,659</b>	<b>1,463,300,565</b>
	Less: Received during the year	(1,121,183,602)	(1,021,252,937)
	<b>Closing Balance</b>	<b>256,380,058</b>	<b>442,047,628</b>
	(a) Name wise Accounts receivable are shown in <b>Schedule-05</b> .		
	(b) Classification schedule as required by schedule XI of Companies Act 1994 is as follows:		
	<b>Ageing of the above debtors' balances is as follows:</b>		
	Below 180 days	252,332,282	437,090,209
	Above 180 days	4,047,776	4,957,419
		<b>256,380,058</b>	<b>442,047,628</b>

	Amount in Taka	
	30-Jun-25	30-Jun-24
I. Accounts Receivable considered good in respect of which the company is fully secured.	252,332,282	437,090,209
II. Accounts Receivable considered doubtful or bad.	4,047,776	4,957,419
<b>Total</b>	<b>256,380,058</b>	<b>442,047,628</b>

The company has also assessed whether there is any significant credit risk involved as per IFRS 9 and the requirement of providing Expected Credit Loss as per the IFRS. However, no such allowance has been provided as 100% of the Trade Receivable is recoverable in time.

#### 7.00 Advance Income Tax (AIT)

##### Opening Balance

Add : Tax Deduction at Import u/s 120 of ITA	118,352,190	64,871,672
Add : Tax Deduction from Sale u/s 89 of ITA	33,207,369	40,051,272
Add: AIT on Interest Income	11,149,343	13,062,154
Add: AIT on Vehicles	176,992	367,092
Add : Income Tax Paid in Cash	112,500	-
	-	-
	<b>162,998,394</b>	<b>118,352,190</b>

Less : Adjustment during this period

<b>Closing Balance</b>	<b>162,998,394</b>	<b>118,352,190</b>
------------------------	--------------------	--------------------

#### 8.00 Advances, Prepayments & Deposits

Advance to Employees	<b>Note:-8.01</b>	10,212,115	4,832,070
Advance against Party	<b>Note:-8.02</b>	59,256,780	49,700,031
Bank Guarantee Margin with Agrani Bank		5,644,579	2,680,263
Security & Earnest Money Deposit		11,009,201	9,375,201
FDR at IPDC Finance		-	11,764,151
VAT Deposit	<b>Note:-8.03</b>	34,336,671	28,043,440
VAT Deduction at Import (Not Adjusted)		3,623,230	3,623,230
VAT Deposit Against (10% of Claim)		4,599,011	4,599,011
		<b>128,681,587</b>	<b>114,617,397</b>

#### 8.01 Advance to Employees

Advance against Salary	1,148,083	998,583
Advance against Expenses	9,064,032	3,833,487
	<b>10,212,115</b>	<b>4,832,070</b>

#### 8.02 Advance against Party

Advance payment to suppliers	58,188,706	32,061,056
<b>Asset in Transit</b>	<b>1,068,074</b>	<b>17,638,975</b>
LC-AGB-000125010040 ( Heat Exchanger -Sul. \$-53288)	1,068,074	-
LC No 120223010342 ( Acid Plant Accessories )	-	4,297,578
LC No 124010004 (Turbine )	-	403,552
LC No 123010463 ( Equip. & Plant Accessories )	-	12,937,846
	<b>59,256,780</b>	<b>49,700,031</b>

The details of Advance Payment to Suppliers has been shown in "Schedule-07".

#### 8.03 VAT Deposit

Opening Balance	28,043,440	9,864,107
<b>Add: Deposit during the year</b>	<b>124,708,763</b>	<b>124,624,924</b>
VAT Cash Deposit	77,240,835	64,900,000
VAT Deduction at Import	10,753,330	14,086,838
AT Deduction at Import	33,120,824	40,051,272
VAT on (Gas & Electricity Bill)	3,593,773	5,586,814
	<b>152,752,202</b>	<b>134,489,032</b>
Less: Adjustment during the year	(118,415,532)	(106,445,592)
<b>Closing Balance</b>	<b>34,336,671</b>	<b>28,043,440</b>

#### 9.00 Cash & Cash Equivalents

<b>Cash in hand</b>	<b>1,424,213</b>	<b>3,406,500</b>
Cash (Head Office)	118,376	240,081
Cash (Factory)-Current	1,305,837	3,166,419
<b>Cash at Bank</b>	<b>32,143,218</b>	<b>32,059,025</b>
Agrani Bank, Principal Branch, CD A/c No 0200000982200	1,231,938	58,953
Agrani Bank, Principal Branch, CD A/c No 0200018008016	302,717	557,188
Agrani Bank, Principal Branch, Margin A/c No 0200022340573	27,084,368	26,121,003
AI Arafah, CD A/c No. 0581020015947	13,693	17,958
BD Krishi Bank CD A/c No. 4001 0210040946	3,920	4,225
IBBL CD A/c No. 20507140100017512	9,319	-
Jamuna Bank CD A/c No. 01030210004758	2,955	3,194
Jamuna Bank CD A/c No. 00110210015998 (New)-1001000143012	-	-
Janata Bank Limited CD A/c No. 0100238383298	96,617	97,537
MTB CD A/c No. 1301010146113	102,260	29,860

	Amount in Taka	
	30-Jun-25	30-Jun-24
Prime Bank A/c No.2127115015947	2,412,675	51,919
SIBL CD A/c No_ 0021330455566	520,869	4,754,115
SIJBL. Banani Br, CD A/c No. 401311100006061	311,443	312,628
Basic Bank, A/c-01010069	20,213	20,213
BDBL Account, CD-001133003901	13,947	13,947
BDBL CD A/c 6521111019973	3,014	3,014
Brac Bank Ltd. Asad Gate Br. CD A/c	6,000	6,000
Dutch-Bangla Bank, CD-10123000271	2,434	2,434
Uttara Bank, CD-21303	4,838	4,838
	<b>33,567,431</b>	<b>35,465,524</b>

(a) Few Bank accounts are inoperative and carried on accounts for number of years without movement.

#### 10.00 Share Capital

##### Authorized Capital :

150,00,000 Ordinary Shares of Tk. 10/- each	<b>150,000,000</b>	<b>150,000,000</b>
---	--------------------	--------------------

##### Issued, Subscribed, Called-up & Paid-up Capital:

Paid-up Capital (1,620,000 Ordinary Shares of Tk. 10 each)	16,200,000	16,200,000
Add: Issue of Right Share in year 1995	16,200,000	16,200,000
Add: Issue of Bonus Share in year 1997	8,100,000	8,100,000
Add: Issue of Bonus Share in year 2012	8,100,000	8,100,000
Add: Issue of Bonus Share for year 2013	14,580,000	14,580,000
Add: Issue of Bonus Share for year 2014	15,795,000	15,795,000
Add: Issue of Bonus Share for year 2015-2016	7,897,500	7,897,500
Add: Issue of Bonus Share for year 2016-2017	4,343,620	4,343,620
Add: Issue of Bonus Share for year 2017-2018	27,364,830	27,364,830
Add: Issue of Bonus Share for year 2018-2019	29,645,230	29,645,230
	<b>148,226,180</b>	<b>148,226,180</b>

The details of Paid-up Capital are shown in "Schedule-10 (C)".

#### 11.00 Share Premium

The above share premium has been carried forward in the financial statements since 1995. This represents premium @ Tk. 200 per share collected on issue of right shares of 162,000.

#### 12.00 Revaluation Reserves

<b>Opening Balance</b>	<b>378,379,820</b>	<b>383,978,224</b>
Less: Depreciation on Revaluation	(4,188,901)	(4,570,126)
Less: Deferred Tax on Revaluation Depreciation	(942,503)	(1,028,278)
<b>Closing Balance</b>	<b>373,248,416</b>	<b>378,379,820</b>

(a) One consultant, namely, Dr. Engg. Khurshad-ul-Islam Phd. in Industrial & Process Engineering (Germany) of Bangladesh. Bangladesh Resources Management and Development Company revalued company's Plant & Machinery and Equipment in the Middle of year 2008 on replacement cost basis.

Another civil Engineering Consultant revalued Land at present market price and Building including other civil construction at replacement cost basis in the year 2008.

(b) **Revaluation reserve was taken into accounts as per Board's decision:**

##### Details of Revaluation Reserve are as under:

Machinery and Equipment	483,200,000	483,200,000
Land	89,266,750	89,266,750
Building & Other Civil Construction	80,200,149	80,200,149

##### Revaluation Value (Net of Depreciation)

Other Assets	652,666,899	652,666,899
<b>Total Revaluation at replacement cost</b>	<b>656,872,362</b>	<b>656,872,362</b>

Less: Written down value as on 31.12.2008

##### Revaluation Reserve

<b>Less: Depreciation Adjustment</b>	<b>105,017,594</b>	<b>100,828,693</b>
--------------------------------------	--------------------	--------------------

For the year 2012

For the year 2013

For the year 2014

For the year 2015

For the period 2016 (6 months)

For the year 2016-2017

For the year 2017-2018

For the year 2018-2019

For the year 2019-2020

For the year 2020-2021

For the year 2021-2022

For the year 2022-2023

For the year 2023-2024

For the year 2024-2025

Less: Deferred Tax Adjustment on Depreciation on Revaluation

**Balance as on closing Date**

12,978,569	12,978,569
11,817,372	11,817,372
10,765,461	10,765,461
9,812,209	9,812,209
4,474,096	4,474,096
8,556,441	8,556,441
7,809,323	7,809,323
7,131,491	7,131,491
6,516,288	6,516,288
5,957,708	5,957,708
5,450,333	5,450,333
4,989,276	4,989,276
4,570,126	4,570,126
4,188,901	-
(13,163,563)	(12,221,060)
<b>373,248,416</b>	<b>378,379,820</b>

Amount in Taka	
30-Jun-25	30-Jun-24
(c) Details of depreciation calculation on revalued assets have been shown in <b>Schedule-09</b> .	
(d) Depreciation on Revalued assets had been recognised in statement of profit or loss and other Comprehensive Income in line with Para-41 of IAS-16 and transfer has been made between revaluation reserve and retained earning in compliance with the requirement of the IAS 16 since 2012	
<b>13.00 Retained Earnings</b>	
Accumulated Profit (Opening Balance)	354,127,509
Net Profit/(Loss) after tax for the period	11,040,592
Approved Cash Dividend	(17,787,142)
Adjustment of Realized Depreciation on Revaluation	4,188,901
	<b>351,569,860</b>
	<b>354,127,509</b>

<b>14.00 Long Term Loan</b>	
<b>Opening Balance</b>	
Agrani Bank Term Loan	592,304,529
Term Loan from IPDC Finance	571,389,111
	<b>72,200,853</b>
<b>Add: Addition During the period</b>	
Agrani Bank Term Loan (Interest & Charges)	69,669,492
Term Loan from IPDC Finance Interest	2,531,361
	<b>163,074,786</b>
<b>Less: Payment during the period</b>	
Agrani Bank Term Loan	139,628,005
Term Loan from IPDC Finance	23,446,780
	<b>103,884,964</b>
<b>Less: Transferred to Current Liability during the period</b>	
Agrani Bank Term Loan	103,884,964
Term Loan from IPDC Finance	-
	<b>397,545,633</b>
<b>Closing Balance</b>	
Agrani Bank Term Loan	397,545,633
Term Loan from IPDC Finance	-
	<b>475,374,113</b>

- a) Agani Bank sanctioned Project Loan of Tk. 50.91 crore vide letter no. প্রশা/খন/প্রকল্প/ওয়াটা কেমিক্যালস /11/2018 dated 18 December 2018 for financing BMRE project cost at 70:30 debt equity ratio and repayable in 30 (Thirty) quarterly installment with interest @ of 11% p.a (as per MOU). Considering Corona Virus (Covid - 19) Pandemic effect, Agani Bank revised project loan repayment period and instalment size vide letter no. প্রশা/খন/প্রকল্প/ওয়াটা কেমিক্যালস/299/2021 dated 06 April 2021 against our proposal, total instalment 28 nos and the 1st instalment had been started 13 / 04 / 2021 each amounting tk,2,59,71,241/- on quarterly basis.
- b) IPDC Finance Ltd. sanctioned Project Loan of Tk. 5.00 crore vide letter no. IPDC/WCL/2021/34661 dated February 04, this loan is repayable in 60 (Sixty) monthly installment (each amounting Tk10,87,121/-) with interest @ of 14% p.a (as per MOU) starting from March 10, 2021 upto February 10, 2026. This year the loan of IPDC Finance has been closed before its maturity time. That means early settlement of IPDC Finance Loan.

<b>15.00 Deferred Tax Liability</b>	
Deferred tax liability on taxable temporary differences between carrying amount as per accounts and tax base amounts has been calculated into accounts in line with IAS-12.	
a) Deferred Tax Recognised on Taxable Temporary Difference	39,980,020
b) Deferred Tax Recognised on Depreciation of Revaluation Increases	942,503
<b>Closing Balance of Deferred Tax Liability</b>	<b>40,922,523</b>
Computation of deferred tax liability on taxable temporary differences and deferred on revaluation increase are shown at Schedule-09	<b>43,819,035</b>

<b>16.00 Lease Liability</b>	
<b>Opening Balance</b>	3,804,781
Add: Addition during the period	
Interest Expense	420,084
	<b>4,224,865</b>
Less: Paid during the period	750,000
<b>Closing Balance</b>	<b>3,474,865</b>
Lease Liability-Long Term	2,624,755
Lease Liability-Current	850,110
	<b>3,474,865</b>
	<b>3,804,781</b>

<b>17.00 Bank Overdraft and Loans</b>	
Agrani Bank CC Hypo, Principal Branch	694,924,660
Agrani Bank Incentive Loan, Principal Branch	205,438,960
<b>Note:-17.01</b>	<b>900,363,620</b>
	<b>670,697,094</b>
	<b>201,885,247</b>
	<b>872,582,341</b>

<b>17.01 Agrani Bank Incentive Loan under Stimulus Package</b>	
During Pandemic Corona Virus (COVID 19) crisis, the Government has declared various Stimulus Packages as working capital loan for industries, SME and other who are affected by COVID 19. Under this package, Agrani Bank has sanctioned working capital loan of Taka 19.00 crore in favor of the Company on 15 June 2020 according to BRPD Circular 08 dated 12 April 2020. This loan carries interest at rate of 13%.	

	Amount in Taka	
	30-Jun-25	30-Jun-24
<b>18.00 Current Portion of Long Term Loan</b>		
Agrani Bank Term Loan	103,884,964	103,884,964
Term Loan from IPDC Finance	-	13,045,452
	<b>103,884,964</b>	<b>116,930,416</b>
<b>19.00 Short Term Loan (Unsecured)</b>		
<b>Opening Balance</b>	<b>176,601,258</b>	<b>388,944,249</b>
Md. Nazrul Islam (Managing Director)	71,301,258	273,644,249
A.H.M Abdullah (Director)	105,300,000	115,300,000
<b>Add: Loan received during the year</b>	<b>107,950,000</b>	<b>35,246,500</b>
Md. Nazrul Islam (Managing Director)	107,950,000	35,246,500
A.H.M Abdullah (Director)	-	-
<b>Less : Loan paid during the year</b>	<b>210,165,336</b>	<b>247,589,491</b>
Md. Nazrul Islam (Managing Director)	174,117,334	237,589,491
A.H.M Abdullah (Director)	36,048,003	10,000,000
<b>Closing Balance</b>	<b>74,385,922</b>	<b>176,601,258</b>
Md. Nazrul Islam (Managing Director)	5,133,924	71,301,258
A.H.M Abdullah (Director)	69,251,997	105,300,000
<b>20.00 Trade Payables</b>		
<b>Opening Balance</b>	<b>987,401</b>	<b>747,160</b>
Add: Purchase / addition during the year (Import /Local)	115,851,814	232,155,302
Less: Payment / adjustment during the year	<b>116,839,215</b>	<b>232,902,462</b>
Less: Unclaimed Credit Balance written back	(115,494,821)	(231,915,061)
<b>Closing Balance</b>	<b>1,344,394</b>	<b>987,401</b>
The details has been shown in "Schedule-07".		
<b>21.00 Liabilities for Expenses</b>		
Audit Fee Payable	633,504	633,504
Welfare Expenses Payable	461,645	461,645
Directors Salary & Allowances Payable	<b>Note:-21.01</b>	988,567
Salaries & Wages Payable (Head Office & Factory)	4,351,517	3,952,750
Utilities Bill Payable	3,353,077	7,583,886
Party Bill Payable	13,385,032	3,157,026
Source VAT & Tax Payable	<b>Note:-21.02</b>	(4,322,138)
	(4,322,138)	(1,854,551)
	<b>18,851,204</b>	<b>14,922,828</b>
<b>21.01 Directors Salary &amp; Allowances Payable</b>		
Md. Nazrul Islam (Managing Director)	574,571	574,571
A H M Abdullah (Director)	218,396	218,396
Mahamudul Hasan (Director)	139,600	139,600
Consultant Remuneration	56,000	56,000
	<b>988,567</b>	<b>988,567</b>
<b>21.02 Source Tax and VAT Payable</b>		
TDS on Party Bill/Dividend	3,696,328	5,268,906
TDS on Salary & Remuneration	(324,560)	(26,189)
VAT Payable on Party Bill	(7,693,905)	(7,097,268)
	<b>(4,322,138)</b>	<b>(1,854,551)</b>
<b>22.00 Workers Profit Participation Fund &amp; Welfare Fund</b>		
<b>Opening Balance</b>	<b>47,690,608</b>	46,742,224
Add: Addition during this period	907,297	948,384
Less: Paid during this period	<b>48,597,905</b>	<b>47,690,608</b>
	<b>48,597,905</b>	<b>47,690,608</b>
<b>23.00 Provision for Taxation</b>		
<b>Opening Balance</b>	<b>24,872,073</b>	11,809,919
Add: Provision made during the period (U/s 163 of ITA)	11,149,343	13,062,154
Less: Provision For Previous Years (Over) / Under -(2021-2022)	(204,976)	-
Less: Adjustment during this period	<b>35,816,440</b>	<b>24,872,073</b>
<b>Closing Balance</b>	<b>35,816,440</b>	<b>24,872,073</b>

	Amount in Taka	
	30-Jun-25	30-Jun-24
<b>24.00 Unclaimed Dividend Account</b>		
1 Dividend Year - 2010	0	76
2 Dividend Year - 2011	-	92
3 Dividend Year - 2014	0	59
4 Dividend Year - 2015 -2016	0	148
5 Dividend Year - 2016 -2017	0	163
6 Dividend Year - 2017 -2018	(0)	73,766
7 Dividend Year - 2018 -2019	4,743	618,658
8 Dividend Year - 2019 -2020	871,317	871,317
9 Dividend Year - 2020 -2021	765,815	765,815
10 Dividend Year - 2021 -2022	505,303	505,303
11 Dividend Year - 2022 -2023	390,918	348,044
12 Dividend Year - 2023-2024	633,824	-
	<b>3,171,920</b>	<b>3,183,442</b>

The details has been shown in "Schedule-10".

**25.00 Net Assets Value (NAV) Per Share**

Net Assets Value	<b>Note:-25.01</b>	905,444,455	913,133,509
Number of shares outstanding		14,822,618	14,822,618
<b>NAV Per Share</b>		<b>61.09</b>	<b>61.60</b>

**25.01 Net Assets Value (NAV)**

Total Assets	2,533,803,846	2,693,901,803
Less: Non-Current Liabilities	(441,092,911)	(522,218,011)
Less: Current Liabilities	(1,187,266,480)	(1,258,550,283)
	<b>905,444,455</b>	<b>913,133,509</b>

**26.00 Revenue (Net of VAT)**

Gross Sales	<b>Note:-26.01</b>	931,902,906	819,837,945
Less: VAT on Sales	<b>Note:-26.03</b>	(118,415,534)	(106,445,592)
		<b>813,487,372</b>	<b>713,392,353</b>

**26.01 Gross Sales**

**A. Revenue from Sale of Goods**

Sulphuric Acid	629,072,517	587,377,440
Alum Sulphate	217,238,376	226,546,254
Linear Alkyl Benzene Sulphonic Acid	37,092,012	5,914,251
Zinc Sulphate	240,000	-
Magnesium Sulphate	260,000	-
	<b>883,902,906</b>	<b>819,837,945</b>

**B. Revenue from Services (Contract Manufacturing)**

Zinc Sulphate (Contract Manufacturing)	48,000,000	-
	<b>931,902,906</b>	<b>819,837,945</b>

(a) Product wise sales quantity, rate, value and VAT thereon during the years have been shown in "Schedule-04".  
 (b) The company earned Tk. 4.80 crore from contract manufacturing of Zinc Sulphate for Asad Trading during FY 2024-25, which has been recognized as revenue from services under IFRS-15.

**26.02 Per Share Gross Sales**

Gross Sales	931,902,906	819,837,945
Number of Shares	14,822,618	14,822,618
<b>Per Share Sales</b>	<b>62.87</b>	<b>55.31</b>

In the last few years, sales (market demand) have been fluctuating which has taken on an unpredictable character. Our sales team is trying to overcome the obstacle by facing global economic recession, drop of growth the country's GDP, post pandemic Corona Virus (COVID - 19) situation , ongoing Russia & Ukraine war, unstable situation of Middle East, volatile political situation of the country as a result Sales of Alum Sulphate was Decreased in value by Tk.9,307,878 but increased sales quantity and Sulphuric Acid, LABSA (Test Manufacturing) , Zinc Sulphate and Magnesium Sulphate were Increased by Tk.41,695,077/-, Tk. 31,177,761/-, Tk. 240,000/- and Tk. 260,000/- respectively, therefore per share gross sales has increase in this year.

**26.03 VAT on Sales**

VAT on Sulphuric Acid Sale	82,052,937	76,614,449
VAT on Alum Sulphate Sale	28,335,440	29,549,511
Linear Alkyl Benzene Sulphonic Acid	1,766,286	281,632
VAT on Zinc Sulphate Sale (Exempted)	-	-
VAT on Magnesium Sulphate Sale (Exempted)	-	-
VAT on Zinc Sulphate (Contract Manufacturing)	6,260,870	-
	<b>118,415,534</b>	<b>106,445,592</b>

(a) Product wise Sales with quantity, rate, value and VAT thereon during the period have been shown in "Schedule-04".

		Amount in Taka	
		2024-2025	2023-2024
<b>27.00</b>	<b>Cost of Sales</b>		
	Raw Materials Consumed	<b>Note:-27.01</b>	474,092,089
	Carriage Inward		-
	Store & Spares used	<b>Note:-27.02</b>	516,500
	Factory Overheads	<b>Note:-27.03</b>	103,220,436
	<b>Cost of goods manufactured</b>		<b>577,829,025</b>
	Opening Stock of Finished Goods		14,316,264
	<b>Cost of goods available for sales</b>		<b>592,145,289</b>
	Closing Stock of Finished Goods		(19,421,204)
			<b>572,724,085</b>
			<b>494,495,799</b>
<b>27.01</b>	<b>Raw Materials Consumed</b>		
	Rock Sulphur		347,153,639
	Alum Hydrate		83,825,494
	Zinc Ash		-
	Magnesium Powder		-
	Linear Alkyl Benzene		43,112,956
			<b>474,092,089</b>
			<b>362,001,233</b>
	(a) Movement of raw materials stock showing opening stock, purchased and consumed during the year and closing stock quantity and value have been shown in "Schedule-02".		
	(b) Raw materials stock had been valued at weighted average purchase price.		
<b>27.02</b>	<b>Store &amp; Spares Used</b>		
	<b>Opening Balance</b>		4,517,225
	Add: Purchase During the year		7,218,353
	<b>Store &amp; Spares available for Used</b>		<b>11,735,578</b>
	<b>Less: Used during the year</b>		<b>516,500</b>
	For Production		516,500
	For BMRE (Capital WIP).		-
	<b>Closing Balance</b>		<b>11,219,078</b>
			<b>4,517,225</b>
<b>27.03</b>	<b>Factory Overheads</b>		
	Air & Water Test Fee		53,400
	Gas Bill		2,736,329
	Electric Bill		14,585,905
	Fire Insurance Expense		2,072,301
	Packing Materials		587,200
	Product Testing expense		549,015
	Wages & Salaries including Overtime & Bonus		43,442,167
	Chemical Purchase for ETP/ATP/LAB		773,830
	Day Labourer for Misc Works		382,902
	Fuel for Fork Lift		157,307
	Oxygen & L.P Gas Purchase		167,200
	Day Labourer for Alum Breaking		1,089,300
	Loading & Unloading inward		-
	Oil & Lubricant		536,976
	Medical Expenses (Factory)		49,091
	Repairs & Maintenance (General -Factory)		-
	Spare Parts for Repairs & Maintenance (Plant & Machinery)		290,700
	Transport License		320,000
	Factory Depreciation	<b>Note:-27.04</b>	35,426,813
			<b>103,220,436</b>
			<b>126,645,069</b>
<b>27.04</b>	<b>Factory Depreciation</b>		
	Depreciation on Plant & Machinery		27,004,160
	Depreciation on Factory Building		8,377,835
	Depreciation on Factory Boundary Wall		12,531
	Depreciation on Laboratory Equipment		32,286
			<b>35,426,813</b>
			<b>38,814,084</b>
<b>28.00</b>	<b>Administrative, Selling and Distribution Expenses</b>		
	Salaries & Allowances including Eid Bonus (Office)		14,625,550
	Annual Subscription to Listed Companies		254,227
	Director Salary & Allowances Including Eid Bonus	<b>Note:-28.01</b>	10,565,429
	Bank Charges and Commission		752,293
	Business Development Expenses		-
	Car Repairs & Maintenance (Spare Parts and Service Charge)		404,640
	CDBL Line Charges		34,650
	Charity & Donation (Factory & Office)		52,500
	Computer Operating Expenses (Tonner etc Purchase)		275,826
			<b>15,342,615</b>
			<b>254,226</b>
			<b>10,560,000</b>
			<b>908,509</b>
			<b>38,700</b>
			<b>777,916</b>
			<b>37,800</b>
			<b>111,120</b>
			<b>194,780</b>

	Amount in Taka	
	2024-2025	2023-2024
Credit Rating Expenses	80,625	80,625
Consultant Remuneration	720,000	720,000
Conveyance (Office & Factory)	130,988	157,985
Crokères & Cutlery	4,680	6,150
Dish Bill (Factory & Office)	12,300	20,400
Electric Bill (Office)	254,697	622,987
Cooking Goods ( Rich , Fish ,Vegetable etc)	369,231	-
Entertainment expense(Factory & Office)	533,260	1,346,504
Gas Bill (Office)	12,880	20,980
Fire Insurance Expense	-	904,475
Internet Expenses (Factory & Office)	309,344	271,750
License Renewal Expenses	641,551	329,204
Medical Expenses	85,625	-
Mobile Expenses (Office & Factory)	91,490	187,905
News Paper & Periodicals (Factory & Office)	11,857	10,775
Office Expenses (Factory & Office) /Health & Hygienic goods	250,281	271,770
Audit Fee	523,250	633,504
Annual General Meeting & Board Meeting Expenses	294,850	380,340
Office Stationery (Factory & Office)	379,629	342,067
Fuel for Vehicles	1,107,405	1,152,522
Parking & Toll Charge	55,410	86,736
Photocopy Charge (Factory & Office)	9,656	81,334
Postage & Courier and Fax Exp.	26,473	8,570
Renewal of Tax Token & Fitness Certificate	10,257	306,056
Repair & Maintenance-Office Equipment (Spare Parts)	60,450	71,090
Stamp Purchase	59,932	74,308
Telephone Bill (Office)	6,270	7,807
Travelling Expenses	127,265	20,500
Water Bill (Office & Factory)	86,659	68,462
Fish & Deer Upkeep (Factory)	142,730	147,845
Tree Plantation	3,000	41,540
Carriage Outward	804,590	2,300,200
Tender Schedule & Others	70,347	187,700
Advertisement & Publicity	320,323	1,068,075
Day Labourer for Unloading (Outward)	860,270	1,811,270
Depreciation (Office)	2,899,800	3,099,361
	<b>38,322,490</b>	<b>45,066,463</b>

#### 28.01 Director's Salary & Allowances Payable

(i) Md. Nazrul Islam, Managing Director	4,805,429	4,800,000
(ii) Mr. A.H.M Abdullah, Director	3,000,000	3,000,000
(iii) Mr. Mahmudul Hasan, Director	1,800,000	1,800,000
(v) EID Bonus (For Director'S)	960,000	960,000
	<b>10,565,429</b>	<b>10,560,000</b>

#### 28.02 Depreciation (Office)

Depreciation on Motor Vehicles	1,216,714	1,351,904
Depreciation on Bi-Cycle	172	191
Depreciation on Furniture & Fixture	286,578	314,931
Depreciation on Office Equipment	516,617	541,520
Depreciation on Computer	80,221	88,051
Depreciation on Generator	29,379	32,643
Depreciation on ROU Asset	770,120	770,120
	<b>2,899,800</b>	<b>3,099,361</b>

#### 29.00 Finance Expenses

Interest on Agrani Bank C.C (Hypo)	89,085,970	74,373,884
Interest on Stimulus Package Loan	26,304,855	21,836,982
Interest on Project Loan	69,619,492	61,212,492
Interest on IPDC Loan	2,455,241	2,797,012
Interest on Lease Liability	420,084	484,479
	<b>187,885,642</b>	<b>160,704,849</b>

Finance Cost, which shows a notable increase in the company's finance expenses over the last three years from BDT 143,505,161 in 2022-2023, to BDT 160,704,849 in 2023-2024, and further to BDT 187,885,642 in 2024-2025. The major portion of the current year's finance cost comprises interest on Agrani Bank C.C (Hypo) amounting to BDT 89,085,970, Project Loan BDT 69,619,492, and Stimulus Package Loan BDT 26,304,855. The continuous rise in finance costs is mainly due to increased bank borrowings and higher interest rates, which have adversely affected the company's profitability and liquidity position.

		Amount in Taka	
		2024-2025	2023-2024
<b>30.00</b>	<b>Non-operating Income</b>		
Fish Sale		2,576,875	2,573,260
Misc. Sales Income		1,036,250	2,041,310
Interest Income (FDR)		884,961	2,176,242
		<b>4,498,086</b>	<b>6,790,812</b>
<b>31.00</b>	<b>Income Tax Expenses</b>		
Major component of tax expenses			
In compliance with the requirements of para - 79 of IAS-12:Income tax, the major components of tax expenses are given below:			
Current Tax Expense (Provisional)	<b>Note:-31.01</b>	11,149,343	13,062,154
Over Provision-(2021-2022)		(204,976)	-
Deferred Tax Expenses /(Income)	<b>Note:-31.02</b>	(3,839,015)	(3,955,497)
		<b>7,105,352</b>	<b>9,106,657</b>
<b>31.01</b>	<b>Reconciliation of Tax Expenses with Accounting Profit and Applicable Effective Tax Rate.</b>		
<b>Net profit befor tax</b>		18,145,944	18,967,671
Statutory Tax @ 22.5%		4,082,837	4,267,726
<b>Income Tax Act u/s 163</b>			
a) Tax 1% U/s 163 of ITA,2023		8,134,874	4,280,354
b) Tax U/s 89 of ITA,2023		11,149,343	13,062,154
c) Tax on applicable rate		4,082,837	4,267,726
<b>Current Tax Expenses whichever is higher</b>		<b>11,149,343</b>	<b>13,062,154</b>
<b>Effective Tax Rate</b>		<b>61.44%</b>	<b>68.87%</b>
Current tax has been charged at the rate applicable to the company, subject to provision of section 163 taking higher income of- (a) at the rate of 1% of total gross receipts,(b) tax deducted at source for corporate sales u/s 89 and tax deducted at source of bank interest income u/s 102, (c) at the applicable tax rate on taxable income. The company recognised current tax expense net of BDT 7,105,352/. The effective tax rate is also 61.44% of profit before statutory tax.			
<b>31.02</b>	<b>Deferred Tax Expense/(Income)</b>		
Carrying Value of Fixed Assets (WDV) at Balance Sheet Date		786,770,083	815,910,571
Less: Revaluation Increase		(302,899,931)	(307,088,833)
<b>Net Carrying Cost</b>		<b>483,870,152</b>	<b>508,821,738</b>
Less: Land Value		(113,946,085)	(106,402,620)
<b>Net Carrying cost (Net of Land &amp; Land Development) (A)</b>		<b>369,924,067</b>	<b>402,419,118</b>
<b>Right-of-Use (ROU) Asset (B)</b>		<b>3,080,471</b>	<b>3,850,591</b>
<b>Lease Liability ( C)</b>		<b>(3,474,865)</b>	<b>(3,804,781)</b>
<b>Total Carrying Value at Balance Sheet Date (A+B-C)</b>		<b>369,529,673</b>	<b>402,464,928</b>
Less: Tax Based WDV (Estimated)		(191,840,695)	(212,283,788)
<b>Temporary Taxable Differences</b>		<b>177,688,978</b>	<b>190,181,140</b>
<b>Deferred Tax on Depreciation on Revaluation-Increase</b>			
Deferred Tax Liability on Temporary Taxable Difference @ 22.5%		39,980,020	42,790,757
Deferred Tax on Depreciation on Revaluation Increase through OCI		942,503	1,028,278
<b>Deferred Tax Liability on 30th June, 2025</b>		<b>40,922,523</b>	<b>43,819,035</b>
Less: Opening Deferred Tax Liability		(43,819,035)	(46,746,254)
Less: Deferred Tax on Revaluation Transferred to Revaluation Reserve		(942,503)	(1,028,278)
<b>Deferred Tax Expenses (Income) Recognised during the period</b>		<b>(3,839,015)</b>	<b>(3,955,497)</b>
<b>32.00</b>	<b>Earning per share (EPS)</b>		
Basic Earning Per Share , as per IAS - 33 ,			
is calculated as below:			
<b>EPS =</b>	<b>Net Profit After Tax</b>	<b>=</b>	<b>11,040,592</b>
	<b>Number of Share</b>		<b>14,822,618</b>
			<b>0.74</b>
			<b>0.67</b>

In the last few years, sales (market demand) have been fluctuating which has taken on an unpredictable character. Our sales team is trying to overcome the obstacle by facing global economic recession, drop of growth the country's GDP, post pandemic Corona Virus (COVID - 19) situation , ongoing Russia & Ukraine war, unstable situation of Middle East, volatile political situation of the country, as a result Sales of Alum Sulphate was Decreased in value by Tk.9,307,878 but increased sales quantity and Sulphuric Acid, LABSA (Test Manufacturing) , Zinc Sulphate and Magnesium Sulphate were Increased by Tk.41,695,077/-, Tk. 31,177,761/-, Tk. 240,000/- and Tk. 260,000/- respectively, therefore per share gross sales has increase in this year. On the other hand increase of Natural Gas bill by 1.80 times, overall Cost of Sales has been Increased by 15.82% comparing the previous year. Moreover Administrative, Selling and Distribution expenses has been decreased and Net Sales has also been Increased by 12.30% but financial expenses has been increased as against same period of the previous year due to change of rate of Bank Interest . By consideration of global economic recession, devaluation of bangladeshi Taka against US Dollar, volatile banking sector.political instability and unrest, after changes situation of July/2024 etc causes significant effect on EPS.

	Amount in Taka	
	2024-2025	2023-2024
<b>33.00 Cash Receipts From Customers and Others</b>		
Gross Sales	931,902,906	819,837,945
Non Operating Income	4,498,086	6,790,812
Trade Receivables_ Decrease (Increase)	185,667,571	196,800,422
Loan & Advance - Net of VAT & Tax _Decrease / (Increase)	(7,770,959)	43,896,095
	<b>1,114,297,603</b>	<b>1,067,325,274</b>
<b>34.00 Cash paid to Suppliers and Others</b>		
Raw Materials Purchase	387,088,814	398,382,122
Stores & Spares Purchase	7,218,353	4,456,960
Material in Transit_ Increase / (Decrease)	(31,096,386)	(65,712,517)
Trade Payables-(Increase) / Decrease	(356,993)	(240,242)
	<b>362,853,788</b>	<b>336,886,323</b>
<b>35.00 Cash paid to Employees and for Other Expenses</b>		
Salaries & Allowances including Eid Bonus (Office)	58,067,717	66,037,275
Carriage Inward	-	136,250
Factory Overheads (Excl. Wages & Salary and Depreciation)	24,351,456	37,136,324
Administrative & Marketing Exp. (Excl. Salaries, Depr. & Exch. Loss)	20,797,140	26,624,487
Finance costs	187,885,642	160,704,849
Liabilities for Expenses _Decrease (Increase)	(3,998,569)	11,733,977
	<b>287,103,386</b>	<b>302,373,162</b>
<b>36.00 Cash paid for VAT &amp; Tax</b>		
<b>(a) Payment of VAT</b>	<b>124,708,763</b>	<b>125,081,145</b>
VAT Deposit in Cash	77,240,835	64,900,000
VAT Paid at Import	10,753,330	14,086,838
AT Paid at Import	33,120,824	40,051,272
VAT on Utility Bill	3,593,773	5,586,814
VAT Deposit Against (10% of Claim)	-	456,221
<b>(b) Payment of Tax</b>	<b>44,166,613</b>	<b>53,480,518</b>
AIT on Import	33,207,369	40,051,272
AIT Deduction from Sale Bill	11,149,343	13,062,154
AIT on Interest Income	(190,100)	367,092
Payment of Tax in Cash	-	-
<b>Total (A+B)</b>	<b>168,875,375</b>	<b>178,561,663</b>
<b>37.00 Acquisition of Non-current Assets</b>		
Addition to Fixed Assets (Net of Adjustment)	8,416,005	846,600
Addition for Capital Work in Progress	104,960,789	25,380,219
Payment of Lease Liability	400,109	1,229,918
	<b>113,776,902</b>	<b>27,456,737</b>
<b>38.00 Loan Received</b>		
Loan from Agrani Bank	27,781,279	13,328,710
Project Loan from Agrani Bank (Interest)	69,669,492	71,490,917
Term Loan from IPDC Finance (Interest)	2,531,361	2,812,012
Shortterm Loan Received	107,950,000	35,246,500
	<b>207,932,132</b>	<b>122,878,139</b>
<b>39.00 Loan Repaid</b>		
Project Loan Payment to Agrani Bank	139,628,005	33,100,000
Term Loan Payment from IPDC Finance	23,446,780	13,045,452
Shortterm Loan Repayment	210,165,336	247,589,491
	<b>373,240,122</b>	<b>293,734,943</b>
<b>40.00 Dividend Paid</b>		
Dividend Paid	18,278,256	21,885,882
Less: Sale of Fraction Share	-	-
	<b>18,278,256</b>	<b>21,885,882</b>
Unclaimed Dividend Account balance (Except last three years) amounting Tk. 12,75,338/- has been transferred to <b>Capital Market Stabilization Fund</b> ( SND A/c No. 0010311521301 Community Bank Bangladesh Ltd., Gulshan Corporate Branch, Dhaka ) after deducting TDS Compling with the Commission's Directive No. BSEC/CMRRCD/2021-386/03 - dated 14 January 2021 during the year.		
<b>41.00 Net Operating Cash Flow Per Share (NOCFPS)</b>		
Net Operating Cash Flows	295,465,055	249,504,125
Weighted average number of shares	14,822,618	14,822,618
	<b>19.93</b>	<b>16.83</b>

Amount in Taka		
2024-2025	2023-2024	

The Efficacy of our Sales Division has Increased Significantly, their remarkable contribution not only help to boost up sales but also declined accounts receivable by Tk. 185,667,571 for that operating Cash has shown positive Impact. Collection from Sales Increased by Tk. 46,972,330/- though Payment for Raw Materials & Trade Creditors was also Increased by Tk.25,967,464/- and Wages & Others Expenses and Payment of VAT and Tax is Decreased by Tk. 372,383/- and Tk. 9,313,906/- respectively against the same period of the previous year. But Sales & Trade Debtors collection is proportionately Higer than payments. As a result Cash Flow from Operating Activities stand at TK.295,465,055/- which causes the significant increase in NOCFPS.

#### 42.00 Reconciliation of Net Profit with Cash Flows from Operating Activities

<b>Profit before Tax</b>	18,145,944	18,967,671
<b>Adjustment for:</b>		
Add: Depr. on Property, Plant and Equipment	37,556,493	41,143,325
Add: Depreciation of ROU Assets	770,120	770,120
Add: Contribution to WPFF	907,298	948,384
Add /Less: (Incr.) / Decr. in Inventory	106,292,868	30,587,915
Add / Less: (Incr.) / Decr. in Trade Receivables	185,667,571	196,800,422
Add / Less: (Incr.) / Decr. in Loans, Adv. & Deposits (Excl. VAT)	110,644,573	150,341,687
Add / Less: Incr. / (Decr.) in Trade Payables	356,993	240,242
Add / Less: Incr. / (Decr.) in Liabilities for Expenses	3,998,571	(11,733,977)
<b>Cash Generated from Operations</b>	<b>464,340,430</b>	<b>428,065,789</b>
Less: VAT & Income Tax Paid	(168,875,375)	(178,561,663)
<b>Net Cash (used in) / generated from operating activities</b>	<b>295,465,055</b>	<b>249,504,126</b>

#### 43.00 Depreciation of Revaluation Adjustment

Depreciation on Revaluation adjustment	4,188,901	4,570,126
	<b>4,188,901</b>	<b>4,570,126</b>

(a) Depreciation on partial revaluation increase of Plant & Machinery as well as Building had been charged during the period 2024-2025 amounting to Tk. 4,188,901/- and adjusted in statement of Changes in Equity. Details has been shown in "Schedule-09".

#### 44.00 Provision of tax liability between accounts and Final Assessment

Assessment Year	Account-ing Year	Tax Provision as per Accounts	Tax Liability as per Final Assessment	Difference of Tax Provision as per Final Assessment	Adjustment of Advance of Tax	Tax Liability Provision
2015-2016	2014	11,017,752	11,017,752	U/s 82BB	-	-
2016-2017	2016	14,853,225	14,853,225	U/s 82BB	-	-
2017-2018	2016-2017	11,633,292	11,633,292	U/s 82BB	-	-
2018-2019	2017-2018	15,697,637	15,697,637	U/s 82BB	-	-
2019-2020	2018-2019	46,838,132	46,838,132	U/s 82BB	-	-
2020-2021	2019-2020	42,542,869	42,542,869	U/s 82BB	-	-
2021-2022	2020-2021	22,061,365	22,061,065	U/s 82BB	-	300
2022-2023	2021-2022	18,197,965	17,992,989	U/s 183(7)/163/289/184/292	-	(204,976)
2023-2024	2022-2023	11,809,619			-	11,809,619
2024-2025	2023-2024	13,062,154			-	13,062,154
2025-2026	2024-2025	11,149,343			-	11,149,343
<b>Total</b>		<b>218,863,353</b>	<b>182,636,961</b>	<b>-</b>	<b>-</b>	<b>35,816,440</b>

#### 45.00 Proposed Dividend

(a) Cash Dividend Tk. 14,822,618/-

Cash Dividend has been recommended by the board of Directors on paid-up capital of Tk. 148,226,180/- @ 10% in their meeting held on 06 November 2025 subject to the approval by the shareholders in the 43th AGM will be held on 24 December, 2025.

#### 46.00 Additional Information as per Requirement of the Companies Act, 1994

(a) Total number of factory staffs (each received annual salaries & wages Tk. 16,000 & above) was 84 nos.

(b) Total number of H/O staffs ( each received annual salaries & wages Tk. 16,000 & above) was 17 nos.

(C) Payment to Directors as Remuneration & Perquisite in the Period has been shown in Note-29.01.

#### 47.00 Plant Capacity & Utilization

Name of Products	Attainable Capacity (Qty.M.Ton)		Actual Production	
	Annual	Year End	(Qty M.Ton)	% of Capacity
Sulphuric Acid	48,000,000	48,000,000	44,034,390	91.74%
Alum Sulphate	18,000,000	18,000,000	6,067,400	33.71%
Linear Alkyl Benzene Sulphonic Acid	7,200,000	7,200,000	266,028	3.69%
Zinc Sulphate	6,000,000	6,000,000	-	0.00%
Magnesium Sulphate	6,000,000	6,000,000	-	0.00%

#### 49.00 Commission, Brokerage & Discount to the Selling Agent

Company had no selling agent as such no payment of commission, brokerage and discount was made.

#### 50.00 Contingent Liability

Commissioner of Customs, Excise and VAT Commissionarate, Dhaka has raised claim amounting to Tk. 41,427,896 based on their audit objection vide letter dated 11.08.2014. Against this claim, company has filed appeal with Appellate Commissioner on deposit of amount Tk. 4,142,790. The case is still pending with appellate Tribunal. Another demand claimed by Customs Exice & Vat Commissionerate ,Dhaka by cancelling rebate for Tk. 22,81,103 and imposed fine for Tk. 45,62,206/- as because non-submission of price declaration in time. Against this claim a writ petition has been filed on payment of Tk. 456,220.60 before the Hon'ble High Court Division. . Hon'ble Justice stayed the order of claim and the writ petition now pending for hearing. No additional liability had been accounted.

#### 51.00 Related Parties & Transactions

Related parties and transactions are considered in line with IAS-24 as under:

Related parties disclosure , details of which are as follows

a) Short Term Employee Benefit:

i) Director Salary & Allowances

Name	Designation	Amount in taka	
		2024-2025	
Total	Payable		
Md. Nazrul Islam	Managing Director	4,805,429	334,571
Mr. A.H.M. Abdullah	Director	3,000,000	218,396
Mr. Mahmudul Hasan	Director	1,800,000	139,600
Festival Bonus		960,000	240,000

b) Post Employees Benefits : Nil

c) Others Long-Term Benefits: Nil

d) Termination Benefits: Nil

e) Share - Based Payment : Nil

f) Short Term Loan with Managing Director:

Short Term loan to Managing Director (Mr. Nazrul Islam) was free of interest.

SN	Name of Party	Opening Balance	Transaction		Closing Balance
			Taken	Refund	
1	Md. Nazrul Islam	71,301,258	107,950,000	174,117,334	5,133,924
2	A.H.M Abdullah	105,300,000	-	36,048,003	69,251,997
		176,601,258	107,950,000	210,165,336	74,385,922

g) Apart from the above, the company didn't made any transaction with related parties in normal course of business and or a arm's length basis.

#### 51.01 Top Five Salaried Officers

Name	Designation	Amount in taka	
		Refund	
Total	Payable		
Shamsul Huq	Company Secretary	1,110,504	92,542
Md. Ali Hasan	Chief Financial Officer	1,738,344	144,862
Md. Mahbubul Hasan Bhuiyan	Financial Controller	560,000	140,000
Md. Abu Taher Bhuyan	General Manager ( Factory)	1,459,308	121,609
A S M Farhan Reza	Maintenance Eng. (Civil)	1,163,532	96,961

#### 52.00 Recent Events and Trends in our business view:

Despite increase of Natural Gas bill , overall Cost of Sales has been Increased by 15.82% as against same period of the previous year . Moreover Administrative ,Selling and Distribution Expenses has also been decreased except financial expenses(due to higher rate of interest charged by Bank), but Sales has been Increased by 12.30% as against same period of the previous year due to volatile situation/short demand of local industries, which causes significant effect on our industry.

#### 53.00 Event after the Reporting Period

There is no other significant events after the reporting date that may affect the reported amounts in the financial statements of the Company for the period ended 30 June 2025.

**WATA CHEMICALS LIMITED**  
**Schedule of Property, Plant & Equipment (PPE)**  
**As at 30th June, 2025**

**Schedule-01**

SL No.	Name of Assets	Cost / Revaluation			Rate	Depreciation		Written Down Value 30.06.2025
		As at 01.07.2024	Addition this period	Adjustment this period		As on 01.07.2024	Addition this period	
01	Land & Land Development	106,402,620	7,543,465	-	113,946,085	-	-	-
02	Plant & Machinery & Equip.	984,041,469	660,000	-	984,701,469	10%	463,639,868	490,644,028
03	Factory Building	263,310,331	-	-	263,310,331	5%	95,753,632	104,131,467
04	Boundary Wall	784,468	-	-	784,468	15%	700,927	713,458
04	Laboratory Equipment	646,944	-	-	646,944	15%	431,703	463,989
05	Motor Vehicles	31,388,326	-	-	31,388,326	10%	19,221,189	20,437,903
06	Bi-Cycle	5,200	-	-	5,200	10%	3,477	3,650
07	Furniture & Fixture	6,367,134	-	-	6,367,134	10%	3,501,356	3,787,934
08	Office Equipment	9,443,524	95,540	-	9,539,064	10%	4,313,540	4,830,157
09	Computer & Software	1,378,308	117,000	-	1,495,308	10%	585,850	829,237
10	Generator	989,835	-	-	989,835	10%	696,047	725,426
		<b>Total as on 30.06.2025</b>	<b>1,404,758,159</b>	<b>8,416,005</b>	<b>1,413,174,164</b>		<b>588,847,589</b>	<b>626,404,082</b>
		<b>Total as on 30.06.2024</b>	<b>1,403,911,559</b>	<b>846,600</b>	<b>1,404,758,159</b>		<b>547,704,264</b>	<b>41,143,325</b>
							<b>588,847,589</b>	<b>815,910,571</b>
<b>NB:</b> Cost of Land Tk. 75,43,465 (Deed No. 2070 , Dated 17/2/2025)								
<b>NB:</b> (a) Depreciation has been charged following reducing balance method.								
(b) Depreciation on addition has been charged for the period from the date of acquisition.								
(c) Depreciation has been charged on Plant & Machinery which were in use as under:								
Particulars		WDV	Addition		Depreciable Value		Rate	Depreciation
Depreciation on Sulfuric Acid Plant Unit-1	38,655,994	-		38,655,994	x	10%	=	3,865,599
Depreciation on Sulfuric Acid Plant Unit-2	169,066,869	-		169,066,869	x	10%	=	16,906,687
Depreciation on Alum Sulphate Plant Unit-1	14,041,530	-		14,041,530	x	10%	=	1,404,153
Depreciation on Zinc Plant	12,581,398	-		12,581,398	x	10%	=	1,258,140
Depreciation on Magnesium Plant	22,069,850	-		22,069,850	x	10%	=	2,206,985
Depreciation on Utilities Plant	13,185,962	660,000		13,845,962	x	10%	=	1,362,596
<b>Total</b>	<b>269,601,603</b>	<b>660,000</b>		<b>270,261,603</b>				<b>27,004,160</b>

**WATA CHEMICALS LIMITED**  
**Schedule of Property, Plant & Equipment (PPE)**  
**As at 30 June, 2024**

**Schedule-01**

SL No.	Name of Assets	Cost / Revaluation			Rate	As on 01.07.2023	Addition this period	Depreciation this period	As on 30.06.2024	Written Down Value 30.06.2024
		As at 01.07.2023	Addition this period	Adjustment this period						
01	Land & Land Development	106,402,620	-	-	106,402,620	-	-	-	-	106,402,620
02	Plant & Machinery & Equip.	983,889,869	151,600	-	984,041,469	10%	433,690,665	29,949,202	-	463,639,868
03	Factory Building	263,310,331	-	-	263,310,331	5%	86,934,858	8,818,774	-	95,753,632
04	Boundary Wall	784,468	-	-	784,468	15%	686,184	14,743	-	700,927
04	Laboratory Equipment	571,944	75,000	-	646,944	15%	400,337	31,366	-	431,703
05	Motor Vehicles	31,388,326	-	-	31,388,326	10%	17,869,285	1,351,904	-	19,221,189
06	Bi-Cycle	5,200	-	-	5,200	10%	3,286	191	-	3,477
07	Furniture & Fixture	6,248,134	119,000	-	6,367,134	10%	3,186,425	314,931	-	3,501,356
08	Office Equipment	8,942,524	501,000	-	9,443,524	10%	3,772,019	541,520	-	4,313,539
09	Computer & Software	1,378,308	-	-	1,378,308	10%	497,799	88,051	-	585,850
10	Generator	989,835	-	-	989,835	10%	663,404	32,643	-	696,047
<b>Total as on 30.06.2024</b>		<b>1,403,911,559</b>	<b>846,600</b>	<b>-</b>	<b>1,404,758,159</b>		<b>547,704,264</b>	<b>41,143,325</b>	<b>-</b>	<b>588,847,589</b>
<b>Total as on 30.06.2023</b>		<b>1,389,152,639</b>	<b>4,753,920</b>	<b>-</b>	<b>1,403,911,559</b>		<b>502,964,153</b>	<b>44,740,109</b>	<b>-</b>	<b>547,704,263</b>
<b>Total as on 30.06.2024</b>		<b>299,399,204</b>	<b>151,600</b>							<b>856,207,296</b>
<b>Total as on 30.06.2023</b>		<b>299,399,204</b>	<b>151,600</b>							<b>29,949,202</b>

**NB:** (a) Depreciation has been charged following reducing balance method.

(b) Depreciation on addition has been charged for the period from the date of acquisition.

(c) Depreciation has been charged on Plant & Machinery which were in use as under:

Particulars	WDV	Addition	Depreciable Value	Rate	Depreciation
Depreciation on Sulfuric Acid Plant Unit-1	42,951,105	-	42,951,105	10%	= 4,295,110
Depreciation on Sulfuric Acid Plant Unit-2	187,852,077	-	187,852,077	10%	= 18,785,208
Depreciation on Alum Sulphate Plant Unit-1	15,601,700	-	15,601,700	10%	= 1,560,170
Depreciation on Zinc Plant	13,979,331	-	13,979,331	10%	= 1,397,933
Depreciation on Magnesium Plant	24,522,056	-	24,522,056	10%	= 2,452,206
Depreciation on Utilities Plant	14,492,937	151,600	14,644,537	10%	= 1,458,575
<b>Total</b>	<b>299,399,204</b>	<b>151,600</b>	<b>299,550,804</b>		<b>29,949,202</b>

**WATA CHEMICALS LIMITED**  
**Movement of Raw Materials Stock**  
**For the year ended 30th June, 2025**

Particulars	Opening Stock		Purchased during the period		Adj. during the period		Consumption		Closing Stock		
	1-Jul-24		2024-2025		2024-2025		2024-2025		30-Jun-25		
	Qty. (M.Ton)	Amount in Taka	Qty. (M.Ton)	Amount in Taka	Qty. (M.Ton)	Amount in Taka	Qty. (M.Ton)	Amount in Taka	Qty. (M.Ton)	Amount in Taka	
Rock Sulphur	2,943.819	56,762,725	12,018,000	297,145,012	842	158.88	-	15,502.216	347,153,639	301,603	6,754,098
Alumina Hydrate	667.494	36,515,331	936.141	49,222,836	-	-	-	1,723.196	83,825,494	39,319	1,912,673
Zinc Ash	1,980	46,728	-	-	-	-	-	-	-	1,980	46,728
Magnesium Powder	1,340	30,150	-	-	-	-	-	-	-	1,340	30,150
Linear Alkyl Benzene	23.750	4,087,817	200,000	40,720,966	-	-	-	215.282	43,112,956	8,468	1,695,827
<b>Total</b>	<b>3,638.383</b>	<b>97,442,751</b>	<b>13,154.141</b>	<b>387,088,814</b>	<b>1,001</b>	<b>-</b>	<b>-</b>	<b>17,440.694</b>	<b>474,092,089</b>	<b>352.710</b>	<b>10,439,475</b>

**Raw Materials consumption in relation with production (Input Ratio)**  
**For the year ended 30th June, 2025**

Product Name	Raw Materials Used		Production		Consumption of RM		Value of Consumed Materials		Average rate (Per M.Ton) In Taka	
	Qty. (M.Ton)	Production	Input Ratio (Per Ton)	Purchased Materials	Own Product Internal used	Purchased Raw Materials used	Own Product Internal used	In Taka		
Sulphuric Acid	44,034.39	0.350	15,502.216	-	347,153,639	-	-	-	22,394	
Aluminum Sulphate	6,067.40	0.290	1,723.196	3,640.440	-	83,825,494	-	-	48,645	
Do	6,067.40	0.600	-	-	-	-	-	-	7,884	
Zinc Sulphate	-	0.380	-	-	-	-	-	-	-	
Do	-	0.620	-	-	-	-	-	-	-	
Magnesium Sulphate	-	0.180	-	-	-	-	-	-	-	
Do	-	0.820	-	-	-	-	-	-	-	
LABSA	266.03	0.750	215.282	-	-	43,112,956	-	-	-	
Do	266.03	0.105	27.933	-	-	-	-	-	-	
<b>Total</b>	<b>56,701.25</b>	<b>17,468.627</b>	<b>3,640.440</b>	<b>474,092,089</b>	<b>-</b>	<b>-</b>	<b>28,700,114</b>	<b>-</b>	<b>22,394</b>	

**Movement of Raw Materials Stock**  
**For the Period Ended 30th June, 2024**

Particulars	Opening Stock		Purchased during the period		Adj. during the period		Consumption		Closing Stock	
	1-Jul-23		2023-2024		2023-2024		2023-2024		30-Jun-24	
	Qty. (M.Ton)	Amount in Taka	Qty. (M.Ton)	Amount in Taka	Qty. (M.Ton)	Amount in Taka	Qty. (M.Ton)	Amount in Taka	Qty. (M.Ton)	Amount in Taka
Rock Sulphur	1,868.219	50,191,616	16,232,000	292,061,093	-	-	15,156.400	285,489,984	2,943.819	56,762,725
Alumina Hydrate	92.523	4,123,751	2,102.941	106,321,030	-	-	1,527.970	73,929,449	66,494	36,515,331
Zinc Ash	1,980	46,728	-	-	-	-	-	-	1,980	46,728
Magnesium Powder	1,340	30,150	-	-	-	-	-	-	1,340	30,150
Linear Alkyl Benzene	38.750	6,669,617	-	-	-	-	-	-	23,750	4,087,817
<b>Total</b>	<b>2,002.812</b>	<b>61,061,861</b>	<b>18,334.941</b>	<b>398,382,122</b>	<b>-</b>	<b>-</b>	<b>16,699.370</b>	<b>362,001,233</b>	<b>3,638.383</b>	<b>97,442,751</b>

**WATA CHEMICALS LIMITED**  
**Movement of Finished Goods Stock**  
**For the year ended 30th June, 2025**

**Schedule-03**

Particulars	Opening Stock		Production during the period	Internal Used during the period	Sale during the period	Closing Stock	
	1-Jul-24	2024-2025				2024-2025	30-Jun-25
	Qty. M.Ton	Amount in Taka	Qty. M.Ton	Qty. M.Ton	Qty. M.Ton	Qty. M.Ton	Amount in Taka
Sulphuric Acid	728.345	7,370,518	44,034.390	-	40,790.500	414.242	4,121,712
Alumina Sulphate	325.100	6,609,283	6,067.400	3,557.993	6,253.600	138.900	3,039,271
Linear Alkyl Benzene Sulphonic Acid	2.000	264,507	266.028	-	194.000	74.028	12,260,221
Zinc Sulphate	2.000	39,096	-	-	2.000	-	-
Magnesium Sulphate	2.000	32,860	-	-	2.000	-	-
<b>Total</b>	<b>1,059.445</b>	<b>14,316,264</b>	<b>50,367.818</b>	<b>3,557.993</b>	<b>47,242.100</b>	<b>627.170</b>	<b>19,421,204</b>

**WATA CHEMICALS LIMITED**  
**Movement of Finished Goods Stock**  
**For the Period Ended 30th June, 2024**

Particulars	Opening Stock		Production during the period	Internal Used during the period	Sale during the period	Closing Stock	
	1-Jul-23	2023-2024				2023-2024	30-Jun-24
	Qty. M.Ton	Amount in Taka	Qty. M.Ton	Qty. M.Ton	Qty. M.Ton	Qty. M.Ton	Amount in Taka
Sulphuric Acid	416.815	5,096,034	43,298.000	-	39,825.070	728.345	7,370,518
Alumina Sulphate	479.100	9,859,878	5,269,000	3,161,400	5,423,000	325.100	6,609,283
Linear Alkyl Benzene Sulphonic Acid	18.250	2,438,095	20.000	-	36.250	2.000	264,507
Zinc Sulphate	2.000	39,096	-	-	-	2.000	39,096
Magnesium Sulphate	2.000	32,860	-	-	-	2.000	32,860
<b>Total</b>	<b>918.165</b>	<b>17,465,963</b>	<b>48,587.000</b>	<b>3,161,400</b>	<b>45,284.320</b>	<b>1,059.445</b>	<b>14,316,264</b>

**WATA CHEMICALS LIMITED**  
**Sales (Net of VAT)**  
**For the year ended 30th June, 2025**

**Schedule-04**

Particulars	2024-2025			
	Quantity (M. Ton)	Gross Sale Value (Including VAT) In Taka	VAT on Sale In Taka	Sale Value (Net of VAT) In Taka
<b>A. Revenue from Sale of Goods</b>				
Sulphuric Acid	40,791	629,072,517	82,052,937	547,019,580
Alumina Sulphate	6,254	217,238,376	28,335,440	188,902,936
Linear Alkyl Benzene Sulphonic Acid	194	37,092,012	1,766,286	35,325,726
Zinc Sulphate (VAT Exempted)	2	240,000	-	240,000
Magnesium Sulphate (VAT Exempted)	2	260,000	-	260,000
<b>A. Sub-total (Goods Sales)</b>	<b>47,242</b>	<b>883,902,906</b>	<b>112,154,664</b>	<b>771,748,242</b>
<b>B. Revenue from Services (Contract Manufacturing)</b>				
Zinc Sulphate (Contract Manufacturing)	2,000	48,000,000	6,260,870	41,739,130
<b>B. Sub-total (Service Revenue)</b>	<b>2,000</b>	<b>48,000,000</b>	<b>6,260,870</b>	<b>41,739,130</b>
<b>Total (A+B)</b>	<b>49,242</b>	<b>931,902,906</b>	<b>118,415,534</b>	<b>813,487,372</b>

**WATA CHEMICALS LIMITED**  
**Sales (Net of VAT)**  
**For the Period Ended 30th June, 2024**

Particulars	2023-2024			
	Quantity (M. Ton)	Gross Sale Value (Including VAT) In Taka	VAT on Sale In Taka	Sale Value (Net of VAT) In Taka
Sulphuric Acid	39,825.070	587,377,440	76,614,449	510,762,991
Alumina Sulphate	5,423.000	226,546,254	29,549,511	196,996,743
Linear Alkyl Benzene Sulphonic Acid	36.250	5,914,251	281,632	5,632,619
Zinc Sulphate (VAT Exempted)	-	-	-	-
Magnesium Sulphate (VAT Exempted)	-	-	-	-
<b>Total</b>	<b>45,284.320</b>	<b>819,837,945</b>	<b>106,445,592</b>	<b>713,392,353</b>

**WATA CHEMICALS LIMITED**  
**Trade Receivables**  
**As at 30th June, 2025**

**Schedule-05**

Sl. No.	Name of Customers	Amount in Taka	
		30-Jun-25	30-Jun-24
1	Bhandhal Jhuri WTP-CWASA	23,508,003	-
2	BSK Chemical Industries Ltd.	1,831,950	-
3	City Fresh Toiletories Ltd	378,546	-
4	Goadnail Water Works	3,174,616	-
5	Green Dot Corporation.Ltd	63,492	63,492
6	H.K. Enterprise	6,341,554	2,842,518
7	Kohinoor Chemical Company Ltd.	4,596,435	-
8	Modunaghat Water Treatment Plant	5,883,372	-
9	Mohara Division (CWASA)	-	8,341,220
10	M/s Asad Trading	83,710,003	192,962,657
11	M/s. Asad Trading Unit-2	1,136,764	23,802,564
12	M/s Aysha Trading Corporation	1,302,598	1,602,598
13	M/s Dewan Enterprise	381,366	148,516
14	M/s. Dohar Chemicals	47,571	260,612
15	M/s Faruk Chemical Industries Ltd.	1,622,362	1,622,362
16	M/s Masud Auto Parts & Chemicals	230,390	129,778
17	M/s M.R. Chemicals	23,688,112	21,550,720
18	M/s New Molla Traders	2,157,419	4,957,419
19	M/s Tarek Enterprise	204,503	204,503
20	M/s. Zharna Chemical Supply Co.	603,117	530,151
21	M/s Zharna Traders	3,110,815	156,632
22	New Sun Chemicals	367,590	4,072,918
23	Rashid Enterprise	2,278,177	563,108
24	Saidabad Water Treatment Plant	-	31,830,513
25	Karnaphuli Pani Shodhonagar (CWASA)	16,653,375	15,599,422
26	S.M Chemicals	68,294,690	130,425,565
27	Uttara Chemicals	1,821,150	190,360
28	Younus Paper Mills Ltd.	390,001	190,000
29	Zhu Xiao Long Industries Ltd.	2,602,087	-
<b>Total</b>		<b>256,380,058</b>	<b>442,047,628</b>

**WATA CHEMICALS LIMITED**

**Trade Payables**  
**As at 30th June, 2025**

**Schedule-06**

Sl. No	Particulars	Amount in Taka	
		30-Jun-25	30-Jun-24
1	Aesthetic Engineering Service	60,000	-
2	Electromach Engineering	231,880	231,880
3	Jamuna Trading Corporation	205,231	-
4	Nippon Paint (BD) Private Ltd	527,341	-
5	Safe Power Electric Company	90,000	-
6	Tara Beebi International	229,941	513,593
7	Waterchem Technology	-	241,927
<b>Total</b>		<b>1,344,393</b>	<b>987,400</b>

**WATA CHEMICALS LIMITED**

**Advance to Suppliers**  
**As at 30th June, 2025**

**Schedule-07**

Sl. No	Particulars	Amount in Taka	
		30-Jun-25	30-Jun-24
1	Abir Shiping Limited ( C & F )	19,397,224	11,194,423
2	Aristocrate Advisors & Arrangers	1,200,000	-
3	Asis Refrigeration & Electric	1,064,287	414,287
4	Bengal Interior	200,000	-
5	Dexterous Engineering	265,535	50,000
6	Dhaka Engineering Works (Md. Shihab)	2,711,000	-
7	Expert Engineering Survey Consultant	50,000	
8	F. Rahman Construction ( Fazlur Rahman )	2,617,100	-
9	Gentech Power International	1,400,000	1,000,000
10	Inovative Technology International	1,409,225	1,409,225
11	Md. Najmul Sanitary Engineer	20,000	-
12	MM Corporation ( C & F )	14,367,586	9,597,317
13	M/s Fahim Transport Agency	5,006,444	953,704
14	M/S Harun Rong Bitan	984,500	-
15	M/s MHR Brick Field	950,000	-
16	M/s Monowara Enterprise	39,913	5,700,000
17	MS Enterprise	160,000	160,000
18	New Boiler Museum	645,300	645,300
19	Rasel International Ltd.	1,002,605	-
20	Robi Painting Interior & Exterior	762,306	110,000
21	Rooftec Trade	2,165,000	600,000
22	SA Cargo Service	71,000	-
23	Speed Engineering	200,000	-
24	Talukdar Transport	609,000	-
25	The Kohinoor Transport Service	60,000	-
26	Turbo Technology Ltd.	460,000	10,000
27	Waterchem Technology	139,482	-
28	Water Ion Exchange	231,200	216,800
<b>Total</b>		<b>58,188,706</b>	<b>32,061,056</b>

**WATA CHEMICALS LIMITED**  
**Calculation of Deferred Tax Liability**  
**For the year ended 30th June, 2025**

**Schedule-08**

**(a) Carrying amount at Balance Sheet date**

**i) Carrying Cost of Fixed Assets-WDV (Net of Land Value & Revaluation increase):**

Particulars	Amount in Taka			
	30-Jun-25	30-Jun-24	30-Jun-23	30-Jun-22
Written Down Value (As per Schedule-1)	786,770,083	815,910,571	856,207,296	896,188,486
<b>Less: Revaluation Increase</b>	<b>302,899,931</b>	<b>307,088,833</b>	<b>311,658,958</b>	<b>318,010,818</b>
Plant & Machinery Increase	353,253,863	353,253,863	353,253,863	353,253,863
Factory Building Increase	54,663,662	54,663,662	54,663,662	54,663,662
Less: Depreciation of Revaluation	(105,017,594)	(100,828,692)	(96,258,567)	(89,906,708)
	<b>483,870,152</b>	<b>508,821,738</b>	<b>544,548,338</b>	<b>578,177,668</b>
Less: Land Value	(113,946,085)	(106,402,620)	(106,402,620)	(106,402,620)
<b>Net WDV (Except Land Value &amp; Revaluation)</b>	<b>369,924,067</b>	<b>402,419,118</b>	<b>438,145,718</b>	<b>471,775,048</b>
<b>ii) Carrying value of Right-of-use (ROU) asset</b>	<b>3,080,471</b>	<b>3,850,591</b>	<b>4,620,711</b>	<b>5,390,830</b>
<b>iii) Carrying value of Lease Obligation</b>	<b>(3,474,865)</b>	<b>(3,804,781)</b>	<b>(4,970,302)</b>	<b>(4,313,861)</b>
<b>Total Carrying value at Balance Sheet date (i+ii+iii)</b>	<b>369,529,673</b>	<b>402,464,928</b>	<b>437,796,126</b>	<b>472,852,017</b>

**(b) Carrying amount as Tax Base**

**Tax Based Fixed Assets-WDV as on 30th June. 2025**

**As per Tax Depreciation Schedule as shown below (Including addition during year):**

Particulars	Amount in Taka			
	30-Jun-25	30-Jun-24	30-Jun-23	30-Jun-22
Plant & Machinery	119,645,132	132,279,036	146,825,106	162,914,507
Factory Building	57,204,310	63,560,344	70,622,605	78,469,561
Motor Vehicle & Bi-cycle	6,643,012	7,381,124	8,201,249	5,965,999
Furniture & Fixture	2,532,125	2,813,472	3,007,080	3,339,230
Office Equipment (including computer)	5,438,823	5,830,597	5,977,441	5,255,651
Laboratory Equipment	363,801	404,223	374,137	415,708
Generator	13,492	14,991	16,657	18,508
	<b>191,840,695</b>	<b>212,283,788</b>	<b>235,024,275</b>	<b>256,379,164</b>
<b>(c) Temporary Taxable Difference (a-b)</b>	<b>177,688,978</b>	<b>190,181,140</b>	<b>202,771,852</b>	<b>216,472,853</b>
<b>(d) Deferred Tax Liability on Temporary Taxable Difference (C*22.5%)</b>	<b>39,980,020</b>	<b>42,790,757</b>	<b>45,623,667</b>	<b>48,706,392</b>
<b>(e) Deferred Tax Recognised on Depreciation of Revaluation</b> Charged for the Period @22.5% (Schedule-10)	<b>942,503</b>	<b>1,028,278</b>	<b>1,122,587</b>	<b>1,226,325</b>
<b>(f) Deferred Tax Liability as on 30th June' 2024 (d+e)</b>	<b>40,922,523</b>	<b>43,819,035</b>	<b>46,746,254</b>	<b>49,932,717</b>

**Computation of Tax Based WDV of Fixed Assets  
As on June 2025 (As per 3rd Schedule of ITA, 2023)  
Assessment Year-2025-2026**

Description of Assets	Opening WDV as on 1-Jul-24	Addition during the year	Total	Rate of Dep.	Depreciation for the period	Closing WDV 30-Jun-25
Plant & Machinery	132,279,036	660,000	132,939,036	10%	13,293,904	119,645,132
Factory Building	63,560,344	-	63,560,344	10%	6,356,034	57,204,310
Motor Vehicles & Bi-Cycle	7,381,124	-	7,381,124	10%	738,112	6,643,012
Furniture & Fixture	2,813,472	-	2,813,472	10%	281,347	2,532,125
Office Equipment (Including Computer)	5,830,597	212,540	6,043,137	10%	604,314	5,438,823
Laboratory Equipment	404,223	-	404,223	10%	40,422	363,801
Generator	14,991	-	14,991	10%	1,499	13,492
<b>Total</b>	<b>212,283,788</b>	<b>872,540</b>	<b>213,156,328</b>		<b>21,315,633</b>	<b>191,840,695</b>

**WATA CHEMICALS LIMITED**  
**Depreciation Adjustment with Revaluation Reserve**

**Schedule-09**

Particulars	Plant & Machinery	Factory Building	Total
<b>Revaluation Increase</b>	353,253,863	54,663,662	407,917,525
<b>Depreciation Charged on Revaluation Increase</b>	102,453,863	54,663,662	157,117,525
<b>Rate of Depreciation</b>	<b>10%</b>	<b>5%</b>	
For the Year 31.12.2012	10,245,386	2,733,183	12,978,569
For the Year 31.12.2013	9,220,848	2,596,524	11,817,372
For the Year 31.12.2014	8,298,763	2,466,698	10,765,461
For the Year 31.12.2015	7,468,887	2,343,323	9,812,209
For the Period 30.06.2016 (6 Months)	3,360,999	1,113,097	4,474,096
For the Year 30.06.2017	6,385,899	2,170,542	8,556,441
For the Year 30.06.2018	5,747,308	2,062,015	7,809,323
For the Year 30.06.2019	5,172,577	1,958,914	7,131,491
For the Year 30.06.2020	4,655,320	1,860,968	6,516,288
For the Year 30.06.2021	4,189,788	1,767,920	5,957,708
For the Year 30.06.2022	3,770,809	1,679,524	5,450,333
For the Year 30.06.2023	3,393,728	1,595,548	4,989,276
For the Year 30.06.2024	3,054,355	1,515,770	4,570,126
For the Year 30.06.2025	2,748,920	1,439,982	4,188,901

(a) Depreciation on Plant & Machinery had been charged on partial revaluation increase amounting to Tk. 102,453,863 against total revaluation increase of Tk. 353,253,863 which is equal to 29% of total revaluation increase on Plant & Machinery value.

(b) Adjustment in respect of depreciation on revaluation increase for the year 2024-2025 for total amount of Tk.4,188,901/- had been made through "Change in Equity Statement".

**WATA CHEMICALS LIMITED**  
**Statement of Yearwise Unclaimed Dividend Account**

**Schedule-10**

SL No.	Year of Dividend	Amount of Taka		
		Demat Schedule-10 (A)	Non Demat Schedule-10 (B)	Total
1	Dividend Year - 2010	-	73,626	73,626
2	Dividend Year - 2011	9,480	88,352	97,832
3	Dividend Year - 2014	19,856	57,428	77,284
4	Dividend Year - 2015 -2016	18,961	143,571	162,532
5	Dividend Year - 2016 -2017	76,760	157,928	234,688
6	Dividend Year - 2017 -2018	88,305	143,739	232,044
7	Dividend Year - 2018 -2019	59,834	558,824	618,658
8	Dividend Year - 2019 -2020	56,365	814,951	871,317
9	Dividend Year - 2020 -2021	66,956	698,859	765,815
10	Dividend Year - 2021 -2022	39,425	465,878	505,303
11	Dividend Year - 2022 -2023	311,804	79,114	390,918
12	Dividend Year - 2023 -2024	571,985	61,839	633,824
<b>Subtotal (A)</b>		<b>1,319,730</b>	<b>3,344,110</b>	<b>4,663,840</b>

**Yearwise Statement of Transfer to ICB**

SL No.	Year of Dividend	Amount of Taka		
		Demat Schedule-10 (A)	Non Demat Schedule-10 (B)	Total
1	Dividend Year - 2010		73,626	73,626
2	Dividend Year - 2011	9,480	88,352	97,832
3	Dividend Year - 2014	19,856	57,428	77,284
4	Dividend Year - 2015 -2016	18,961	143,571	162,532
5	Dividend Year - 2016 -2017	76,760	157,928	234,688
6	Dividend Year - 2017 -2018	14,539	143,739	158,278
7	Dividend Year - 2017 -2018	73,766		73,766
8	Dividend Year - 2018 -2019	59,834	554,081	613,915
<b>Unclaimed Dividend Transferred Subtotal (B)</b>				<b>1,491,920</b>
<b>Less: TDS on Dividend</b>				<b>(216,582)</b>
<b>Unclaimed Dividend Account Net Transferred Subtotal (A)</b>				<b>1,275,338</b>
<b>Unclaimed Dividend Account Balance (A-B) = C</b>				<b>3,171,920</b>

**WATA CHEMICALS LIMITED**  
**Statement of Yearwise Unclaimed Dividend Account (Demat)**

Sl. No.	Folio Number / BO Account Number	BO Short Name	Amount in Taka
<b>Dividend Year - 2010</b>			
1	115	MR. MAHMUDUL KARIM	600.00
2	929	MR. ANWAR HOSSAIN	240.00
3	947	MR. MD. NURUL ISLAM	600.00
4	1268	BRIG(RTD) A.S. MAHMUD	300.00
5	1340	MRS LAILA AZAD	960.00
6	1466	MR. ZAFRUL HASSAN	900.00
7	1839	MR. SANJIB KUMAR SARKER	240.00
8	1867	MR. MOHAMMAD MOFAZZAL HOSSAIN	240.00
9	2031	MR. SK. TOWHIDUL ISLAM	540.00
10	2053	MR. KAZI EYEAR AHAMED	300.00
11	2059	DR. MD. REZAUL ISLAM	60.00
12	2492	MRS MOMATAZ BEGUM	600.00
13	2526	MRS. SHAMIM RRA BEGUM	480.00
14	2527	MRS. HOSNE ARA BEGUM	480.00
15	2531	MR. MD. TALIBUR RAHMAN	300.00
16	2628	MR. MD. ABDUL HANNAN	300.00
17	2894	M/S GRAMEEN SECURITIES MANAGEMENT LTD	240.00
18	3060	MRS RANA DEY & LINA DEY	60.00
19	3130	MR. SUKUMAR SAHA & DEEPTI SAHA	240.00
20	3309	MRS ROKEYA MUSTAFA	1,200.00
21	3899	MR. SIRAJUL ISLAM	60.00
22	4052	MR. ABM TAJ RIFAT RAHMAN	60.00
23	4054	MR. ABM ZIAUR RAHMAN SIDDIQUE	120.00
24	4055	MRS KAMRUN NAHAR ZIA	60.00
25	1416	MR. ANWAR HOSSAIN	300.00
<b>Dividend Year - 2010 Total</b>			<b>9,480.00</b>

1	1201510014710691	MD. KAMRUZZAMAN	50.00
2	1201510021598012	MD. JAHIRUL ISLAM	400.00
3	1201560041126772	SYED ALMAMUN FERDOUS	250.00
4	1201580004127538	MONZURUL HAQ SHOAIB	145.00
5	1203020028523450	HOSNE ARA BEGUM	300.00
6	1201590050426375	MD. ASLAM DEWAN	50.00
7	1201590051862887	SHAMIMA NASRIN	50.00
8	1203020029935552	MD. MATTIOR RAHMAN	150.00
9	1201630045555367	MD. MOSHIN BHUIYAN	150.00
10	1201640016732895	MD. MONIRUZZAMAN	130.00
11	1203260035235210	ANWAR HOSSAIN	200.00
12	1201720005541440	MD. ROWNOK HOSSAIN	200.00
13	1203040039208129	MD. MOBARAK MIAH	250.00
14	1201770004506089	MD. REFAUL HAQUE	156.00
15	1201920003792892	MD. REZAUL HOQUE	156.00
16	1201920004180382	MD. KHORSHID ALAM	78.00
17	1201920016544249	MD. SIRAJUL HAQUE	500.00
18	1202000000510321	MR. TUHIN SAHA	200.00
19	1202000000746831	SYED AZIZUDDIN HOSSAIN	390.00
20	1202030051416940	MD. SAIFUL ALAM	200.00
21	1202050014238609	MD. ISMAIL HOSSAIN	620.00
22	1202090052018791	REZZAUL HASSAN BHUIYAN	500.00
23	1202150034889796	MRS. TAHMINA KHATUN	200.00
24	1202160026345022	A.K.M SHAKHAWAT HOSSAIN	500.00
25	1201530051727223	SAMIR KUMAR DAS	500.00
26	1202400021519308	TARIQUL AHAMMED	500.00
27	1202450049443661	MD. NAZIB MAHMUD SHAJIB	700.00
28	1202550034335073	MD. KHAIRUZZAMAN BARBHUIYAN	337.50
29	1202630034422084	MOHAMMED ALAM	400.00
30	1202790004130279	KAZI TOHIDUL ISLAM	430.00
31	1202800033993929	SABITA MAJUMDER	50.00
32	1202820001863729	MD. MASUD ALI KHAN	250.00
33	1202820005793012	EMRAN ALI MUNSHI	162.50
34	1202820055023821	MD. NAZMUL HAQUE	405.00
35	1202830012300560	MD. ALI AKBAR	200.00
36	1202830036339521	MOHAMMED HEDAYET ULLA	200.00

Sl. No.	Folio Number / BO Account Number	BO Short Name	Amount in Taka
37	1202890055939133	TASMIN HAQUE	150.00
38	1202980004963993	MD. SAYED AHMED	200.00
39	1203020021006566	ASHIS KUMAR SARKER	120.00
40	1203020033812170	KAMRUN NAHAR	120.00
41	1203110027165487	MD. NASIR HOSSAIN (RIAZ)	150.00
42	1203180000218186	MOHAMMAD HABIB ISMAIL BHUIYAN	500.00
43	1203180026465676	MUNSHI MOSHIUR RAHMAN	250.00
44	1203250009640481	MD. GOLAM MUSTAFA PATWARY	250.00
45	1203280024343477	MD. SAIFUL ISLAM	800.00
46	1203410004962541	MOHAMMAD SK.SALIM	300.00
47	1203490040399606	MD AMJAD HOSSAIN MOJUMDER	300.00
48	1203510040303421	SONIA PARVIN	500.00
49	1203650011829016	MD. TASIN KADIR	500.00
50	1203680020541138	MD. SAIFUL ISLAM	600.00
51	1203880028619778	SYED A.K.M SALIM	1,000.00
52	1204310032213428	MD ANWAR HUSSAIN	500.00
53	1204310044231270	BADRUN NAHAR JOLLY	200.00
54	1204490033483479	KHAIRUNESSA AHMED	150.00
55	1205790056101973	MD. MIZANUR RAHMAN	700.00
56	1202030039342132	LAILA AKTER	150.00
57	1202320004124237	SUKUMAR SAHA	156.00
58	1202380015314652	MD. MUZIBUR RAHMAN	156.00
59	1202410041024124	MD. SERAZUL ISLAM	130.00
60	1202060021112783	MD. NAZMUL HUDA	303.50
61	1203630043576651	HASINA ZAHAN	805.00
62	1204490038099344	MD. HAFIJUR RAHMAN	365.00
63	1203680056604220	BISHWAJIT PAUL	425.00
64	1203140005122842	FIROZ AHAMED	26.00
65	1203730055704503	SHIRIN AKTER	89.00

Dividend Year - 2014 Total

19,855.50

**Dividend Year - 2015 -2016**

1	1202280031977251	SUMAN SAHA	10.00
2	1202060022072884	MD. JAHIR UDDIN MALLICK	250.10
3	1202020000276552	MR. TAPAN CHANDRA BHOWMIK	202.14
4	1202030017628510	M. ANISUR RAHMAN RAJIB	32.04
5	1202160015301686	MOSAMMATH ANJUMANARA BEGUM	128.16
6	1202140016197110	HASAN MD. SHAHARIAR ALAM	32.04
7	1202150000883541	MD. SHAHJAHAN KAZI	30.00
8	1202090000370235	MR MD RUHUL AMIN	400.00
9	1202090006416897	MRS JENY HAZRA	90.10
10	1202090033242807	S.M. HABIBUL HASAN	20.00
11	1202140021332940	MD. AMJAD HOSSAIN KHAN SOHEL	96.12
12	1202140000222060	MR. ABUL BASHER KHAN	202.14
13	1202820001358022	PILOO MIAH	390.00
14	1202720027309786	EXCELLENT INVESTMENT LTD.	180.10
15	1202840004183774	MD. ABUL HASHAM	202.14
16	1201510014710691	MD. KAMRUZZAMAN	200.10
17	1202200032506780	MD. SAIFUL ISLAM	80.10
18	1202250021689238	MR. BADAL CHANDRA BHADRA	90.10
19	1202200010746881	KAMRUN NAHAR	210.10
20	1202370025689468	MOUSUMI JASMIN	242.14
21	1202320004124327	SUKUMAR SAHA	390.00
22	1202370009654541	PARVIN SULTANA	500.00
23	1202160014856756	UMA RANI DAS	390.00
24	1204490044971698	MD. SHAH ALAM	330.00
25	1203500030291431	MD. IMRAN SHARIF	210.00
26	1203730059169358	SHASAN BARUA	30.00
27	1203610019206904	BIPLOB KUMAR BISWAS	224.18
28	1203650042930417	ALAMGIR	60.00
29	1203020034742759	MD. MAMUN	210.00
30	1203210021482164	MD. HABIBUR RAHMAN MOLLA	260.10
31	1203630055342568	MD. NURUS SALAM	170.00
32	1203630055343024	MD. NURUS SALAM	100.00
33	1203520010424504	MD. FAYSAL	250.00
34	1203450004122139	MD. RASED ALI	300.10
35	1203410044843426	ANOWER ALI	500.00
36	1202800033993953	HAZERA KHATUN	488.16

Sl. No.	Folio Number / BO Account Number	BO Short Name	Amount in Taka
37	1202640004301300	BILKIS AKTER	1,350.00
38	1203270013245461	MD. DAIN ISLAM	100.00
39	1203280048614271	MD. ARIF BILLAH	500.00
40	1203040040294561	MS. NASIMA AKTER	272.14
41	1203040048604887	SUNZEDA SULTANA	930.00
42	1203060008131578	RASHID IQBAL	200.00
43	1203080001334260	ME. ASADUZZAMAN TALUKDER	550.00
44	1201580018634032	MR. MASUDUZZAMAN	300.00
45	1201900046492328	MD. KAMAL KHAN	450.00
46	120200000030326	MR. KAZI SHAHIDUL ISLAM	250.00
47	1201890061184321	MD. YONUS MIA	32.04
48	120190000105976	PRODIP KUMAR DAS	10.00
49	1202020000451453	MR MD YEASIN MOLLA	500.00
50	1201560000768916	HASIN AHMED	592.14
51	1201480026343074	DELOWAR HOSSAIN	532.14
52	1201850020959682	MR MD. ARIF	700.10
53	1204760020513691	SYED ABDUL NOOR	550.00
54	1202270049765251	BEAUTY AHMED	200.00
55	1201640000137356	MOSADDEQUL HUQ	500.00
56	1201480020672759	KAZI ABUL KASHEM	1,000.00
57	1201940041253327	MD. SHAHABUDDIN	250.00
58	1203670060527870	HARU LAL DAS	400.00
59	1203350001131152	AZAD RAHMAN KHAN	390.00
60	1202630017977283	MD. EYASHIR ARAFAT	50.00
61	1202820000193584	MURAD ALI KHAN	322.04
62	1203680059822716	MOHAMMAD HOSSEN	260.10
63	1202420025474289	MD. MASUDUR RAHMAN	100.00
64	1202420025474297	MD. MASUDUR RAHMAN	40.00
65	1202840041494991	NIGAR SULTANA	50.00
66	1203520058588136	SHAH MUNTASIR MAMUN	80.00

Dividend Year - 2015 -2016 Total **18,961**

**Dividend Year - 2016 -2017**

1	120147000429811	MD. MOHIBUL ISLAM CHOWDHURY	223.38
2	1201470038352716	MD. SHAHJAHAN MIAH	83.38
3	1201510009709592	MD. FIRDOUS ALAM	603.38
4	1201510023333625	MD. MAHBUBUR RAHMAN POLASH	1,000.00
5	1201540023371081	SHAH MOHAMMAD IBRAHIM	163.38
6	1201580004093403	MD. FARID UDDIN	60.00
7	1201720004510758	MD. ELIAS	2,500.00
8	1201770003494098	2046 - MD. ANWAR HOSSAIN	343.38
9	1202050001719501	MR. MD.MAHFUZUR RAHMAN BHUIYAN	1,601.65
10	1202080016703044	MD.TAZ UDDIN	200.15
11	1202160017261331	MD. MAHABUBUR RAHMAN	360.00
12	1202450000749908	MOKHLES ALAM	100.00
13	1202580032662095	ZIAUL ASHRAF	481.50
14	1202640011144253	M. BAZLUR RASHID	342.70
15	1202870000093671	MAKSUD OMAR	201.80
16	1203040035532558	MD. JAHANGIR ALAM NASIM	1,000.00
17	1203100045440850	MD. ASHRAFUL ISLAM	40.45
18	1203140040410212	MRS. SHARDA ZAMAN	100.00
19	1203370005242561	MD. ELIAS	2,200.00
20	1203510015413164	MOHAMMMAD ABDUR ROB	222.25
21	1203680043602101	KHONDOKER FARID HASSAN	1,000.00
22	1203880016928552	HENRY BOWER	2,102.70
23	1203880030410709	BILKIS BEGUM PARUL	1,900.00
24	1203880035355813	RASMA BEGUM	2,000.00
25	1204090032342239	ABURI INTERNATIONAL	4,581.50
26	1204430022313969	SUSHANTA BANIK	100.00
27	1204500044710328	MST. NURUNNAHAR	320.00
28	1204880051582393	MD. KAMRUZZAMAN MASUM	900.00
29	1205780040480537	RIAZ UDDIN AHMED	80.00
30	1205780062840091	MR. ASADUZZAMAN	1,000.00
31	1301020000991905	RUPALI BANK LTD. F. EX.CORP.BR.	7,021.80
32	1605310047501168	SUSPENSE ACCOUNT BONUS SHR	7,021.80
33	1201720016118034	DR.MD.SHAMSUL ALAM	279.00
34	1201720019673740	MD.ABDUR RASHID	218.10
35	1201720026263107	MD.ABU HANIF	200.00

Sl. No.	Folio Number / BO Account Number	BO Short Name	Amount in Taka
36	1201720026537601	MD.ABU HANIF	393.00
37	1201720029919275	HASINA AKTER	300.00
38	1201720039377129	SURAIYA AKTER	1,000.00
39	1201720053881433	MD. GOLAM SAROAR	1,000.00
40	1201720054888263	TASLIMA HAQUE	151.00
41	1201720062992992	SWAPAN KUMAR PAUL	662.00
42	120173000096766	MR SK. FAZLUL KARIM	173.00
43	1201730001138526	MR.MOHAMMAD JAHIRUL QUAYUM.	547.00
44	1201730001138550	MR.RASHEDUL QUAYUM.	1,095.00
45	1201730045715702	MD.ALAMGIR HOSSEN	202.00
46	1201730053847605	SYED MOKBUL AHMED	345.00
47	1201730061373477	MD ZAKIR HOSSAIN	6,420.00
48	1201730062365545	MD.SHAHID MIA	70.75
49	1201740021933409	DR.MD.GIASH UDDIN	499.00
50	1201740040197270	GOL AFROZ BEGUM	300.00
51	1201740049177917	MD. ABDUR ROB JOMADDER	6,691.00
52	1201740062593272	MD.SHAHEENUR REZA TALUKDER	540.00
53	1201740063021086	ADNAN FORHAD	1,342.00
54	1201750000136054	MD. AMIRUL ISLAM	382.00
55	1201770004506089	3003 - MD. REFAUL HAQUE	547.00
56	1201770045625821	12335-MODON KUMAR SHEN	2,482.00
57	1201810000020139	AHMED MAHMUDUR RAHMAN KHAN	28.30
58	1201810000024137	S.M. ABU HASSAN	1,095.00
59	1201810005247190	MOSHER REF HOSSAIN BHUIYAN	1,229.80
60	1201810018456965	SHARMIN NAHAR	7,400.00
61	1201820015772793	MD.ELIAS	572.00
62	1201820025691931	MAHMUD HASSAN	470.00
63	1202010041752355	MD. KAMRUZZAMAN	60.00
64	1202030045726506	MOHAMMAD SAFIQU R RAHMAN	20.00
65	1202080056428649	MD. BILLAL HOSSAIN	90.75
66	1202090000596748	M.A KAMAL UDDIN	100.00
<b>Dividend Year - 2016 -2017 Total</b>			<b>76,760</b>

**Dividend Year - 2017 -2018**

1	1201470008028437	MD. ABUL MILLAT	
2	1201480003801374	MD. ABDUL MOIEZ	800.00
3	1201510009928150	TAPAN CHANDRA MALLIK	100.00
4	1201530037652758	UMME AMARA SHATHI	890.00
5	1201530064669531	MD. JAHID HOSSAIN	200.00
6	1201540062892659	MD.MASUM	50.00
7	1201540064004962	HASIB AHMED	50.00
8	1201540064677016	ARPITA BARUA	50.00
9	1201560000014437	MUSFIQU R RAHMAN	400.00
10	1201560017562958	MD. FAZLUL HAQUE	100.00
11	1201560043472526	MD.AMIR HOSSAIN	100.00
12	1201570000158687	NASREEN JAHAN	570.00
13	1201570010363026	MOMTAZ BEGUM	10.00
14	1201570010346068	MOMTAJ BEGUM	10.00
15	1201580000054883	MR. MD. BAZLUR RAHMAN	10.00
16	1201580000332567	MR. MOHAMMAD ABDUL AZIZ	182.00
17	1201580000332947	MRS.RAHMAT-A-KHODA	450.00
18	1201580007732987	MD ZAHID HOSSAIN	98.00
19	1201580007732995	MD ZAHID HOSSAIN	98.00
20	1201580020961361	MRS.MAHTABA HASAN	1,000.00
21	1201580023349051	KHANDOKER AHSAN HABIB	456.00
22	1201580026277956	MD. ABDUS SALAM FARAZI	260.00
23	1201580036213002	ENAETH HOSSAIN	250.00
24	1201580038401462	MD. AKRAM ULLAH KHAN	60.00
25	1201580039363404	SUMAN HOSSAIN	490.00
26	1201580062031686	H.M.ELIUS ASHMOAL	250.00
27	1201580066432920	MD.MAMUNUR RASHID	190.00
28	1201590000369022	MR. SUDHIR KUMAR ROY	100.00
29	1201590018577968	MOHAMMED MAHABUBUR RAHMAN	314.00
30	1201590018643591	SABERA BEGUM	1,000.00
31	1201590019495019	SUKDEB BANIK	1,000.00
32	1201590020610028	MD SHAH ALAM SIDDIQUE	900.00
33	1201590021784370	MD BELAL HOSSAIN	100.00
34	1201590024920695	MD. ATIKUR RAHMAN	1,160.00

Sl. No.	Folio Number / BO Account Number	BO Short Name	Amount in Taka
35	1201590025249373	BIDDUT DEY	350.00
36	1201590026014084	MD. ISTIAK ALAM	50.00
37	1201590033204253	MD. ARMAN ALI	10.00
38	1201590033438087	KAZI MOHAMMED JASHIM UDDIN	310.00
39	1201590034088717	MD. BAHAUDDIN FAHIM	200.00
40	1201590060549478	JAMIUL ISLAM BISWAS	240.00
41	1201590062893711	PRITHWI RAJ ACHARJEE	1,000.00
42	1201600021440356	KAMRUN NAHAR	350.00
43	1201630020517612	MD. KAMRUL ISLAM	500.00
44	1201630048600000	SIDDIQUE HOSSAIN	120.00
45	1201630051692097	KOHINOOR AKTER	200.00
46	1201630053351251	NAYAR SULTANA	200.00
47	1201690012317163	MD.ABDULLAH EL KAFI	100.00
48	1201700005866168	MITRA BHATTACHARJEE	370.00
49	1201700042343143	BONY ISRAEL	200.00
50	1201700058109210	MD. IQBAL HASAN	100.00
51	1201700062425368	MOHAMMED MOSLEM MIAZI	100.00
52	1201700067099974	MD. SHAHNEWAZ ISLAM	10.00
53	1201710000920918	MD. SALEH ABDULLAH	450.00
54	1201710002551632	ABU BAKER SIDDIQUE	100.00
55	1201710018121512	MD. ABDUR RAZZAQUE	300.00
56	1201710029114521	MD. DIDARUL ALAM	600.00
57	1201720020177796	KAZI SAIDUL HAQUE	300.00
58	1201720027179367	MD.ABDULLAH	50.00
59	1201720039377129	SURAIYA AKTER	50.00
60	1201730000017093	MD. AMDADUL HAQUE	270.00
61	1201730040440166	SHAH MD. MAMUN-OR-RASHID	50.00
62	1201730058783794	SHAH MD.MAMON OR RASHID	150.00
63	1201740016764208	SHAHIDA AFROZ	1,000.00
64	1201740020688771	K.M. ASHADUZZAMAN	1,000.00
65	1201740060729339	TOWFIQUE RAHMAN	800.00
66	1201740060802111	MD. HAMIDUL ISLAM	500.00
67	1201740064858677	ARIFUR RAHMAN	100.00
68	1201770003494098	2046 - MD. ANWAR HOSSAIN	476.00
69	1201810000780617	MD. NASIR UDDIN HOWLADER	200.00
70	1201820006052801	SAIFUDDIN AHMED	1,000.00
71	1201820017388449	JIBAN KRISHNA BHOWMIK	1,000.00
72	1201820018090713	MD.NEYAMUL HAQUE	990.00
73	1201820026062113	GOPAL CHANDRA PAUL	260.00
74	1201820026698248	SHEIKH MD. SARWAR HOSSAIN	1,000.00
75	1201820028183658	MD. FARUQUL ALAM BHUIYAN	750.00
76	1201820030364311	ABU NAHID EBNE HASHEM RIAN	1,000.00
77	1201820030813948	ABU NAHID EBNE HASHEM RIAN	1,086.00
78	1201820032307928	ANUP KANTI DAS	100.00
79	1201820042281166	MD.KUTUB UDDIN	300.00
80	1201820044758208	MD. ABU TAREQ	830.00
81	1201820045605281	MD. ABDUS SATTAR	100.00
82	1201820049696345	SHANKAR CHADRA ROY	900.00
83	1201820051704431	S.M ABU SAYEM HIMEL	100.00
84	1201820052500644	COMPUTER NETWORK SYSTEMS LTD.	270.00
85	1201820052929992	MOHAMMAD BORHAN UDDIN	240.00
86	1201820053315962	JASIM MOHAMMAD	400.00
87	1201820062543763	MOHAMMAD SARWAR ALAM	100.00
88	1201820062549637	SIDDIQUR RAHMAN	1,000.00
89	1201820062756598	MD. ABUL MOHSIN	100.00
90	1201820062771407	MEER MONIRUZZAMAN	300.00
91	1201820062962733	MD HUMAYUN KOBIR SHAHEEN	282.00
92	1201900021292851	K.B. AZGAR AHMED	200.00
93	1201900046492328	MD. KAMAL KHAN	94.00
94	1201910063653948	MIR ASRAFUL ISLAM	480.00
95	1201910064124208	MD. SHAHADAT HOSEN	10.00
96	1201910067068140	SYED IMRAN AHMED	230.00
97	1201920064421727	PANKAJ ROY CHOWDHURY	550.00
98	1201930062731574	ISHTIAQ HYDER KHAN	100.00
99	1201940016242123	DEWAN MUHTANEK FAHIM	240.00
100	1201940034093871	SHETOL IGNATIOUS GONSALVES	10.00
101	1201940060184726	ASHRAF ALI KHAN	100.00

Sl. No.	Folio Number / BO Account Number	BO Short Name	Amount in Taka
102	1201950000342151	ABDUS SALAM ARIF	602.00
103	1201950005103818	WORLD. COM LTD.(UNIT-1)	500.00
104	1201950006719859	GAZI MARUF HASAN	100.00
105	1201950007057341	MASUK AHMED PATWARY	50.00
106	1201950011592595	KAZI RAHILA FERDOUSI	350.00
107	1201950011738007	NOORJAHAN BEGUM	190.00
108	1201950062213752	FARUK AHMED	758.00
109	1201950062614114	MD. IBRAHIM HOSSAIN	200.00
110	1201950062708566	ABUL KASEM MD ASADUZZAMAN	500.00
111	1201950064814059	KAMAL UDDIN	100.00
112	1201950065364835	ZOHURA KHATUN	500.00
113	1201960003775238	JANNATUL AFROZ	320.00
114	1201960030170059	MD RAKIBUL HASSAN	64.00
115	1201960030330785	MD GIAS UDDIN	270.00
116	1201960039682159	TULSHI CHANDRA SARKER	300.00
117	1201960058567343	PARVIN ISLAM	100.00
118	1201960063836406	GAZI ABUL KASHEM	580.00
119	1201960064482411	MD ABBAS UDDIN	720.00
120	1201960064554397	RAJIB DEB NATH	426.00
121	1201960065371863	MAJUMDER TRADERS	1,080.00
122	1201980001612225	MUKTA AKTER	560.00
123	1201980003833720	MOHAMMAD SHAH ALAM	250.00
124	1201980032144190	FATEMA KHANAM	650.00
125	1201990002305166	FARIDA YASMIN	324.00
126	1202000016415571	S M SHFIQL AMIN FERDAUSI	260.00
127	1202010062981388	SHOPNO BILASH CO-OPERATIVE LTD	100.00
128	1202020017934909	MD. LITON	226.00
129	1202020044604614	KAMOL SARKER	130.00
130	1202020055388473	MD. ABU SUFIAN MOZUMDER	440.00
131	1202020058311101	RASHEDUL ISLAM	100.00
132	1202020058383955	ELMI BINTA SHAWKAT	30.00
133	1202020062579738	KHALED HASAN	80.00
134	1202050010850066	MR. MD. SIDDIQUR RAHMAN	200.00
135	1202050017237104	MD. SAMIUL ISLAM	600.00
136	1202060000131086	MD. MUZAMMEL HAQUE	334.00
137	1202060015308447	MD. SALIM MOLLA	300.00
138	1202060015492829	MD. TAYABUR RAHMAN	280.00
139	1202060024800710	MD. TAYEBUR RAHMNA	142.00
140	1202060024800729	MST. ROKIYA	284.00
141	1202060063762077	MD. RUBEL HOSSAIN	50.00
142	1202090000050601	ADVOCATE S K SEN	284.00
143	1202090006416897	MRS JENY HAZRA	392.00
144	1202090021484751	SM MASUDUL HAQUE	630.00
145	1202090040791291	MR. ABU BAKAR SIDDIK	200.00
146	1202090045220104	MD. MOFAJJAL HOSSAIN	40.00
147	1202090050231231	MUHAMMED SHAMSUDDIN	100.00
148	1202120065940652	MD. SHOHAG	428.00
149	1202130048740849	MD MOKDED MOLLAH	60.00
150	1202140016294592	MD ANWARUL MALEK	600.00
151	1202140055267304	MD. ATIQUR RAHMAN	530.00
152	1202150000209662	MR. IFTEKHAR AHMED	54.00
153	1202150006167292	SHEFALI AKTAR	50.00
154	1202150007465550	FABIAN S. GOMES	500.00
155	1202160015955641	K.B AZGAR AHMED	410.00
156	1202160016673729	MD. SYEDUR RAHMAN	10.00
157	1202160062450631	SAYED AHMED KHAN	100.00
158	1202190042843513	KHALEDUN NAHAR	300.00
159	1202190056240071	SHORIFA ISLAM	408.00
160	1202200000097265	S M KOWSAR	1,000.00
161	1202200000395216	MD. MOHIUDDIN (MOHIN)	50.00
162	1202200012099772	MUHAMMAD SHOWKAT IMRAN	300.00
163	1202200022402995	MUHAMMAD MIZANUR RAHMAN	280.00
164	1202200023977252	RABEYA KHATUN	110.00
165	1202200062574818	M0HAMMAD ABUL FAZAL SHARKAR	60.00
166	1202210005091829	MIR ASGAR ALI	390.00
167	1202220060635872	SHARIF MUHAMMED FAZLAE ELAHI	1,000.00
168	1202220062018509	MD. HUMAYUN KABIR PATWARY	1,000.00

Sl. No.	Folio Number / BO Account Number	BO Short Name	Amount in Taka
169	1202240043148895	MUHAMMAD MIZANUR RAHMAN	260.00
170	1202240053836887	MD.ABIDUZZAMAN	100.00
171	1202260016303007	MOSTAFA KAMAL UDDIN	392.00
172	1202280017412966	MD. MASUM KABIR	100.00
173	1201470044290625	MD. AMDADUL HAQUE	100.00
174	1201510040013792	AMINUR RAHMAN	390.72
175	1201510052140119	MR. MD. ABDUL MATIN	425.00
176	1201580000413429	MR. MD. SHAHJAHAN ALI	1,000.00
177	1201590043543150	MOHAMMAD ALI ZINNAH	1,000.00
178	1201590065754527	MD. MONIRUL ISLAM	142.00
179	1201630015273623	MD.MAHBUB MUSA	1,020.00
180	1201720000010083	S.M. MONIRUZZAMAN	269.00
181	1201730012454807	SAYED JISHAN	100.00
182	1201770004506089	MD. REFAUL FAQUE	450.00
183	1201810000024137	S.M. ABU HASSAN	900.00
184	1201820025958355	MANISHA BANERJEE	929.00
185	1201820028591104	JINNATH ARA	200.00
186	1201820040805587	MD.JALAL HOSSAIN	409.00
187	1201820064727297	HAFIZA BEGUM	849.20
188	1202000016415588	BEGUM HANUFA KHANAM	50.00
189	1202020055363286	H. A. FATTAH	500.00
190	1202030001491280	HANNAN SHIKDER	350.00
191	1202090016909892	MAHAMUDA ANWAR	400.00
192	1202150021893963	MD. ANISUZZAMAN	300.00
193	1202240062726636	AZM OBAIDUR RAHMAN	500.00
194	1202400059020908	MOHAMMAD ALI	54.00
195	1202400059020916	MOHAMMAD ALI	54.00
196	1202400059803098	GOLAM FARUQ CHOWDHURY	294.00
197	1202400060282019	MD. MOSLIM UDDIN	180.00
198	1202400060309399	MASHUKAT TABASSUM	100.00
199	1202400060825912	MST. ZARINA BEGUM	30.00
200	1202400062903212	MD. MAHABUBUL ISLAM PATWARY	100.00
201	1202580004121359	ABDUR RAHIM MOLICK	10.00
202	1202620003924269	SHAKWAT HOSSAIN CHOWDHURY	30.00
203	1202830004996822	MS. HELEN IMRAN	10.00
204	1202830049597471	MD. SHAMSUJJAMAN	289.20
205	1202840039367967	DIPU KUMAR BARUA	315.00
206	1202840061199123	MD. SOHEL HOSSAIN	144.00
207	1202850022451475	MOHAMMED MIZANUR RAHMAN	98.00
208	1202960016990217	MUHAMMAD MAKSUDUR RAHMAN	120.00
209	1203020054906682	ABDUL OHAB	90.00
210	1203060027285616	MST. MASUM JAHAN	313.04
211	1203060058506931	MD. ABDUL MALAK	1,000.00
212	1203140040932728	SOHEL AHMED	1,085.00
213	1203150031058257	MD HALIM MIAH	259.00
214	1203150043475016	ATAUR RAHMAN	200.00
215	1203180028694524	MD.ARIFUL ISLAM	249.20
216	1203180066038139	SHADMAN SAKIB NOOR	1,000.00
217	1203320007137704	MD. A. KADER	500.00
218	1203360049818881	ABU TAMIM MUHAMMAD JAHIR IMAM	330.00
219	1203510023287254	HOSNEARA BEGUM	104.00
220	1203520010562607	MD. FAZAL AHMED	500.00
221	1203620064808314	SHAHERA BEGUM	461.00
222	1203630019313069	MD. SAIDUR RAHMAN	475.00
223	1203650059460315	YEASMIN SHARMIN	100.00
224	1203730044477621	MD. ABDUL QUADER KHONDAKER	475.00
225	1203780032827144	MD. NUR ISLAM MINAR CHODURI	94.00
226	1203780036007131	MAMUNUR RASHID	200.00
227	1203780044544221	NAZRUL ISLAM RIPON	50.00
228	1203780044601372	ABU FOYEZ	40.00
229	1203810013051230	MD. HANNAN BISWAS	431.00
230	1203940001584652	MR.MOHD ALI XAHANGIR	168.00
231	1204050038831097	MIZANUR RAHMAN	500.00
232	1204070066462823	ABDUR RAB	1,000.00
233	1204220014583322	MD. FARUK HOSSAN	200.00
234	1204220058583117	MOHAMMAD AKRAM HOSSAIN	90.00
235	1205690062264788	MD. TANVER AHMED	200.00

Sl. No.	Folio Number / BO Account Number	BO Short Name	Amount in Taka
236	1205690062655134	MOHAMMAD KAMRUZZAMAN	124.00
237	1601880027509823	MD SADAK AHMED	200.00
238	1602170046045411	A.R. CONSULTATION	255.36
239	1605220046887775	RIL-I/A:R0598	50.00
240	1201540023371081	SHAH MOHAMMAD IBRAHIM	426.60
241	1201540066432757	SALMA BEGUM	70.00
242	1201590046703684	NARGIS AKTHER KHANOM	342.80
243	1201590046703716	MD. REZAUL KARIM	161.40
244	1201820015136905	AHSANUL ALAM	269.00
245	1202080056428649	MD. BILLAL HOSSAIN	400.40
246	1202150000494009	KAMRUN NAHAR	450.00
247	1202400000011286	MD.SHAHIDUL ISLAM	600.00
248	1202420038830274	BILLAL HOSSAIN	141.40
249	1202640011144253	M. BAZLUR RASHID	251.40
250	1202850044451976	MOHAMMED BABUL	20.00
251	1203060048514301	HABIB ULLAH	167.60
252	1203110016505517	MD.KHORSHED ALAM DHALI	127.60
253	1203150062820865	MD ABDUR RASHID	250.00
254	1204170028015826	MD.ABUL HASNAT BHUIYAN	1,000.00
255	1204390041516796	SHEIKH MD. KALA MIAH	100.00
256	1204570026085039	HAMIDA BEGUM	191.40
257	1301020025720820	MD. BILLAL HOSSAIN	420.40
258	1602170020158076	ABDUR RAHIM	245.20
<b>Dividend Year - 2017 -2018 Total</b>			<b>88,305</b>

**Dividend Year - 2018 -2019**

1	1201500017673573	MD. NAZIMUDDIN	210.00
2	1201510018278367	MAKHAM CHANDRA GINE	330.00
3	1201510052140119	MR. MD. ABDUL MATIN	279.00
4	1201530000256649	SHARIFUL MOSLEMIN KHAN	1,845.00
5	1201580027132721	MD. BILLAL HOSSAIN	92.55
6	1201580028051016	IFFAT ARA IRIN	546.00
7	1201580028058663	IFFAT ARA IRIN	666.00
8	1201600021885841	AFZAL HOSSAIN	186.00
9	1201700058727100	RAHONUMAYA RAHMAN	954.00
10	1201720000010083	S.M. MONIRUZZAMAN	225.00
11	1201720025773881	MD.SHAMAUN ALI	12.00
12	1201730000096766	MR SK. FAZLUL KARIM	276.00
13	1201730018669152	JESMIN AKTER	1,110.00
14	1201770004506089	MD. REFAUL HAQUE	1,845.00
15	1201820015136905	AHSANUL ALAM	225.00
16	1201820015355755	GOLAM DASTAGIR	105.00
17	1201820040805587	MD.JALAL HOSSAIN	801.00
18	1201820045585722	MR. PINTU DEY	234.00
19	1201820068186192	MD. ISMAIL	600.00
20	1201830000068316	MD. A. AZIZ MIAH	600.00
21	1201830037729695	MD. ASHIK UZZAMAN	300.00
22	1201830039764537	SHUVA DAS	246.00
23	1201840043175462	M MOHIBUR RAHMAN	570.00
24	1201890018214697	MD. ALI AKBAR KHAN	360.00
25	1201890062003335	MOHAMMAD ERFAN UDDIN	210.00
26	1201900025234879	MD. SANOWAR HOSSAIN	102.00
27	1201910062702981	PLACID GOMES	192.00
28	1201950005432329	MD. KAMAL HOSSAIN	102.75
29	1201950046125940	CHANDAN KUMAR KUNDO	270.00
30	1202020020096693	MR AREF BARKAT	600.00
31	1202020021463734	KHOKON CHANDRA DASH	750.00
32	1202020022958847	MUHAMMAD ALAMGIR HOSSAIN	165.00
33	1202080056428649	MD. BILLAL HOSSAIN	189.00
34	1202090016478245	SK. NASIR UDDIN	330.00
35	1202120000086916	ASM RUBAIYAT FARMAN	300.00
36	1202120046580424	MST. NAZMA	93.00
37	1202140062434461	SHAHANA BEGUM	510.00
38	1202150000209662	MR. IFTEKHAR AHMED	117.00
39	1202150015007492	MD.SHAHIDUL HASAN	93.00
40	1202240050172710	MOHAMMAD SAIFUR RAHMAN	210.00
41	1202280017884275	ABUL HOSEN	330.00
42	1202400001337320	MOHAMMAD ANSAR UDDIN	750.00

Sl. No.	Folio Number / BO Account Number	BO Short Name	Amount in Taka
43	1202400019484116	MD LITON AKTER	786.00
44	1202400059020908	MOHAMMAD ALI	117.00
45	1202400059020916	MOHAMMAD ALI	117.00
46	1202400060331252	MD. AWAL BHUIYAN	117.00
47	1202400060337134	MD. AWAL BHUIYAN	117.00
48	1202400061028191	MD. ZAHURUL ISLAM	315.00
49	1202400061028215	CHAMPA BEGUM	303.00
50	1202400068794505	TABUSSUM AKTER	141.00
51	1202420038830274	BILLAL HOSSAIN	93.00
52	1202450018342618	MR. RIZWAN FERDOUS RAHMAN	1,440.00
53	1202450046145043	DAWoudUR RAHMAN	600.00
54	1202450053579490	MST. RABEYA KHATUN	93.00
55	1202450053765286	MD. ASHRAFUL ALAM CHOWDHURY	300.00
56	1202460058403331	REAZUL HAQUE	291.00
57	1202580004121359	ABDUR RAHIM MOLICK	185.10
58	1202580015208210	MR. FARID UDDIN AHMED	186.00
59	1202630007871977	REZAUL HAQ	300.00
60	1202640011144253	M. BAZLUR RASHID	432.00
61	1202650035762549	MAHABUB UDDIN AHMED	210.00
62	1202760003928995	MD. SHAMSUZZAMAN	12.00
63	1202810004232429	MD. SALIM ULLAH	96.00
64	1202820005793012	EMRAN ALI MUNSHI	93.00
65	1202830004996822	MS. HELEN IMRAN	300.00
66	1202830044722621	MAHADI HASSAN BHUIYAN	900.00
67	1202830054919956	BIPUL KUMAR GOSWAMI	1,230.00
68	1202900000014595	K. J. CHOWDHURY	3,000.00
69	1202950022039879	MD. ABDUL BARI	287.10
70	1203000046244125	MAHFUJA MIZAN	1,590.00
71	1203000054877461	MD ABDUL LATIF	117.00
72	1203010017953165	ABDULLAH-AL- MAMUN	1,467.00
73	1203010019017090	MARY SARKAR	510.00
74	1203020014783940	MONJERA TASMIN	717.00
75	1203060049579292	SHAMIM AHMED	360.00
76	1203110032199786	MD. IBRAHIM KHALIL	117.00
77	1203110048712185	BEAUTI SULTANA	186.00
78	1203120067536701	MD. HAFEZ AHMED	60.00
79	1203150043475016	ATAUR RAHMAN	120.00
80	1203210045516370	MD. ABUL HOSSAIN	300.00
81	1203210048464594	MD. ALAMGIR HOSSAIN	93.00
82	1203210064162810	MD. MOSHIUR RAHMAN MAZUMDER	186.00
83	1203260004150305	ALI KAUSAR MUHAMMAD FIROZ	234.00
84	1203370001145977	MRS. SHAMIMA ALAMGIR	600.00
85	1203370003275438	ZAHIDUL ISLAM	1,500.00
86	1203490062694725	MD. ALI AKBER	750.00
87	1203510007942577	MD. ABDULLAH AL-MAMUN	300.00
88	1203510023287254	HOSNEARA BEGUM	402.00
89	1203570064426449	MONOWARA BEGUM	93.00
90	1203680048779113	MD. MOHI US SUNNAT CHOWDHURY	60.00
91	1203730044477621	MD. ABDUL QUADER KHONDAKER	1,302.00
92	1203730068133151	MD. NURER NOBI	1,500.00
93	1203780041625444	SAMIA FERDOWSI	546.00
94	1203800013052045	MD. ZAKIR HOSSAIN	102.75
95	1203800024282461	ZAKIA SULTANA CHOWDHURY	153.00
96	1203810008459280	MR SHAHJAHAN	287.85
97	1203850060115871	MATIUR RAHMAN KHAN	72.00
98	1203850060117689	MATIUR RAHMAN KHAN	270.00
99	1203940001584652	MR. MOHD ALI XAHANGIR	288.00
100	1204070040489115	RAZU AHAMED	2,400.00
101	1204070067190024	D. M. SAKHAWAT HOSSAIN	2,700.00
102	1204340063406964	MD. MAHMUDUL HAQUE	900.00
103	1204440062111669	MD RASHID AHMED	630.00
104	1204570039437313	MD. SAIFUL ISLAM	180.00
105	1205670019722454	ZAHID MALEQUE	1,890.00
106	1205890068334285	MR. SHAHARIA	1,170.00
107	1301860001230119	MD MODU MIAH	338.85
108	1601880019854440	MD. TAWHIDUL ISLAM	300.00
109	1601880037421042	MD MOGAFFER RAHAMAN	2,049.00

Sl. No.	Folio Number / BO Account Number	BO Short Name	Amount in Taka
110	1602170000519510	SHAILA RAHMAN	3,000.00
Dividend Year - 2018 -2019 Total			59,834
<b>Dividend Year - 2019 -2020</b>			
1	1201510033830267	SHAHANAJ AKTER	77.00
2	1201510052140119	MR. MD. ABDUL MATIN	10.50
3	1201510067935022	KAMRUN NAHAR BEGUM	1,750.00
4	1201560015202842	MD. SAIYOD ALI	812.00
5	1201580009232618	FATEMA AKTHER	87.50
6	1201580027132721	MD. BILLAL HOSSAIN	2.97
7	1201600021885841	AFZAL HOSSAIN	35.00
8	1201700052288953	SHIPLU CHANDRA MALAKER	87.50
9	120172000010083	S.M. MONIRUZZAMAN	196.00
10	1201720023285908	RAKHI DAS PURKAYASTHA	1,575.00
11	1201770003494098	2046 - MD. ANWAR HOSSAIN	1,634.50
12	1201780016015821	Md. Faizullah	148.75
13	1201820040805587	MD.JALAL HOSSAIN	1,036.00
14	1201820045585722	MR. PINTU DEY	77.00
15	1201870001708063	SAZZADUN NESSA	35.00
16	1201890068096361	KASHFIA JAHAN	35.00
17	1201900025234879	MD. SANOWAR HOSSAIN	157.67
18	1201900037329476	SUJIT CHANDRA SAHA	182.00
19	1201940000174715	MD.HELAL UDDIN	35.00
20	1202020011902527	ABDUL JALIL	52.50
21	1202030039342132	LAILA AKTER	2,625.00
22	120205000043469	MD. GOLAM MOSTAFA	70.00
23	1202050020751499	MD. MANGAL MIA	175.00
24	1202120046580424	MST. NAZMA	59.50
25	1202130020903986	MD MOHIUDDIN	350.00
26	1202150000209662	MR. IFTEKHAR AHMED	38.50
27	1202150015007492	MD.SHAHIDUL HASAN	3.50
28	1202150018934480	RAJIYA BEGUM	28.00
29	1202250060732813	AMENA BEGUM	280.00
30	1202250060732831	AMENA BEGUM	164.50
31	1202250062283986	SHUBHA MIA	238.00
32	1202260016303007	MOSTAFA KAMAL UDDIN	87.50
33	1202260034212684	NUR MOHAMMAD	350.00
34	1202270042128369	MD HASAN	28.00
35	1202270045467509	MD. SANOWAR HOSSAIN	24.50
36	1202280017884275	ABUL HOSEN	126.00
37	1202320062481363	FAHMIDA PARVIN	28.00
38	1202400000011286	MD.SHAHIDUL ISLAM	227.50
39	1202400020408731	MD. SHAFIQUL ISLAM (BITU)	8,403.50
40	1202400025933837	MD. SAIFUL ISLAM	175.00
41	1202400061028191	MD. ZAHURUL ISLAM	63.00
42	1202400062560161	MD. MOSAROF HOSSEN	154.00
43	1202420038830274	BILLAL HOSSAIN	3.50
44	1202460058403331	REAZUL HAQUE	35.00
45	1202490027037330	BHANU BEGUM	105.00
46	1202530062033337	GAZI TAMIM HOSSAIN	52.50
47	1202550034335073	MD. KHAIRUZZAMAN BARBUIYAN	350.00
48	1202580035234232	SHAMIM AHMED	525.00
49	1202640011144253	M. BAZLUR RASHID	630.00
50	1202760053740966	SAMIR KUMAR BISWAS	245.00
51	1202820005793012	EMRAN ALI MUNSHI	3.50
52	1202830016163287	MRS. HELANA PARVIN SOOMA	1,050.00
53	1202890026577494	MOHAMMAD ABDUL QUDDUS	787.50
54	1202960066709509	MD. MASUM	1,750.00
55	1203000010714607	MD. ABDUL BATEN MOLLAH	8,596.00
56	1203010019017090	MARY SARKAR	479.50
57	1203020014783940	MONJERA TASMIN	913.50
58	1203040032344270	JALAL UDDIN AHMED	259.00
59	1203060039783510	MD. MORSHED ALAM	42.00
60	1203110034452292	MD.ABDUL KHALIK	87.50
61	1203110048712185	BEAUTI SULTANA	7.00
62	1203180058528951	MD. ABDUR RAB	70.00
63	1203190020223736	MD. HARUN	70.00
64	1203370000173796	MUNNI BEGUM	700.00

Sl. No.	Folio Number / BO Account Number	BO Short Name	Amount in Taka
65	1203370003275438	ZAHIDUL ISLAM	2,145.50
66	1203570034090793	MANJUARA AZAD	49.00
67	1203570064426449	MONOWARA BEGUM	3.50
68	1203650059756027	NARGIS LAILA	49.00
69	1203680055257382	NAKIBA SULTANA	560.00
70	1203730044477621	MD. ABDUL QUADER KHONDAKER	1,634.50
71	1203800013052045	MD.ZAKIR HOSSAIN	17.85
72	1203850060115871	MATIUR RAHMAN KHAN	98.00
73	1203850060117689	MATIUR RAHMAN KHAN	129.50
74	1203910034764752	WALIUL BARI CHOWDHURY	2,302.65
75	1203940001584652	MR.MOHD ALI XAHANGIR	420.00
76	1203940027369086	RUSDANA BEGUM	969.50
77	1203980039904699	RAZIN IMRAN	35.00
78	1204090029654634	MD. NASIR UDDIN SARDER	17.50
79	1204310027739129	BIKASH CHANDRA CHANDA	17.50
80	1204340063406964	MD. MAHMUDUL HAQUE	1,312.50
81	1204490062192562	TAMIZ UDDIN AHMED	1,158.50
82	1204570039437313	MD. SAIFUL ISLAM	262.50
83	1204570046295284	ABU KHAER	350.00
84	1204820036556967	MD. SAIFUL ISLAM	7.00
85	1205150032410349	A. T. M. SHOEB	175.00
86	1205690000372475	MAJOR TOWHID BIN AHMED	1,249.50
87	1205690055236332	A.F.F.M JAKIR HOSSAIN	164.50
88	1205720058964866	MAHMUDA AKTER	350.00
89	1206000004434111	MAHBUBA AKHTER	2,800.00
90	1601880024966171	MOHAMMAD KHORSHED ALAM	252.00
91	1601880043165802	RANJIT PAUL	17.50
92	1602170045260020	SAKHAWAT HOSSAIN	105.00
93	1605280067341774	LBIL - L8307	350.00
94	1201820068186192	MD. ISMAIL	175.00
95	1203060005251348	IMTIAZ AHMED	350.00
96	1605170068844082	CBCRL CLIENT A/C- CN242	350.00

Dividend Year - 2019 -2020 Total **56,365.39**

**Dividend Year - 2020 -2021 (Without TAX)**

1	1201510052140119	MR. MD. ABDUL MATIN	7.65
2	1201560034965232	Shahnaj Pravin	255.00
3	1201580000037518	MR. SHAKIL AHMED	510.00
4	1201580021169326	TANIA BINTE QURAISHI	12.75
5	1201580021169417	TANIA BINTE QURAISHI	15.30
6	1201580032541258	MD. ASSADUZZAMAN	15.30
7	1201730068497714	SEWLI AKTER	255.00
8	1201820040805587	MD.JALAL HOSSAIN	754.80
9	1201820045585722	MR. PINTU DEY	38.25
10	1201820060708878	AZIM SHAH	75.60
11	1201830048968721	MD. ALI AHSAN	2,700.00
12	1201890068066432	MD.ZUBAER ALAM	25.50
13	1201900025234879	MD. SANOWAR HOSSAIN	84.15
14	1201940059439041	MD. MOZAHIDUL ISLAM	117.30
15	1201950005081955	Md.Delwar Hossain	7.65
16	1202050000043469	MD. GOLAM MOSTAFA	54.00
17	1202270074019591	MD. YAKUB ALI	765.00
18	1202320062481363	FAHMIDA PARVIN	20.40
19	1202550065445863	MAHBUBA BEGUM	877.50
20	1202720020840902	MD. AMIR HOSSAIN	51.00
21	1202760065100231	FARUK HOSSAIN	38.25
22	1202850012450461	SYEDA SAYELA ASMA	331.50
23	1202850045428753	MD. HABIBUR RAHMAN	252.45
24	1203040032344270	JALAL UDDIN AHMED	188.70
25	1203040042848071	IQBAL AHMED KHAN	387.60
26	1203110034452292	Md.Abdul Khalik	17.85
27	1203510023287254	HOSNEARA BEGUM	234.60
28	1203520058400534	MD. KAIRUL	45.90
29	1203520058400542	MOKTER MIA	45.90
30	1203520073800614	EASMIN AKTER	5.10
31	1203520073800705	EASMIN AKTER	5.10
32	1203520073800903	BITI BEGUM	5.10
33	1203520073801199	MD. AYETHULLAH	20.40

Sl. No.	Folio Number / BO Account Number	BO Short Name	Amount in Taka
34	1203630021248363	MOHAMMAD JAMAL HOSSAIN SHAHJI	2.55
35	1203680037686931	OLI ULLAH	765.00
36	1203680055257382	NAKIBA SULTANA	892.50
37	1203730016095051	MOHD MAZBAH UDDIN AKTHER	51.00
38	1203830037928133	MD. NAJRUL ISLAM	127.50
39	1203880029199274	MAKSUDA AKTER	51.00
40	1204040051011266	ABU TORAB ALI	38.25
41	1204390023243439	MOHAMMAD ABDUL MAZID	25.50
42	1204450073180981	Yasin Mia	188.70
43	1204450073180991	Yasin Mia	188.70
44	1204450073181009	Md.Mohiuddin	188.70
45	1204450073181017	Md.Mohiuddin	188.70
46	1204450073181025	Abu Mohammad Adnan	188.70
47	1204450073181033	Abu Mohammad Adnan	188.70
48	1204450073181068	Md.Abdullah Al Mamun	188.70
49	1204450073181076	Md.Abdullah Al Mamun	188.70
50	1204450073181084	Meskatul Mostafa Tazal	188.70
51	1204450073181092	Meskatul Mostafa Tazal	188.70
52	1204450073181108	Mohammed Tarek	188.70
53	1204450073181116	Mohammed Tarek	188.70
54	1204450073181124	Amir Hossain	188.70
55	1204450073181132	Amir Hossain	188.70
56	1204450073181140	Md.Iqbal Hossan	188.70
57	1204450073181159	Md.Iqbal Hossan	188.70
58	1204450073181167	Md.Milon Hossen	188.70
59	1204450073237525	Aminul Islam	188.70
60	1204450073237533	Aminul Islam	188.70
61	1205210045491819	Mrs. Popy Chakraborty	68.85
62	1205300062657521	MD ZOYNAL ABEDIN	2.55
63	1205590058445892	NEWTECH ENTERPRISE LIMITED	32,400.00
64	1601880052725812	Mohammad Nazrul Islam	173.40
65	1601880052725839	Mohammad Nazrul Islam	173.40
66	1201580019898670	MRS NILUFA AKHTER	86.70
67	1201580027132721	MD. BILLAL HOSSAIN	2.55
68	1201590066720588	MOSHARAF HOSSEN	63.75
69	1201590066720761	MOHAMMAD SALA UDDIN	63.75
70	1201590066721186	MOHAMMAD SALA UDDIN	63.75
71	1201590068026631	WAHED MAHBUB CHOWDHURY	63.75
72	1201590068026641	WAHED MAHBUB CHOWDHURY	63.75
73	1201640001226691	Nurun Nessa	67.50
74	120172000010083	S.M. MONIRUZZAMAN	142.80
75	1201770003494098	2046 - MD. ANWAR HOSSAIN	1,190.85
76	1201780016015821	SHAMSU UDDIN	127.50
77	1201820033866231	MD. ABDUL HYE	30.60
78	1201890019855091	MD. ABDUS SALAM	280.50
79	1201900037329476	SUJIT CHANDRA SAHA	5.10
80	1201950006884231	Md. Shaha Alam	7.65
81	1201960043538701	MD. ABDUL KAHAR	270.00
82	1202050016091187	MR. MD. TOFAZZAL HOSSAIN	255.00
83	1202060056391041	MD. NUR NABI	107.10
84	1202150018934480	Rajiya Begum	20.40
85	1202400020408731	MD. SHAFIQUL ISLAM (BITU)	6,122.55
86	1202420038830274	BILLAL HOSSAIN	2.55
87	1202460058403331	REAZUL HAQUE	43.35
88	1202470019761764	Md. Abdul Quader	255.00
89	1202550008822249	MRS. ANJUMAN ARA	2,550.00
90	1202550034335073	MD. KHAIRUZZAMAN BARBHUIYAN	255.00
91	1202550037834551	MD. SHAHROZ ANAM	810.00
92	1202640011144253	M. BAZLUR RASHID	459.00
93	1202650014010402	MD. SAIFUL HOQUE	2.55
94	1202930070399210	FULMATI	25.50
95	1202950022039879	MD. ABDUL BARI	132.60
96	1203020014783940	MONJERA TASMIN	665.55
97	1203110041771842	RUMANA RASHID MINA	499.80
98	1203120012307993	MD. SOLAYMAN	12.75
99	1203260019480118	MOHAMMAD SALIM MIA	45.90
100	1203370000173796	Munni Begum	153.00

Sl. No.	Folio Number / BO Account Number	BO Short Name	Amount in Taka
101	1203460037735471	MONOWARA BEGUM	318.75
102	1203600036922431	TUSHAR AHMED	86.70
103	1203810008459280	MR SHAHJAHAN	20.40
104	1204490062192562	TAMIZ UDDIN AHMED	893.70
105	1204570039437313	MD. SAIFUL ISLAM	150.45
106	1204680045971871	MD. IBRAHIM HOSSAIN	153.00
107	1204690063603778	MD. MASUDUR RAHMAN HOWLADER	550.80
108	1206130000190050	Shiran Sylvester Gomes	981.75
109	1201580009232618	FATEMA AKTHER	63.75
110	1202820005793012	EMRAN ALI MUNSHI	2.55
111	1605640000242587	Mahmuda Khatun	701.25
112	1201950007137811	Mosha Rabeya Akhter	612.00
113	1201950007137870	Mosha Rabeya Akhter	739.50
114	1202140048766436	FORHAD HOSSAIN MAHMUD	86.70
115	1202850008760815	KHAN MOHAMMAD REZAUL KARIM	2.55
116	1201960020876928	Abu Naser Md. Toha	66.30
<b>Dividend Year - 2020 -2021 Total</b>			<b>66,955.65</b>

**Dividend Year - 2021 -2022**

1	1201470004193803	Md. Shahed Ali	1.70
2	1201510052140119	MR. MD. ABDUL MATIN	5.10
3	1201580000037518	MR. SHAKIL AHMED	340.00
4	1201580005744524	MOHAMMAD BAKHTIAR SHAHEED	178.50
5	1201580009232618	FATEMA AKTHER	42.50
6	1201580012703823	MRS.LAILA PARVIN BANU	139.40
7	1201580025547664	MRS. KAMRUN NAHAR	765.00
8	1201580027132721	MD. BILLAL HOSSAIN	1.70
9	1201580073477422	HASNA AHMED	255.00
10	1201700047988288	Md.Shafi ullah	20.40
11	1201780016015821	SHAMSU UDDIN	144.50
12	1201820040805587	MD.JALAL HOSSAIN	503.20
13	1201820045585722	MR. PINTU DEY	20.40
14	1201820056892001	ARUN CHANDRA NATH	62.90
15	1201840054926660	MD. MUSTAFA KAMAL	3.40
16	1201870064055286	MD ABDUR RAHMAN BAKUL	340.00
17	1201900037329476	SUJIT CHANDRA SAHA	68.00
18	1201900044913709	DR. MAHFUZ ARA BEGUM	30.60
19	1201910062092807	HABIBUR RAHMAN KHAN	3,150.00
20	1201940072293381	DIPANGKAR MARAK	108.80
21	1201950007137870	Mosha Rabeya Akhter	493.00
22	1201960057883472	SHAFIQUR RAHMAN CHOWDHURY	9.00
23	1201980073491976	Md Kamal Uddin	17.00
24	1202050000043469	MD. GOLAM MOSTAFA	36.00
25	1202050000241242	MR. KAZI ABDUL MALEK	144.50
26	1202050016091187	MR. MD. TOFAZZAL HOSSAIN	170.00
27	1202060016958629	Nargis Sultana	187.00
28	1202120012307993	MD. SOLAYMAN	8.50
29	1202150018934480	Rajiya Begum	13.60
30	1202200001215382	SAYED AHMED	680.00
31	1202240017985969	MOHAMMAD SHAMIM KHAN	202.30
32	1202260000727880	MR.MD.SERAJUL ISLAM	90.00
33	1202320062481363	FAHMIDA PARVIN	13.60
34	1202400020408731	MD. SHAFIQUL ISLAM (BITU)	4,081.70
35	1202420038830274	BILLAL HOSSAIN	1.70
36	1202450025204968	MD SAIDUR RAHMAN	90.00
37	1202460058403331	REAZUL HAQUE	25.50
38	1202470036850703	Md.Hafizur Rahman	18.00
39	1202550065445863	MAHBUBA BEGUM	585.00
40	1202640007796839	A.G.M.NAZRUL ISLAM	3.40
41	1202640011144253	M. BAZLUR RASHID	306.00
42	1202800021695210	MD SHAHADAT HOSSAIN	261.80
43	1202820003770425	GIAS UDDIN CHOWDHURY	23.80
44	1202820005793012	EMRAN ALI MUNSHI	1.70
45	1202830016478081	ALOK KUMAR SAHA	102.00
46	1202830044657566	MD. RASHED ALI	1.70
47	1202930070399210	FULMATI	17.00
48	1202950022039879	MD. ABDUL BARI	81.60

Sl. No.	Folio Number / BO Account Number	BO Short Name	Amount in Taka
49	1203000073448963	MARUFA AKTER	119.00
50	1203020014783940	MONJERA TASMIN	443.70
51	1203040032344270	JALAL UDDIN AHMED	125.80
52	1203110034452292	Md.Abdul Khalik	11.90
53	1203110041771842	RUMANA RASHID MINA	333.20
54	1203110068156313	MOHAMMAD NAZRUL ISLAM	17.00
55	1203110072234926	MD. JASHIM UDDIN KHAN	170.00
56	1203140044165384	JHUMARA KHATON	357.00
57	1203220006655516	Talukder Luna Yesmin	42.50
58	1203220032021734	MD IQBAL HOSSAIN	68.00
59	1203260019480118	MOHAMMAD SALIM MIA	30.60
60	1203520008030082	MD. MUSHFIQUR RAHMAN	27.20
61	1203520073801199	MD. AYETHULLAH	13.60
62	1203600036922431	TUSHAR AHMED	57.80
63	1203940025319897	KHALEDA PARVEEN	35.70
64	1204040051011266	ABU TORAB ALI	25.50
65	1204140044300334	MOST.BEAUTI KHATUN	8.50
66	1204230039748233	SWAPAN KUMAR SAHA	17.00
67	1204310027739129	BIKASH CHANDRA CHANDA	8.50
68	1204390003791855	MD.MONIRUZZAMAN KHAN	34.00
69	1204390023243439	MOHAMMAD ABDUL MAZID	17.00
70	1204490062192562	TAMIZ UDDIN AHMED	595.80
71	1204520036819898	MD. ABUL KALAM AZAD	204.00
72	1204570038567804	ZAKIA SULTANA	85.00
73	1204570039437313	MD. SAIFUL ISLAM	100.30
74	1204760065149662	NAYEEM HASAN	85.00
75	1205200063262574	Md. Saidur Rahman	180.00
76	1205590032897525	MD. AZMAL HOSSAIN	680.00
77	1205590058445892	NEWTECH ENTERPRISE LIMITED	21,600.00
78	1205660069281666	MD. RASHIDUL ISLAM	85.00
Dividend Year - 2021 -2022 Total			39,425.10

**Dividend Year - 2022 -2023**

1	1201470008095228	Shukla Roy	135.00
2	1201500020694265	MOHAMMED NUR NABI	843.75
3	1201510052140119	MR. MD. ABDUL MATIN	3.83
4	1201520064005030	Ferdaus Ara Faruquee	255.00
5	1201530061563980	ISRAT ARA ZABIN	396.53
6	1201530074571230	CMSF	229,509.45
7	1201560006414416	Lipika Goswami	125.55
8	1201580001375834	BHABDURGA CHOWDHURY	202.50
9	1201580005744524	MOHAMMAD BAKHTIAR SHAHEED	133.88
10	1201580006369850	MD.RUHUL AMIN	1.28
11	1201580009232618	FATEMA AKTHER	31.88
12	1201580012703823	MRS.LAILA PARVIN BANU	104.55
13	1201580013745012	JAKIR HOSSAIN	22.95
14	1201580014101411	HASINATUL SAINZARI	622.20
15	1201580020582481	ANISUZZAMAN KHAN	1.28
16	1201580025547664	MRS. KAMRUN NAHAR	573.75
17	1201580027132721	MD. BILLAL HOSSAIN	1.28
18	1201580027503842	MD. RAFIQL ISLAM	548.25
19	1201580043688354	MOAZZEM HOSSAIN	2,550.00
20	1201580046560023	MOHAMMAD NAJMUSH SAKIB OYAN	51.00
21	1201580063835741	MD. SADAR-E-ELAHI	150.45
22	1201580073477422	HASNA AHMED	191.25
23	1201590027526361	ZAHEDUL ISLAM BHUIYAN	331.50
24	1201590033857255	JAMILUR RAHMAN	1.28
25	1201590039505217	MD. TAFIQL ISLAM	401.63
26	1201590041252581	SARWAR UDDIN	510.00
27	1201590065783516	TANIA AFROZA	255.00
28	1201590069509622	MOHAMMAD MARUF ISLAM	540.00
29	1201600025453156	MUHAMMAD SHAKIK	701.25
30	1201640001226691	Nurun Nessa	33.75
31	1201640023096902	ZAKIR HOSSAIN	267.75
32	1201700002015012	Dr. M. H. Zakaria	19.13
33	1201700008345481	Most. Kamrunnessa Begum	344.25
34	1201700042976092	SELIM REZA	127.50

Sl. No.	Folio Number / BO Account Number	BO Short Name	Amount in Taka
35	1201700053673280	Md. Mahbubul Alam	1.28
36	1201720026610096	DULIA AKTER	242.25
37	1201730068497714	SEWLI AKTER	290.70
38	1201780016015821	SHAMSU UDDIN	108.38
39	1201810019662128	MAHBUBA BINTE AHMED	31.88
40	1201820037682958	MD.RASHID AHAMED	280.50
41	1201820040805587	MD.JALAL HOSSAIN	377.40
42	1201820045585722	MR. PINTU DEY	12.75
43	1201820060708878	AZIM SHAH	37.80
44	1201870056775990	MD.ALAMGIR ISLAM	15.30
45	1201890068002240	KAZI FAZLE RABBI	1,768.50
46	1201890073563412	Md Aminur Rahman	48.45
47	1201900020531122	SHAH MST.BEGOM KAMRON NAHAR	47.18
48	1201900025234879	MD. SANOWAR HOSSAIN	42.08
49	1201900034952697	MM MONOWAR HOSSAIN	216.75
50	1201900040614011	A.B.M AMINUL ISLAM	30.60
51	1201900040674345	MD. AMINUL ISLAM	75.23
52	1201900044913709	DR. MAHFUZ ARA BEGUM	22.95
53	1201930012074210	MAJOR MD. REZAUL ISLAM	127.50
54	1201940018610396	MD. JAMIR	1,275.00
55	1201950007137870	Mosha Rabeya Akhter	369.75
56	1201960068863256	KHAN EHTESHAM	63.75
57	1201960071639766	MD. ENSAN SHARDAR	318.75
58	1201960071647764	SOFIULLAH	340.43
59	1201960071683278	S.M. ATAUR RAHMAN	327.68
60	1201960074738843	AMIRUL ISLAM	318.75
61	1201960074738918	AMIRUL ISLAM	318.75
62	1201980067715767	SUMON AHMED	223.13
63	1202020026196465	Kazi Md.Zahir Hossain	1,657.50
64	1202020064974751	MD. HAFIZUR RAHMAN	405.00
65	1202030017219358	Kismat Ara	3.83
66	1202030017628510	M. Anisur Rahaman Rajib	2.70
67	1202030058003766	Md Misbahul Alam	415.65
68	120205000043469	MD. GOLAM MOSTAFA	27.00
69	1202050000241242	MR. KAZI ABDUL MALEK	108.38
70	1202050016091187	MR. MD. TOFAZZAL HOSSAIN	127.50
71	1202060000575880	Md. Enamul Haque	27.00
72	1202060016958629	Nargis Sultana	140.25
73	1202090004087281	Rozy Talukder	1,611.60
74	1202090020392787	MD NURUL ISLAM	401.63
75	1202090020868250	MD.AHASAN ALI CHOWDHURY	127.50
76	1202090043365411	MR. KHONDOKER NAZMOON NABI	5.10
77	1202090053185578	MOHAMMAD ROBIUL ISLAM	1,785.00
78	1202090053601256	MD. MONIRUZZAMAN KHAN	127.50
79	1202120012307993	MD. SOLAYMAN	6.38
80	1202140000147535	Dr. A.T.M. Fazlur Rahman	1,087.58
81	1202140000402526	Md Tazirul Islam	122.40
82	1202140012570585	MR. FAHIM HASSAN	446.25
83	1202140018216843	MS FATEMA MANNAN	174.68
84	1202140021332940	MD.AMJAD HOSSAIN KHAN SOHEL	2.70
85	1202150018934480	Rajiya Begum	10.20
86	1202200015556468	ABDUL KADER	40.50
87	1202200015556492	ABDUL KADER	94.50
88	1202240017985969	MOHAMMAD SHAMIM KHAN	151.73
89	1202270025522361	Md. Hannan	382.50
90	1202270040780546	MS RINA KHATUN	255.00
91	1202270074019591	MD. YAKUB ALI	382.50
92	1202280065109457	SONIA AKTER	156.83
93	1202280070396656	SHERENA AKTER	99.45
94	1202280070396664	SHERENA AKTER	99.45
95	1202280070452106	MD. MANIK MIA	102.00
96	1202280070468799	MD. MANIK MIA	102.00
97	1202300012518031	SHIAK MOHAMMAD SAMSUDDIN	637.50
98	1202320062481363	FAHMIDA PARVIN	10.20
99	1202350001262899	Syed Zahirul Haque	1.35
100	1202400020408731	MD. SHAFIQL ISLAM (BITU)	3,061.28
101	1202400040279493	MD. MAHMUDUL HASSAN	127.50

Sl. No.	Folio Number / BO Account Number	BO Short Name	Amount in Taka
102	1202400065302147	KHURSHID NAZNIN	20.40
103	1202420038830274	BILLAL HOSSAIN	1.28
104	1202430021736943	ZUBAIR MD.SHABBIR HUSSAIN	63.75
105	1202460058403331	REAZUL HAQUE	19.13
106	1202470019761764	Md. Abdul Quader	51.00
107	1202470031837230	Md.Motiar Rahman Khan	382.50
108	1202470036850703	Md.Hafizur Rahman	13.50
109	1202550008822249	MRS. ANJUMAN ARA	1,275.00
110	1202550036810225	MD. SHAMIM KHAN	35.70
111	1202550036810324	MD. SHAMIM KHAN	35.70
112	1202550045403028	MD. ZAHIDUL ISLAM	35.70
113	1202550045461528	NAZRUL ISLAM	35.70
114	1202580022459091	FORIDA PARVEN	187.43
115	1202580022459166	FORIDA PARVEN	478.13
116	1202610034076986	MD MOSTAFA KAMAL	127.50
117	1202630019312005	INVENT PROMOTIONS	769.50
118	1202640011144253	M. BAZLUR RASHID	229.50
119	1202650065322240	SOHEL RANA	2.55
120	1202650073638583	KHUSRAT JAHAN	102.00
121	1202720041134001	MD. MANIR UZZAMAN	51.00
122	1202720042408124	MD. JAKIR HOSSAIN	293.25
123	1202720067683981	ENDRANY MAZUMDER	136.43
124	1202760019108206	ZIAUR RAHMAN KAMOL	52.28
125	1202760043540221	RATAN KUMAR AGARWALA	191.25
126	1202760053740966	SAMIR KUMAR BISWAS	191.25
127	1202800020376440	MD. ABU JAHID SIDDIQUI	701.25
128	1202820005793012	EMRAN ALI MUNSHI	1.28
129	1202840012676751	MD. JAMAN AKAN	7.65
130	1202850004106421	MD. SALIM	71.40
131	1202850015805575	MOHAMMAD SHEIKH SAADI	270.00
132	1202930033593560	MD ABDUR ROB	76.50
133	1202930042913226	MD. KAMRUL HASAN	382.50
134	1202930070399210	FULMATI	12.75
135	1202950022039879	MD. ABDUL BARI	61.20
136	1202950037528891	MD. MOBAROK HOSSAIN	2,550.00
137	1203000073217349	RAFIQUE AHAMED	127.50
138	1203010007821277	MIHIR KUMAR DAS	53.55
139	1203020014783940	MONJERA TASMIN	332.78
140	1203040044960901	MD. ABDUL MALEK	127.50
141	1203040061166583	SALAH UDDIN	1,466.25
142	1203110034452292	Md.Abdul Khalik	8.93
143	1203110041771842	RUMANA RASHID MINA	249.90
144	1203110072234926	MD. JASHIM UDDIN KHAN	127.50
145	1203140013110471	PARVEEN AKTHER	382.50
146	1203140030308771	DALIYA SULTANA	38.25
147	1203140044165384	JHUMARA KHATON	267.75
148	1203190073763907	USUF KHAN	140.25
149	1203210048425391	MD.SHAHJAHAN	255.00
150	1203210063890247	MD. SIRAJUL ISLAM	2.55
151	1203210065054406	A.S.M Shahriar Mahmud	714.00
152	1203220006655516	Talukder Luna Yesmin	31.88
153	1203220014879987	THE BARAKAH GENERAL HOSPITAL L	135.00
154	1203220032021734	MD IQBAL HOSSAIN	51.00
155	1203260019480118	MOHAMMAD SALIM MIA	22.95
156	1203330036580118	MIZANUR RAHMAN	274.13
157	1203360007668013	A.B.M ZIAUR RAHAMAN	6.75
158	1203410037849601	MD. ABDUL HAKIM	127.50
159	1203520007721861	RAFIQUL ISLAM SIKDER	552.08
160	1203520073801199	MD. AYETHULLAH	10.20
161	1203530028613141	MD. BULBUL MIA	382.50
162	1203530046006261	MST. MOZLEFA KHATUN	36.98
163	1203550036416956	SHAHİ AHMED CHOWDHURY	63.75
164	1203570040365772	SHAMSUZZAMAN	261.38
165	1203600036922431	TUSHAR AHMED	43.35
166	1203620054406055	MD.ABDUL MALIK	255.00
167	1203630027034941	MD. SHAFIUDDIN MIR	25.50
168	1203650048576428	MD. YOUSUF ALI	127.50

Sl. No.	Folio Number / BO Account Number	BO Short Name	Amount in Taka
169	1203650049577161	SHANKER PROSHAD GHOSH	573.75
170	1203680016446038	MRS FARZANA RAHMAN CHOWDHURY	127.50
171	1203680027739129	BIKASH CHANDRA CHANDA	6.38
172	1203680064170257	MD. REZAUL KARIM KHOKON	637.50
173	1203810006454803	A K M SALEH	114.75
174	1203810008459280	MR SHAHJAHAN	10.20
175	1203810043902440	MD MAMUN	135.00
176	1203880000269286	Dr Choudhury Md Showkat Osman	41.85
177	1203940025319897	KHALEDA PARVEEN	26.78
178	1204040051011266	ABU TORAB ALI	19.13
179	1204050032297351	MOHAMMAD HANIF	397.80
180	1204070022850657	MST. SHAJEDA BEGUM	255.00
181	1204070031128208	SHAFIQ UDDIN AHMED	191.25
182	1204090039953623	SUFIA KHATUN	257.55
183	1204090045107621	MD. REZAUL KARIM	4,080.00
184	1204140063943221	MD. IFTEKHARUL ISLAM	7.65
185	1204170019123390	MIR FEROZ UDDIN	191.25
186	1204240062886210	MST. MOUSUMEE AKTER	133.88
187	1204390003791855	MD. MONIRUZZAMAN KHAN	25.50
188	1204490062192562	TAMIZ UDDIN AHMED	446.85
189	1204500065045031	MD. ABU MORSHED KHAN	875.93
190	1204520036819898	MD. ABUL KALAM AZAD	153.00
191	1204570036871844	JABUN NESA RIMA	255.00
192	1204570038567804	ZAKIA SULTANA	63.75
193	1204570058458173	MIRZA MD. RASHEL BEG	405.00
194	1204690063603778	MD. MASUDUR RAHMAN HOWLADER	275.40
195	1204730040997311	MD. Tanveer Newaz Santanu	344.25
196	1204760065149662	NAYEEM HASAN	63.75
197	1204820047511066	T.M. Rahamot-E-Khuda	159.38
198	1205210045491819	Mrs. Popy Chakraborty	34.43
199	1205590021635910	MD. MUSTAYEN BILLAH	2.55
200	1205590032897525	MD. AZMAL HOSSAIN	510.00
201	1205590058445892	NEWTECH ENTERPRISE LIMITED	16,200.00
202	1205670070707716	MD. EHSANUR RABBI	958.50
203	1205720058964866	MAHMUDA AKTER	127.50
204	1205790075084690	MD. GOLAM MOSTAFA	2,227.50
205	1205950016913661	Md. Abul Kalam Azad	3,187.50
206	1206500037928133	MD. NAJRUL ISLAM	63.75
207	1601880056589394	MD. MAKSUDDUL ISLAM NAHID	255.00
208	1601880059766711	SHAHINA BEGUM	3.83
209	1601880066498849	MIRZA M.S HUSSAIN	234.90
210	1605330047808781	MESBAH UDDIN SURUJ	18.00
211	1605410047523551	PLFSIL-I/A:M0216	52.28
212	1605410063778253	PLFSIL-I/A M2824	51.00
213	1605580052373577	NIRANJAN CHANDRA DEBNATH	135.00
Dividend Year - 2022 -2023 Total			311,804

**Dividend Year - 2023 -2024**

1	1201470008095228	Shukla Roy	108.00
2	1201470018705518	Dr. Md. Nazrul Islam	255.00
3	1201500020694265	MOHAMMED NUR NABI	675.00
4	1201510003884194	MAHMUDA FARZANA AKHTER	185.64
5	1201510003914443	MD. SHAFIQUR RAHMAN	21.42
6	1201510052140119	MR. MD. ABDUL MATIN	3.06
7	1201530074571230	CMSF	173,001.18
8	1201560027503842	MD. RAFIQUL ISLAM	438.60
9	1201580006369850	MD. RUHUL AMIN	1.02
10	1201580009232618	FATEMA AKTHER	25.50
11	1201580012703823	MRS. LAILA PARVIN BANU	83.64
12	1201580013745012	JAKIR HOSSAIN	18.36
13	1201580014101411	HASINATUL SAINZARI	497.76
14	1201580018641921	MD. MOHI UDDIN	306.00
15	1201580020582481	ANISUZZAMAN KHAN	1.02
16	1201580027132721	MD. BILLAL HOSSAIN	1.02
17	1201580037442961	MD. ASADUZZAMAN	408.00
18	1201580046560023	MOHAMMAD NAJMUSH SAKIB OYAN	40.80
19	1201590023484431	MD. SALIM REZA	306.00
20	1201590027526361	ZAHEDUL ISLAM BHUIYAN	265.20

Sl. No.	Folio Number / BO Account Number	BO Short Name	Amount in Taka
21	1201590033857255	JAMILUR RAHMAN	1.02
22	1201590039505217	MD. TAFIQL ISLAM	382.50
23	1201590041252581	SARWAR UDDIN	408.00
24	1201590046672041	FARID AHMED KHAN	102.00
25	1201590049561968	MD. NAZMUL ISLAM	306.00
26	1201590073497020	RONI GHOSH	1,096.20
27	1201600046103757	RATNA RANI DAS	30.60
28	1201630000672243	SHAH ALAM ZAHIRUDDIN	574.56
29	1201640000011326	Md.Louthful Goni Tito	3.06
30	1201640001226691	Nurun Nessa	27.00
31	1201640023096902	ZAKIR HOSSAIN	214.20
32	1201700002015012	Dr. M. H. Zakaria	15.30
33	1201700008345481	Most. Kamrunnessa Begum	275.40
34	1201710048422885	MARK LLOYD GOMES	2.04
35	1201720026610096	DULIA AKTER	193.80
36	1201720067722787	MD. KHALIL ULLAH	6,289.92
37	1201720068938011	AKTER JAHAN	204.00
38	1201730038867920	ABU HENA MD. MORTOJA ZAMAN MIL	188.70
39	1201730044808446	SIKDER MOHAMMAD ALI	1,080.00
40	1201730068497714	SEWLI AKTER	280.50
41	1201780016015821	SHAMSU UDDIN	86.70
42	1201780052046444	MD ZAKIR HOSSAIN PATWARY	432.00
43	1201820037682958	MD.RASHID AHAMED	217.26
44	1201820045585722	MR. PINTU DEY	6.12
45	1201820056892001	ARUN CHANDRA NATH	37.74
46	1201830000751355	Kashem - Humayun	21,958.56
47	1201870056775990	MD.ALAMGIR ISLAM	12.24
48	1201890042101049	LAYLA ARZUMAN LUKHY	1,512.00
49	1201890073563412	Md Aminur Rahman	38.76
50	1201900020531122	SHAH MST.BEGOM KAMRON NAHAR	173.40
51	1201900021781029	MD. MAZEDUL ISLAM	51.00
52	1201900025234879	MD. SANOWAR HOSSAIN	33.66
53	1201900040674345	MD. AMINUL ISLAM	60.18
54	1201900043364088	MD ABDUR RAHIM	510.00
55	1201900050864777	MD. FOKRUL ISLAM	4,012.20
56	1201900075528203	SABRINA KHAN	1,085.28
57	1201950007137870	Mosha Rabeya Akter	295.80
58	1201950063781901	Jesmin Islam	510.00
59	1201960029210723	Md Mahtab Uddin Pradan	1,632.00
60	1201960057883472	SHAFIQUR RAHMAN CHOWDHURY	5.40
61	1201960068863256	KHAN EHTESHAM	51.00
62	1201960076726883	Farhad chowdhury	1,938.00
63	1201980067715767	SUMON AHMED	178.50
64	1202000004349895	JESMIN ARA.	510.00
65	1202020007699011	MR.NANI GOPAL SAHA	145.86
66	1202020055279640	RASHED MAHMUD	15.30
67	1202030017219358	Kismat Ara	3.06
68	120205000043469	MD. GOLAM MOSTAFA	21.60
69	1202050000241242	MR. KAZI ABDUL MALEK	86.70
70	1202050016091187	MR. MD. TOFAZZAL HOSSAIN	102.00
71	1202060033898797	Shafiqul Haider	27.00
72	1202060046447340	SHAFIQUL HAIDER	21.60
73	1202090004087281	Rozy Talukder	1,289.28
74	1202090043365411	MR. KHONDOKER NAZMOON NABI	4.08
75	1202090053185578	MOHAMMAD ROBIUL ISLAM	1,428.00
76	1202140000402526	Md Tazirul Islam	97.92
77	1202140012570585	MR. FAHIM HASSAN	357.00
78	1202140018216843	MS FATEMA MANNAN	139.74
79	1202150018934480	Rajiya Begum	8.16
80	1202160020238498	MD, IDRISH ALI	12.24
81	1202190045056719	SAIHAM KNIT COMPOSITE LIMITED	81.60
82	1202200015556468	ABDUL KADER	32.40
83	1202200015556492	ABDUL KADER	75.60
84	1202240017985969	MOHAMMAD SHAMIM KHAN	118.32
85	1202250008570858	MOTIUR RAHMAN	188.70
86	1202270025522361	Md. Hannan	306.00
87	1202270040780546	MS RINA KHATUN	306.00

Sl. No.	Folio Number / BO Account Number	BO Short Name	Amount in Taka
88	1202280073953495	MAMOTAZ BEGUM	79.56
89	1202280073954069	MAMOTAZ BEGUM	79.56
90	1202280073954224	JESMIN AKTER	79.56
91	1202280073954473	JESMIN AKTER	79.56
92	1202280073955419	RASAL AHMED	79.56
93	1202280073955569	RASAL AHMED	79.56
94	1202300012518031	SHIAK MOHAMMAD SAMSUDDIN	510.00
95	1202320020789801	MD.FARIDUL ISLAM	408.00
96	1202320062481363	FAHMIDA PARVIN	8.16
97	1202350010051714	MRS. BANANI SAHA	612.00
98	1202350063949633	SWAPAN KUMAR SAHA	816.00
99	1202400017993057	MOHAMMAD MAHADI HASSAN	2.04
100	1202400020408731	MD. SHAFIQUL ISLAM (BITU)	2,449.02
101	1202400040279493	MD. MAHMUDUL HASSAN	153.00
102	1202400065302147	KHURSHID NAZNIN	16.32
103	1202420001372110	NASRIN SULTANA	1,122.00
104	1202420018002891	HOSHNEARA BEGUM	8,160.00
105	1202420038830274	BILLAL HOSSAIN	1.02
106	1202430028073772	ABDUL MOTTN KHAN	22.44
107	1202460047568709	MD. NAHIDUZZAMAN (NISHAD)	1,020.00
108	1202460058403331	REAZUL HAQUE	15.30
109	1202470031837230	F.P.M. Motiar Rahman Khan	306.00
110	1202550004303152	DR. DAULATUN NAHAR KHANAM	1,020.00
111	1202550008822249	MRS. ANJUMAN ARA	1,020.00
112	1202550036810225	MD. SHAMIM KHAN	16.32
113	1202550036810324	MD. SHAMIM KHAN	14.28
114	1202550045403028	MD. ZAHIDUL ISLAM	15.30
115	1202550059614051	MIR MD. ABU SUFEAN	204.00
116	1202550062717890	NAHID KHANAM TRISHNA	248.88
117	1202580028747153	MD. SARIFUL ALAM	216.00
118	1202600005966145	MD.SHAKHAWAT HOSSAIN SHEIKH	482.46
119	1202610034076986	MD MOSTAFA KAMAL	102.00
120	1202630019312005	INVENT PROMOTIONS	547.20
121	1202640011144253	M. BAZLUR RASHID	183.60
122	1202640054105068	MD. ZILANY BHUIYAN	670.14
123	1202650062909830	ZAHERA BEGUM	8.16
124	1202680007783217	A.B.M. ZIAUR RAHMAN SIDDIQUE.	5.40
125	1202720042408124	MD. JAKIR HOSSAIN	234.60
126	1202720046512374	MRS TANIA RAHAMAN	5.10
127	1202720067683981	ENDRANY MAZUMDER	109.14
128	1202760019108206	ZIAUR RAHMAN KAMOL	41.82
129	1202760043540221	RATAN KUMAR AGARWALA	153.00
130	1202760053740966	SAMIR KUMAR BISWAS	204.00
131	1202800004118586	RAFIQUL ISLAM	7,075.08
132	1202800020376440	MD. ABU JAHID SIDDIQUI	561.00
133	1202820005793012	EMRAN ALI MUNSHI	1.02
134	1202830015883392	KHANDAKER MAHFUZUL ALAM	85.68
135	1202850004106421	MD. SALIM	159.12
136	1202850015805575	MOHAMMAD SHEIKH SAADI	216.00
137	1202850063720531	MD. IBRAHIM	846.72
138	1202930033593560	MD ABDUR ROB	61.20
139	1202950022039879	MD. ABDUL BARI	37.74
140	1202950037528891	MD. MOBAROK HOSSAIN	2,040.00
141	1203010007821277	MIHIR KUMAR DAS	42.84
142	1203020014783940	MONJERA TASMIN	266.22
143	1203040044960901	MD. ABDUL MALEK	102.00
144	1203040061166583	SALAH UDDIN	1,173.00
145	1203110034452292	Md.Abdul Khalik	7.14
146	1203110041771842	RUMANA RASHID MINA	199.92
147	1203110072234926	MD. JASHIM UDDIN KHAN	109.14
148	1203140013110471	PARVEEN AKTHER	306.00
149	1203140021119247	AZAD MOHAMMAD KAMRUZZAMAN	54.06
150	1203140030308771	DALIYA SULTANA	30.60
151	1203140042978878	AFROZA ZAMAN	21.42
152	1203180000424538	MD.GOLAM MOSTAFA	367.20
153	1203180009433041	MUHAMMED NUSRUM MINALLAH CHY	510.00
154	1203190027263861	MD.LUTFOR RAHMAN	597.72
155	1203190073763907	USUF KHAN	112.20
156	1203210065054406	A.S.M Shahriar Mahmud	558.96
157	1203220006655516	Talukder Luna Yesmin	25.50
158	1203220076672797	SAIFUL ISALM	540.00
159	1203260062615060	MD. ANOWARUL ISLAM	573.24

Sl. No.	Folio Number / BO Account Number	BO Short Name	Amount in Taka
160	1203330036580118	MIZANUR RAHMAN	219.30
161	1203370008464657	MD. SHAKHAWAT HOSSAIN	54.00
162	1203550036416956	SHAHİ AHMED CHOWDHURY	51.00
163	1203590063732521	MD.BILAL UDDIN	76.50
164	1203600036922431	TUSHAR AHMED	34.68
165	1203610070966233	HELENA BEGUM	571.20
166	1203650049577161	SHANKER PROSHAD GHOSH	459.00
167	1203680016446038	MRS FARZANA RAHMAN CHOWDHURY	102.00
168	1203680027739129	BIKASH CHANDRA CHANDA	5.10
169	1203680062855918	SHAMIMA NASRIN TANIA	8,017.20
170	1203680064170257	MD. REZAUL KARIM KHOKON	510.00
171	1203710015273831	MD. SALAHUDDIN	510.00
172	1203710017934157	Faheemul Huq	14,870.58
173	1203810006454803	A K M SALEH	91.80
174	1203810008459280	MR SHAHJAHAN	8.16
175	1203810024165599	Mohammad Arifur Rahman Ridoy	204.00
176	1203810043902440	MD MAMUN	108.00
177	1203880000269286	Dr Choudhury Md Showkat Osman	33.48
178	1203880007983273	MIR FEROZ UDDIN	972.00
179	1203880060681051	MD. MUNJUR ALI	30.60
180	1203940025319897	KHALED A PARVEEN	51.00
181	1203950061174631	MD. MOBARAK ALI	5,202.00
182	1203970069376475	MD. KHOLILUR RAHMAN	10.20
183	1203980016183977	MD. GOLAM FAROOQUE	632.40
184	1204030025107588	MD. ASADUZZAMAN KHAN	750.60
185	1204050032297351	MOHAMMAD HANIF	318.24
186	1204070022850657	MST. SHAJEDA BEGUM	346.80
187	1204070031128208	SHAFIQ UDDIN AHMED	153.00
188	1204090039953623	SUFIA KHATUN	202.98
189	1204090045107621	MD. REZAUL KARIM	3,264.00
190	1204140030018893	MD. SELIM UDDIN	10.20
191	1204140048621018	MD. SHAH ALOM	1,059.48
192	1204170019123390	MIR FEROZ UDDIN	153.00
193	120446000068043	Md. Abdul Kader Akand	204.00
194	1204490062192562	TAMIZ UDDIN AHMED	357.48
195	1204500025145347	ABU TALHA SHAWON	59.16
196	1204500033591925	Md. Aktaruzzaman	1,020.00
197	1204500063401771	MOIN UDDIN	10.80
198	1204500065045031	MD. ABU MORSHED KHAN	700.74
199	1204690063603778	MD. MASUDUR RAHMAN HOWLADER	220.32
200	1204730040997311	MD. Tanveer Newaz Santanu	275.40
201	1204760065149662	NAYEEM HASAN	51.00
202	1204760065150586	TAHMINA AKTHER TANNY	102.00
203	1204820047511066	T.M. Rahamot-E-Khuda	142.80
204	1205210045491819	Mrs. Popy Chakraborty	27.54
205	1205300000205613	MD. NAZRUL ISLAM MAZUMDER	154,008.00
206	1205300048292185	MD. NAZRUL ISLAM MAZUMDER	79,056.00
207	1205590021635910	MD MUSTAYEN BILLAH	2.04
208	1205590032897525	MD. AZMAL HOSSAIN	408.00
209	1205590058445892	NEWTECH ENTERPRISE LIMITED	12,960.00
210	1205720058964866	MAHMUDA AKTER	102.00
211	1205870062962586	Sitara Alamgir	13,270.20
212	1205950069728951	MUZAMMEL HAQUE	37.80
213	120651000410690	MR.MD.CHAND MIAH	20.40
214	1206510004680688	MD. CHAND MIAH	30.60
215	1206510007083650	RABEYA AKHTER	61.20
216	1206510007083669	RABEYA AKHTER	10.20
217	1602170023337998	1688-SMRITA SHEFA SAHA	68.34
218	1603700067966947	ISHTIAK AHMED	102.00
219	1605410047523551	PLFSIL-I/A:M0216	41.82
220	1605410063778253	PLFSIL-I/A M2824	40.80
221	1605580052373577	NIRANJAN CHANDRA DEBNATH	108.00
222	1606720076261741	Josna Mohiuddin	96.90
223	1606720076261774	A K M Mohiuddin & Josna Mohiud	96.90
224	1606720076268808	A.K.M. MOHIUDDIN	102.00
225	1606720076285212	Farjana Rafiq	1,966.68
226	1606720076285635	Meer Sayed Hossain	123.42
227	1606720076295891	Mr. M.K.I Chowdhury	204.00

Dividend Year - 2023 -2024 Total

571,984.80

**WATA CHEMICALS LTD**  
**Statement of Yearwise Unclaimed Dividend Account (Non Demat)**

SL No.	Folio No.	Name	No of Share	Schedule-10 (B)								Amount in in	
				2010	2011	2014	2015 2016	2016 2017	2017 2018	2018 2019	2019 2020	2020 2021	
1	115	MR. MAHMUDUL KARIM	200	200	240	156	390	429	450	1,757	2,562	2,196	1,464
2	164	MR. ABDUS SOBHAN MIAH	50	50	60	39	98	107	113	439	640	549	366
3	203	K.F. CORPORATION (PVT). LTD	17,200	17,200	20,640	13,416	33,540	36,894	38,739	151,081	220,326	188,851	125,901
4	275	MR. SUMIT RAHMAN	200	200	240	156	390	429	450	1,757	2,562	2,196	1,464
5	302	MR. HARUN-AR-RASHID	100	100	120	78	195	215	225	878	1,281	1,098	732
6	318	MR. TAPAN SANKAR HAZRA	150	150	180	117	293	322	338	1,318	1,921	1,647	1,098
7	319	MRS. JENY HAZRA	150	150	180	117	293	322	338	1,318	1,921	1,647	1,098
8	322	MOHD. HARISUL HOQUE	50	50	60	39	98	107	113	439	640	549	366
9	316(B)	MRS. HOSNE ARA BEGUM	200	200	240	156	390	429	450	1,757	2,562	2,196	1,464
10	396	MD. DELWAR HOSSAIN BHUIYAN	250	200	240	156	390	429	450	1,757	2,562	2,196	1,464
11	537	MR. NAYYAR MIRZA BAIG	1,600	1,600	1,920	1,248	3,120	3,432	3,604	14,054	20,495	17,568	11,712
12	554	MRS. BITHI RAY	200	200	240	156	390	429					
13	555	MR. APURBA KUMAR RAY & MRS. BITHI RAY	200	200	240	156	390	429					
14	558	MOSMUM HABIB CHOWDHURY IA-1986	200	200	240	156	390	429	450	1,757	2,562	2,196	1,464
15	828	MRS. HOSNE ARA BEGUM	600	600	720	468	1,170	1,287	1,351	5,270	7,686	6,588	4,392
16	829	MR. ANISUR RAHMAN	1,000	1,000	1,200	780	1,950	2,145	2,252	8,784	12,810	10,980	7,320
17	886	MR. MIRZA ABOO MANSUR	1,000	1,000	1,200	780	1,950	2,145	2,252	8,784	12,810	10,980	7,320
18	893	MR. ABDUR RAUF & MRS. HIRA	250	250	300	195	488	536	563	2,196	3,202	2,745	1,830
19	947	MR. MD. NURUL ISLAM	400	400	480	312	780	858	901	3,514	5,124	4,392	2,928
20	954	MR. M. FARHAD HUSSAIN	400	400	480	312	780	858	901	3,514	5,124	4,392	2,928
21	963	MR. SYED WASEQUE MD. ALI	200	200	240	156	390	429	450	1,757	2,562	2,196	1,464
22	978	MR. A.B.M. ANWARUL ISLAM	50	50	60	39	98	107	113	439	640	549	366
23	1004	MRS. NAZMA HUQ	400	400	480	312	780	858	901	3,514	5,124	4,392	2,928
24	1045	MRS. SHAMSUN NAHAR RAUF	50	50	60	39	98	107	113	439	640	549	366
25	1046	MR. SIRAJ-UD-DAWLA	250	250	300	195	488	536	563	2,196	3,202	2,745	1,830
26	1047	MR. NARAYAN CHANDRA SARKAR	150	150	180	117	293	322	338	1,318	1,921	1,647	1,098
27	1101	MR. MONZURUL HUQ	300	300	360	234	585	644	676	2,635	3,843	3,294	2,196
28	1108	MR. MD. REZWANUL KARIM	200	200	240	156	390	429	450	1,757	2,562	2,196	1,464
29	1110	MR. PIJUSH KANTI CHOWDHURY	250	250	300	195	488	536	563	2,196	3,202	2,745	1,830
30	1158	MR. IMTIAZ AHMED	100	100	120	78	195	215	225	878	1,281	1,098	732
31	1167	MR. MD. MOHIUDDIN IA-16411	50	50	60	39	98	107	113	439	640	549	366
32	1198	MR. SHAFI AHMED	2,400	2,400	2,880	1,872	4,680	5,148	5,405	21,081	30,743	26,351	17,568
33	1202	MRS. JASMIN AHMED	1,400	1,400	1,680	1,092	2,730	3,003	3,153	12,297	17,934	15,372	10,248
34	1203	MR. MOINUL AKBAR MUNNA	2,600	2,600	3,120	2,028	5,070	5,577	5,856	22,838	33,305	28,547	19,032
35	1233	MRS. SUFIA AKHTAR KHATUN	250	250	300	195	488	536	563	2,196	3,202	2,745	1,830
36	1235	MRS. MANJU RANI SARKER	200	200	240	156	390	429	450	1,757	2,562	2,196	1,464
37	1241	MR. MASHUQUR RAHMAN	250	250	300	195	488	536	563	2,196	3,202	2,745	1,830
38	1242	MRS. MAHMUDA RAHMAN	250	250	300	195	488	536	563	2,196	3,202	2,745	1,830

SL No.	Folio No.	Name	No of Share	2010	2011	2014	2015 2016	2016 2017	2017 2018	2018 2019	2019 2020	2020 2021	2021 2022	2022 2023	2023 2024	Amount in	
39	1243	MR. MD. NURUL HOQUE	200	200	240	156	390	429	450	1,757	2,562	2,196	1,464	255	204	10,303	
40	1244	MR. DEEPTI PRASANNA CHOWDHURY	750	750	900	585	1,463	1,609	1,689	6,588	9,607	8,235	5,490	956	765	38,636	
41	1251	MRS. SABRINA KHAN	400	400	480	312	780	858	429	450	1,757	2,562	2,196	1,464	255	-	4,632
42	1268	BRIG A.S. MAHMOOD	200	200	240	156	390	429	450	1,757	2,562	2,196	1,464	-	204	10,303	
43	1285	MR. MD. IKRAMUL BARI	200	200	240	156	390	429	450	1,757	2,562	2,196	1,464	-	-	9,844	
44	1348	MR. MASUD REZA BHUIYAN	250	250	300	195	488	536	563	2,196	3,202	2,745	1,830	319	255	12,879	
45	1349	MRS. YASMIN RAHMAN	250	250	300	195	488	536	563	2,196	3,202	2,745	1,830	319	255	12,879	
46	1420	MR. SHARIF ATTAUR RAHMAN	200	250	300	195	488	536	563	2,196	3,202	2,745	1,830	-	-	1,769	
47	1459	MR. AMINUL ISLAM KHAN	150	180	117	293	322	322	338	1,318	1,921	1,647	1,098	191	153	7,727	
48	1463	DR. TOFAIL AHMED CHOWDHURY	150	150	180	117	293	322	390	429	429	429	-	-	-	1,415	
49	1468	MR. HASIB-BIN-AKBAR	200	240	156	390	429	429	429	429	429	429	-	-	-	1,415	
50	1469	MRS. HAZERA AKBAR	200	240	156	390	429	429	429	429	429	429	-	-	-	1,415	
51	1470	MR. S.M. AKBAR HOSSAIN	200	240	156	390	429	429	429	429	429	429	-	-	-	1,415	
52	1482	MR. MD. RABIUL ISLAM	250	250	300	195	488	536	563	2,196	3,202	2,745	1,830	319	255	12,879	
53	1534	MR. MD. ABU TAUER MIA	750	750	900	585	1,463	1,609	1,689	6,588	9,607	8,235	5,490	956	765	38,636	
54	1547	MR. S.M. ASFAQUZZAMAN	600	600	720	468	1,170	1,287	1,351	5,270	7,686	6,588	4,392	765	612	30,909	
55	1559	MR. MD. FARUK HOSSAIN	250	300	195	488	536	563	563	2,196	3,202	2,745	1,830	319	255	12,879	
56	1561	MRS. NAYAR SULTANA	1,000	1,200	780	1,950	2,145	2,145	2,145	2,145	2,145	2,145	-	-	-	7,075	
57	1564	MR. MD. ABUL HOSSAIN	50	50	60	39	98	107	113	439	640	549	366	64	51	2,576	
58	1600	MRS. TANZIA AFRIN	200	250	240	156	390	429	429	429	429	429	-	-	-	1,415	
59	1608	MR. MUJIBUR RAHMAN	200	200	240	156	390	429	450	1,757	2,562	2,196	1,464	-	-	-	1,769
60	1644	MR. MD. SAYEDUR RAHMAN	200	200	240	156	390	429	450	1,757	2,562	2,196	1,464	255	204	10,303	
61	1650	MR. MD. ALAMGIR	200	200	156	39	98	107	113	439	640	549	366	64	51	10,303	
62	1708	MR. GRACY ROBERT KHAN	50	60	60	39	98	107	113	439	640	549	366	64	51	2,576	
63	1753	MR. IFTEKHAR-UL-ISLAM	400	400	480	312	780	858	901	3,514	5,124	4,392	2,928	510	408	20,606	
64	1773	MR. MD. ABDULLAH	200	200	240	156	390	429	450	1,757	2,562	2,196	1,464	255	204	10,303	
65	1777	MR. MD. SHAHDUR RAHMAN	100	100	120	78	195	215	225	878	1,281	1,098	732	128	102	5,152	
66	1805	MR. M.A. SAMAD MIAH	250	300	195	488	536	563	563	2,196	3,202	2,745	1,830	319	255	12,879	
67	1822	MR. MD. MOHIUDDIN	250	300	195	488	536	563	563	2,196	3,202	2,745	1,830	319	255	12,879	
68	1839	MR. SANJIB KUMAR SARKER	200	200	240	156	390	429	450	1,757	2,562	2,196	1,464	255	204	10,303	
69	1844	MR. MD. SHAHDAT HOSSIAN	250	300	195	488	536	563	563	2,196	3,202	2,745	1,830	319	255	12,879	
70	1846	MR. M.A. TAHER	250	300	195	488	536	563	563	2,196	3,202	2,745	1,830	319	255	12,879	
71	1859	MR. IMDADUL HOQUE	250	300	195	488	536	563	563	2,196	3,202	2,745	1,830	319	255	12,879	
72	1860	MR. SHAMSUDDIN AHMED	100	100	120	78	195	215	225	878	1,281	1,098	732	128	102	5,152	
73	1882	MR. MD. SHAFKAT HOSSAIN	500	600	390	975	1,073	1,126	4,392	6,405	5,490	3,660	638	510	25,758		
74	1898	MR. TOFAZZAL HOSSAIN	150	180	117	293	322	322	338	901	3,514	5,124	4,392	-	-	1,399	
75	1899	MR. MD. SOLAIMAN MIAH	50	50	60	39	98	107	113	439	640	549	366	64	51	2,576	
76	1905	MR. MD. JUBAIR- BIN-AMIR (RUMI)	250	250	300	195	488	536	563	2,196	3,202	2,745	1,830	319	255	12,879	
77	1908	MR. SYED RIZWANUR RAHMAN	500	600	390	975	1,073	1,126	4,392	6,405	5,490	3,660	638	510	25,758		
78	1909	MR. MOHAMMAD ALI	100	100	120	78	195	215	225	878	1,281	1,098	732	128	102	5,152	
79	1914	MR. BADIUZZAMAN SARDER	50	50	60	39	98	107	113	439	640	549	366	64	51	2,576	
80	1917	MR. NIKHIL KRISHNA SAHA	50	50	60	39	98	107	113	439	640	549	366	64	51	2,576	
81	1928	MR. NAHIDUL HAQUE	1,000	1,000	1,200	780	1,950	2,145	-	-	-	-	-	-	-	7,075	

SL No.	Folio No.	Name	No of Share	2010	2011	2014	2015 2016	2016 2017	2017 2018	2018 2019	2019 2020	2020 2021	2021 2022	2022 2023	2023 2024	Amount in
82	1929	MR. A.M. GHULAM WAHEED	50	50	60	39	98	107	113	439	640	549	366	64	51	2,576
83	1952	MR. NESAR UDDIN AHMED	50	50	60	39	98	107	113	439	640	549	366	64	51	2,576
84	1957	MR. MD. MOMINUR RASHID	100	100	120	78	195	215	225	878	1,281	1,098	732	128	102	5,152
85	1958	MR. MD. SHAFIQUL ISLAM	50	60	39	98	107	113					-	-	-	466
86	1962	MR. RAQIB UDDIN CHOWDHURY	200	240	156	390	429						-	-	-	1,415
87	1970	MR. MD. KAMAL UDDIN	1,800	1,850	2,220	1,443	3,608	3,968					-	-	-	354
88	1979	MR. MD. SAIDUR RAHMAN	500	500	600	390	975	1,073	1,126	4,392	6,405	5,490	3,660	638	510	13,089
89	1984	MR. ZEHADUL ISLAM	150	150	180	117	293	322	338	1,318	1,921	1,647	1,098	191	153	25,758
90	2001	MR. MD. AKBAR HOSSEN	600	720	468	1,170	1,287						-	-	-	4,245
91	2002	MR. MD. MONIR HOSSEN DULAL	200	240	156	390	429						-	-	-	1,415
92	2008	MRS. MAHBUBA RAHIMA BEGUM	50	50	60	39	98	107	113	439	640	549	366	64	51	2,576
93	2009	MR. KAZI ADIL AHMED SHAFI	50	50	60	39	98	107					-	-	-	354
94	2011	MR. MOHD. AMIZAD HOSSAIN	100	100	120	78	195	215	225	878	1,281	1,098	732	128	102	5,152
95	2015	MR. BABUL BISWAS	250	300	195	488	536						-	-	-	1,769
96	2019	MRS. BASANA DAS	50	50	60	39	98	107	113	439	640	549	366	64	51	2,576
97	2020	MR. PRIYALAL DAS	50	50	60	39	98	107	113	439	640	549	366	64	51	2,576
98	2029	MR. MD. HARUN-UR-RASHID BHUIYAN	1,250	1,250	1,500	975	2,438	2,681	2,815	10,980	16,012	13,725	9,150	1,594	1,275	64,394
99	2035	MR. MD. ALAUDDIN	250	250	300	195	488	536	563	2,196	3,202	2,745	1,830	319	255	12,879
100	2043	MR. ZAHIRUL HAQUE	250	250	300	195	488	536	563	2,196	3,202	2,745	1,830	319	255	12,879
101	2047	MR. MD. SAIFUL ISLAM	250	300	195	488	536	563	2,196	3,202	2,745	-	-	-	-	10,475
102	2048	MR. OBAIDULLAH	200	250	300	195	488	536	563	2,196	3,202	2,745	1,830	255	204	12,764
103	2049	MR. MD. REZAUL ISLAM	250	250	300	195	488	536	563	2,196	3,202	2,745	1,830	319	255	12,879
104	2053	MR. KAZI EYEAR AHAMED	200	200	240	156	390	429					-	-	-	1,415
105	2059	DR. MD. REZAUL ISLAM	50	50	60	39	98	107	113	439	640	549	366	64	51	2,576
106	2062	MR. S.M. NURUL ALAM	200	250	300	195	488	536	563	2,196	3,202	2,745	1,830	255	204	12,764
107	2064	MR. MD. MEHER UDDIN	800	900	1,080	702	1,755	1,931	2,027	7,905	11,529	9,882	6,588	1,020	816	46,134
108	2065	DR. SUKUR ALAM KHAN	250	250	300	195	488	536	563	2,196	3,202	2,745	1,830	319	255	12,879
109	2077	MR. MANJUR MORSHED KOBIR	50	50	60	39	98	107	113	439	640	549	366	64	51	2,576
110	2079	MR. HUMAYUM KABIR	250	250	300	195	488	536	563	2,196	3,202	2,745	1,830	319	255	12,879
111	2096	MR. MD. MOAZZEM HOSSAIN	150	150	180	117	293	322	338	1,318	1,921	1,647	1,098	191	153	7,727
112	2097	MR. MD. BAHAUDDIN MRIDHA	50	50	60	39	98	107	113	439	640	549	366	64	51	2,576
113	2099	DR. MASUDA SALMA	400	400	480	312	780	858					-	-	-	2,830
114	2102	MR. HAMIM CHOWDHURY	50	50	60	39	98	107	113	439	640	549	366	64	51	2,576
115	2116	MR. MD. QUAMIRUZZAMAN KHAN	250	250	300	195	488	536	563	2,196	3,202	2,745	1,830	319	255	12,879
116	2125	MR. MD. ABUL HOSSAIN	450	450	540	351	878	965	1,014	3,953	5,764	4,941	3,294	574	459	23,182
117	2127	MR. SHAH JALAL UDDIN KHAN	50	50	60	39	98	107	113	439	640	549	366	64	51	2,576
118	2152	MR. IMTIAZ AHMED	250	250	300	195	488	536	563	2,196	3,202	2,745	1,830	319	255	12,879
119	2157	MR. SK. TALUKDER	50	50	60	39	98	107	113	439	640	549	366	64	51	2,576
120	2158	MR. ANWARUL HASAN	50	50	60	39	98	107	113	439	640	549	366	64	51	2,576
121	2168	MR. MOZAMMEL HAQUE	200	200	240	156	390	429	450	1,757	2,562	1,916	1,464	255	204	10,303
122	2177	MR. RAFIQUL ISLAM	500	500	600	390	975	1,073	1,126	4,392	6,405	5,490	3,660	638	510	25,758

SL No.	Folio No.	Name	No of Share	2010	2011	2014	2015 2016	2016 2017	2017 2018	2018 2019	2019 2020	2020 2021	2021 2022	2022 2023	2023 2024	Amount in in
123	2181	MR. A.H.M. SHAMSUL ALAM	50	50	60	39	98	107	113	439	640	549	366	64	51	2,576
124	2187	MRS. SELIMA AKHTER NILUFA BANU	50	50	60	39	98	107	113	439	640	549	366	64	51	2,576
125	2190	MR. MD. IFTEKHAR ALI	100	120	78	195	215	-	-	-	-	-	-	-	-	708
126	2195	MR. UTPAL DHAR	250	300	195	488	536	563	2,196	3,202	2,745	1,830	319	255	-	12,879
127	2196	MRS. NINA ISLAM	100	100	120	78	195	215	225	878	1,281	1,098	732	128	102	5,152
128	2197	MR. MD. LIAKAT ALI SARKER	50	50	60	39	98	107	113	439	640	549	366	64	51	2,576
129	2199	MR. A.K.M. MAHMUDUR RAHMAN	400	400	480	312	780	858	901	3,514	5,124	4,392	2,928	510	-	20,198
130	2210	MR. KHUSHI MOHAN PAUL	500	500	600	390	975	1,073	1,126	4,392	6,405	5,490	3,660	638	510	25,758
131	2213	MRS. MEHERUN HOSSAIN	750	750	900	585	1,463	1,609	1,689	6,588	9,607	8,235	5,490	956	765	38,636
132	2215	MR. MD. MOSHARRAF HOSSAIN	250	250	300	195	488	536	563	2,196	3,202	2,745	1,830	319	255	12,879
133	2218	MR. ABDUL WAHAB	350	350	420	273	683	751	788	3,074	4,483	3,843	2,562	446	357	18,030
134	2227	MR. MD. ABU BAKAR SIDDIQUE	200	200	240	156	390	429	450	1,757	2,562	2,196	1,464	255	204	10,303
135	2263	MRS. REZIA BEGUM IA-28113	200	200	240	156	390	429	450	1,757	2,562	2,196	1,464	255	204	10,303
136	2282	MR. TOUheed SHAHJAHAN IA-30520	50	50	60	39	98	107	113	439	640	549	366	64	51	2,576
137	2301	MR. MD. TASLIM HOSSAIN IA-30827	200	200	240	156	390	429	450	1,757	2,562	2,196	1,464	255	204	10,303
138	2345	MR. M.A. QUASEM	50	50	60	39	98	107	113	439	640	549	366	64	51	2,576
139	2346	MR. MD. SARWAR HOSSAIN	250	250	300	195	488	536	563	2,196	3,202	2,745	1,830	319	255	12,879
140	2463	MR. SHEIKH ABDUR RAHMAN	250	300	195	488	536	563	2,196	3,202	2,745	1,830	-	-	-	12,305
141	2464	MR. MUNIR HASAN	1,250	1,250	1,500	975	2,438	2,681	2,815	10,980	16,012	13,725	9,150	1,594	1,275	64,394
142	2469	MR. MD. NAZMUL ALAM CHOWDHURY	500	500	600	390	975	1,073	1,126	4,392	6,405	5,490	3,660	638	510	25,758
143	2470	MR. AZIZUL HOQUE SIKDER	400	400	480	312	780	858	901	3,514	5,124	4,392	2,928	510	408	20,606
144	2474	MR. MD. MONIR HOSEN	50	50	60	39	98	107	113	439	640	549	366	64	51	2,576
145	2477	MR. MAUENUL ISLAM	50	50	60	39	98	107	113	439	640	549	366	64	51	2,576
146	2492	MRS. MOMOTAZ BEGUM	500	500	600	390	975	1,073	1,126	4,392	6,405	5,490	3,660	638	510	25,758
147	2505	MR. KANCHAN ALI HOWLADER	100	100	120	78	195	215	225	878	1,281	1,098	732	128	102	5,152
148	2520	MR. MD. SHAMSUDDIN	200	200	240	156	390	429	450	1,757	2,562	2,196	1,464	255	204	10,303
149	2526	MRS. SHAMIM ARA BEGUM	400	400	480	312	780	858	901	3,514	5,124	4,392	2,928	510	408	20,606
150	2527	MRS. HOSNE ARA BEGUM	400	400	480	312	780	858	901	3,514	5,124	4,392	2,928	510	408	20,606
151	2528	MRS. FARHANA BEGUM	400	400	480	312	780	858	901	3,514	5,124	4,392	2,928	510	408	20,606
152	2532	MR. DEWAN ABDUL HAI	100	100	120	78	195	215	225	878	1,281	1,098	732	128	102	5,152
153	2533	MR. MANSOOR AHMED	250	250	300	195	488	536	563	2,196	3,202	2,745	1,830	319	255	12,879
154	2534	MR. ABU SALEH	50	50	60	39	98	107	113	439	640	549	366	64	51	2,576
155	2543	MR. ASHEQUR RASUL	100	100	120	78	195	215	225	878	1,281	1,098	732	128	102	5,152
156	2567	MR. MOZIBUR RAHMAN	250	250	300	195	488	536	563	2,196	3,202	2,745	1,830	319	255	12,879
157	2568	MR. HABIB ULLAH	150	150	180	117	293	322	338	1,318	1,921	1,647	1,098	191	153	7,727
158	2573	MR. MD. MOSTAFA KAMAL	250	300	234	585	644	676	2,635	3,843	3,294	2,196	319	255	15,340	
159	2574	MR. SANWAR HOSSAIN	150	180	117	293	322	338	1,318	1,921	1,647	1,098	732	128	-	7,383
160	2582	MR. TAZIRUL ISLAM	100	100	120	78	195	215	225	878	1,281	1,098	732	128	102	5,152
161	2585	MR. MD. SHAH ALAM	100	100	120	78	195	215	225	878	1,281	1,098	732	128	102	5,152
162	2590	MR. MD. NURUZZAMAN	100	100	120	78	195	215	225	878	1,281	1,098	732	128	102	5,152
163	2593	MR. MD. BAHAUDDIN	250	300	195	488	536	563	2,196	3,202	2,745	1,830	319	255	12,879	
164	2622	MR. MD. ASRAFUZZAMAN	50	50	60	39	98	107	113	439	640	549	366	64	51	2,576
165	2626	MR. MOHIM HASSAN	100	100	120	78	195	215	225	878	1,281	1,098	732	128	102	5,152


SL No.	Folio No.	Name	No of Share	2010	2011	2014	2015 2016	2016 2017	2017 2018	2018 2019	2019 2020	2020 2021	2021 2022	2022 2023	2023 2024	Amount in	
166	2628	MR. ABDUL HANNAN	50	50	60	39	98	107	113	439	640	549	366	64	51	2,576	
167	2632	MR. EMADUR RAHMAN CHOWDHURY	100	100	120	78	195	215	225	878	1,281	1,098	732	128	102	5,152	
168	2633	MR. MD. MANSUR ELAHI	100	100	120	78	195	215	225	878	1,281	1,098	732	128	102	5,152	
169	2640	MRS. ARJUMAN ARA BEGUM	200	200	240	156	390	429	450	1,757	2,562	2,196	1,464	255	204	10,303	
170	2653	MR. SHAH ALAM ZAHIRUDDIN	200	200	240	156	390	429	429	450	1,757	2,562	2,196	1,464	255	-	1,415
171	2703	MRS. AFROZA AHSEN	200	200	240	156	390	429	429	450	1,757	2,562	2,196	1,464	255	204	10,303
172	2706	MR. MD. SHAHIDUL ISLAM	200	200	240	156	390	429	429	450	1,757	2,562	2,196	1,464	255	204	10,303
173	2707	MR. MD. SALIM	200	200	240	156	390	429	429	450	1,757	2,562	2,196	1,464	255	204	10,303
174	2748	MR. MD. ABDUS SALAM	200	200	240	156	390	429	429	450	1,757	2,562	2,196	1,464	255	204	10,303
175	2915	MR. SAYEED	400	400	480	312	780	858	901	3,514	5,124	4,392	2,928	510	408	20,606	
176	3055	MR. KLINTON SARKAR	1,200	1,200	1,440	936	2,340	2,574	2,703	10,541	15,372	13,176	8,784	1,530	1,224	61,818	
177	3076	BRAC	200	200	240	156	390	429	429	450	1,757	2,562	2,196	1,464	255	192	10,291
178	3089	MR. MD. MOYNUL HAQUE MOLLAH	200	200	240	156	390	429	429	450	1,757	2,562	2,196	1,464	255	204	10,303
179	3090	MR. MOHAMMAD SHOWKAT ALI KHAN	200	200	240	156	390	429	429	450	1,757	2,562	2,196	1,464	255	204	10,303
180	3094	MRS. MAHBUBA BEGUM	250	250	300	195	488	536	563	2,196	3,202	2,745	1,830	319	255	12,879	
181	3258	MR. A.H.M. DALLI UDDIN	100	100	120	78	195	215	215	215	215	215	215	215	-	-	708
182	3259	MR. SYED JAMILUR RAB	50	60	39	98	107	107	107	107	107	107	107	107	-	-	354
183	3260	MR. SYED ABDUR RAB	50	60	39	98	107	107	107	107	107	107	107	107	-	-	354
184	3261	MR. S.M. ASHRAF HOSSAIN	50	60	39	98	107	107	107	107	107	107	107	107	-	-	354
185	3304	MRS. SULTANA SHIRIN	200	200	240	156	390	429	429	450	1,757	2,562	2,196	1,464	255	204	10,303
186	3307	MR. NIAZ UDDIN AHMED	200	200	240	156	390	429	429	450	1,757	2,562	2,196	1,464	255	204	10,303
187	3391	DR. M.A. HALIM	200	200	240	156	390	429	429	450	1,757	2,562	2,196	1,464	255	204	10,303
188	3454	MR. MONIR HOSSAIN	200	200	240	156	390	429	429	429	429	429	429	429	-	-	1,415
189	3455	MR. MONSUR ALI	200	240	156	390	429	429	429	429	429	429	429	429	-	-	1,415
190	3546	MR. A.N.M. SHAFIQUL HASAN KHAN	50	50	60	39	98	107	113	439	640	549	366	64	51	2,576	
191	3778	MRS. ZAKIA SULTANA	50	50	60	39	98	107	113	439	640	549	366	64	51	2,576	
192	3791	MR. SHAH ALAM (BABU)	50	50	60	39	98	107	113	439	640	549	366	64	51	2,576	
193	3792	MR. BADAL KHAN	50	50	60	39	98	107	113	439	640	549	366	64	51	2,576	
194	3880	MRS. SYEDA SONIA ALI, IA- 12030	600	600	720	468	1,170	1,287	1,287	1,287	1,287	1,287	1,287	1,287	-	-	4,245
195	890	MR. AGHA YUSUF	106	128	83	207	228	228	228	228	228	228	228	228	-	-	752
196	4118	MR. MD. AZIZUL ISLAM	200	170	204	133	332	365	383	1,493	2,178	2,178	2,178	2,178	255	204	9,375
		<b>Grand Total</b>	<b>68,250</b>	<b>73,626</b>	<b>88,352</b>	<b>57,428</b>	<b>143,571</b>	<b>157,928</b>	<b>143,739</b>	<b>558,824</b>	<b>814,951</b>	<b>698,859</b>	<b>465,878</b>	<b>79,114</b>	<b>61,839</b>	<b>3,344,110</b>	



## FACTORY PREMISES




## FACTORY PREMISES



## FACTORY PREMISES

# RAW MATERIALS





## FINISH PRODUCT

# PROXY FORM



17/B (3rd FLOOR), MONIPURIPARA, SANGSHAD  
AVENUE, DHAKA-1215, PHONE: 58152001,  
58155206 Fax: +880 2 58155091

I/We.....

.....of.....

..... being a member of WATA Chemicals Limited, do hereby appoint  
Mr. /Ms.....of.....

to attend and vote on my/our behalf at the 43rd Annual General Meeting (AGM) of the Company to be held on 9:00 AM, Wednesday,  
December- 24' 2025 at Virtual Platform and at any adjournment thereof.

As witness my / our hand this.....Day of December, 2025

.....

Signature of Proxy



.....

Signature of the Member

BO ID No.

BO ID No.

Notes:

No. of Shares held .....

01. A member entitled to attend and vote in the AGM may appoint a Proxy to attend and vote on his/her behalf.
02. The Proxy Form, duly filed and stamped must be deposited, not later than 48 (Forty Eight) hours before the time fixed for the meeting.
03. Signature of the Member(s) must be in accordance with the Specimen Signature recorded with the Company.
04. As per Article of Association of the Company, no person shall act as a proxy unless he himself is a shareholder of the company.

(Authorized Signature)

WATA CHEMICALS LTD.

.....

Signature Verified)

## ATTENDANCE SLIP



17/B (3rd FLOOR), MONIPURIPARA, SANGSHAD  
AVENUE, DHAKA-1215, PHONE: 58152001,  
58155206 Fax: +880 2 58155091

I/We do hereby record my/our attendance at the 43rd Annual General Meeting (AGM) of the Company being held on 9:00 AM,  
Wednesday, December- 24' 2025 at Virtual Platform. Name of the Member (s)/Proxy:.....

.....

BO ID No of Member:

BO ID No of Proxy Holder:

No. of Shares held .....

.....

Signature of member(s)/Proxy



**FACTORY: MURAPARA, RUPGONJ  
NARAYANGONJ**

**HEAD OFFICE: 17/B, MONIPURIPARA  
SANGSHAD AVENUE, DHAKA-1215**